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Amino acids in symbol 
 
Ala  A  Alanine                        
Arg  R  Arginine                         
Asn  N  Asparagine                              
Asp  D  Aspartic Acid                       
Cys  C  Cysteine                        
Glu  E  Glutamic Acid                        
Gln  Q  Glutamine                        
Gly  G  Glycine  
His  H  Histidine 
Ile  I  Isoleucine 
Leu  L  Leucine  
Lys  K  Lysine  
Met  M  Methionine   
Phe  F  Phenylalanine 
Pro  P  Proline 
Ser  S  Serine 
Thr  T  Threonine 
Trp  W  Tryptophan 
Tyr  Y  Tyrosine 
Val  V  Valine  
 
 
	 5 
Summary 
 
The contribution of a single residue in the structural stability of a whole protein can seem small if its 
position in the structure is not considered. Indeed, the stability of a protein is determined by the 
contribution of many forces among amino acids: hydrophobicity, hydrogen-bonding network and van 
der Waals interactions, salt bridges. Three independent projects were carried out during my PhD 
studies addressing mutations that affect protein fold stability. 
 
I 
 
β2-Microglobulin (β2m), the light chain of the Major Histocompatibility Class I complex (MHC-I), 
can assemble into amyloid fibrils and deposit in joints and bones of patients receiving long term 
haemodialysis, leading to dialysis-related amyloidosis (DRA). 
β2m has been object of many mutational studies to investigate the molecular bases of its aggregation 
propensity. Among other residues, these analyses have pointed out that Trp60 plays a crucial role for 
β2m stability, in particular, W60G β2m, has an increased conformational stability and a reduced 
amyloidogenicity compared to the wild type protein.  
To identify the key-residues that prompt the amyloidogenicity of β2m, the native state dynamics of 
WT β2m and W60G β2m have been compared, combining solution NMR spectroscopy and molecular 
dynamics (MD) simulations. As a result, three β2m variants were designed and characterized: W60G-
Y63W, W60G-N83V and V85E. All mutants have displayed the expected structure, stability and 
aggregation propensity, giving insights into structural determinants of aggregation propensity of WT 
β2m. 
 
II 
 
To date, only a single natural β2m variant at residue Asp76, D76N β2m, has been reported. This 
mutation destabilizes the protein making it more prone to aggregation and has been related to a 
systemic and hereditary amyloid disorder. 
To study the fundamental properties of protein dynamics and stability in solution and in crystal, 
D76N, WT and W60G β2m variants were chosen. These proteins display significant different 
stabilities and aggregation propensities, although conserving well comparable structures, with the 
same crystal symmetry and number of molecules in the asymmetric unit. These properties make them 
suitable as model system to obtain results free of spurious effects, reflecting the changes on protein 
dynamics related to the mutation. 
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Thus, these three variants were used to investigate the correlation between protein stability in solution 
and in crystalline form by Fourier transform infrared spectroscopy (FT-IR). 
FT-IR spectra indicate that each β2m variant displays an increased structural order in the crystals 
compared to the protein in solution; temperature ramps show that increased melting temperatures for 
crystals compared to protein in solution. Nevertheless, the differences in protein stability between the 
three variants are well detectable in crystalline form and they well correlate with the trend observed in 
solution. 
 
III 
 
MHC-I complexes are hetero-trimers composed by the polymorphic heavy chain, the light chain β2m 
and an antigenic peptide. 
The overall structural stability of the complex together with peptide-complex affinity, is fundamental 
for an effective presentation of the antigen: a strong peptide/MHC-I (pMHC) interaction and a time-
extended peptide presentation trigger the best immunogenic CD8+ T-cell response.  
Accordingly, aim of the work is the exploration of the impact on protein fold stability of complex-
stabilizing point mutations on the tumour antigenic peptide NY–ESO157-165 (SLLMWITQC). This 
peptide is expressed by a broad range of tumour types, but not in healthy adult somatic tissue, making 
it an ideal cancer vaccine candidate.  
The in vitro stability of eight complexes has been monitored following the thermal unfolding. All 
complexes bearing the mutated peptides displayed an increase in stability compared to that of the 
complex with the NY–ESO157-165 WT. 
The structural contributions to the stability of the complexes have been investigated through X-ray 
crystallography. Thanks to the structural studies it has been possible to deepen the molecular 
characteristics determining peptide binding to MHC- I molecules and rationalize the optimization of 
the MHC- I anchor residues in tumour epitopes to enhance binding of the peptide to the complex. 
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Part I 
 
1. State of the art 
1.1. Protein folding, stability and aggregation  
1.1.1. Protein fold, stability and dynamics 
The amino acid sequence of a protein contains the information that guides its folding and, therefore, 
its three-dimensional native structure (1). Typically, this native conformation corresponds to a local 
energy minimum reached with the establishment of energetically favourable intra-molecular 
interactions (2, 3). 
The protein fold stability is determined by the combination of many forces that constrain the 
polypeptide chain in its native configuration (4, 5). Most of these are weak non-covalent interactions 
that can act synergically to hold different regions of a polypeptide chain closely together involving 
backbone atoms as well as atoms of the side chains (6). 
Hydrogen bonds stabilize the secondary structural elements of a folded protein connecting the 
carbonyl and amide groups along the polypeptide backbone. In addition, several amino acid side 
chains are also capable of establishing inter- and intra-molecular hydrogen bonds (7). 
The chemistry of amino acid side chains, and therefore distribution of polar and non-polar amino 
acids, is determinant to the protein structure. The non-polar (hydrophobic) side chains interact via 
weak van der Waals interactions. Thus, they tend to cluster in the core of the molecule, avoiding 
contacts with the surrounding solvent. In contrast, polar (hydrophilic) amino acids are usually 
arranged in the external regions of the molecules where they can form hydrogen bonds with other 
polar molecules or with water (8, 9). Furthermore, ionic bonds can occur among charged amino acid.  
Cysteine residues, when oxidized, are the only amino acids capable of forming covalent bonds other 
than peptide bonds, known as disulfide bridges. These covalent bonds can link together two segments 
of a polypeptide chain, further stabilizing the folded structure (10, 11). 
The relationship between structural conformation of proteins and their stability has been widely 
studied. Thermodynamic studies are a suitable tool to predict how proteins changes their conformation 
under different environmental conditions giving information about the stability of proteins.  
Moreover, different strategies for improving protein stability have been set up (12). These include 
increase in the hydrophobic interactions, stabilization through the insertion of disulphide bonds and 
prevention of irreversible processes like aggregation and incorrect folding. 
Once folded, proteins populate an ensemble of conformations at equilibrium. This allows the proteins 
to maintain a high degree of flexibility, often crucial for their function. The biological function of a 
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protein, hence, may often depend not only on its three-dimensional structure, but also on its dynamical 
properties.  The dynamics in a protein allow its conformational changes to respond to the presence of 
other molecules and/or to variations in the environment. Biological and biochemical processes such as 
signal transduction, antigen recognition, protein transport and enzyme catalysis rely on this ability to 
change conformation or to adapt to change.  
Quantitative characterization of protein dynamics can be carried out by Nuclear Magnetic Resonance 
(NMR) spectroscopy, allowing its precise assessment under equilibrium conditions over different time 
scales, from ps-ns to s-min.  
 
1.1.2. Amyloidosis 
The native protein dynamics can be perturbed by several factors leading to misfolding and 
aggregation. Main factors affecting the level of aggregation prone conformers are changes in the 
intracellular environment such as pH, temperature, oxidative stress and metal ions, the protein 
concentration as well as somatic or genetic mutations (3).  
Protein conformational disorders have been linked to various human diseases, defined as diseases by 
misfolding and protein aggregation (13). Among these are amyloidosis, a group of pathologies where 
specific proteins, in parallel or as an alternative to the physiological fold, generate highly structured 
fibrillar aggregates that deposit in tissues. 
About 20 different non-related proteins can undergo into amyloid aggregation in vivo (14), forming 
fibrils with cross-β-sheet quaternary structure (Fig.1): the polypeptide chains assume a cross-β 
arrangement along the growth axis, with their β filaments perpendicular to it (15). The super helical 
structure of the protofilament allows the extension of hydrogen bonds among β filaments along the 
total length of amyloid fibrils, defining their distinctive rigidity and stability (16). Protofilaments wrap 
around each other forming amyloid fibres with diameter ranging between 50 and 150 Å (17). 
 
 
Figure 1. Amyloid structures possess common features. (A) Cryo-electron microscopy imaging of amyloid fibrils. (B, C) 
Atomic-level structure determined by NMR analysis. (D) Schematic representation of the 'cross-β' structure common to 
amyloid fibrils. Adapted from T. P. Knowles, M. Vendruscolo, C. M. Dobson, The amyloid state and its association with 
protein misfolding diseases. Nat Rev Mol Cell Biol 15, 384-396 (2014) (17). 
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Several are the causes that trigger proteins to amyloid aggregation (14). Amyloidosis can result from 
altered conformations assumed by a natively folded protein (18), a drastic increase in protein 
concentration (19), or proteolysis that generate amyloidogenic peptides (20). Moreover, also a 
denaturing stress and/or a mutation can lead to conformational changes affording an intermediate that 
self-assembles into amyloid (21-24).  
The kinetics of amyloid formation can be described with a sigmoidal curve where first a lag phase is 
followed by a quick growth phase and a final plateau regime. Protein monomers undergo 
conformational changes and associate to form oligomeric nuclei. Elongation of fibrils occurs with 
addition of monomers to the ends of existing aggregates leading to form mature fibrils (14, 25). Fibrils 
present a catalytic surface, allowing the formations of new aggregates through the so called 
“secondary nucleation”. Moreover, fragmentation of fibrils may also provide new ends for elongation. 
All these processes, (primary and secondary nucleation, elongation and fragmentation), occur during 
all phases of the aggregation process with different rates depending by the concentration of reacting 
species (Fig.2) (26). 
 
 
 
Figure 2. Amyloid aggregation. (A) Characteristic aggregation curve for amyloid fibril formation. The curve is typically 
divided into a lag phase, a growth phase and a final plateau. (B) Processes occurring during amyloid formation: primary 
nucleation from monomers in solution, elongation (growth) by monomers addition to existing aggregates, surface catalysed 
secondary nucleation from monomers on fibril surface and fragmentation. A from P. Arosio, T. P. Knowles, S. Linse, On the 
lag phase in amyloid fibril formation. Phys Chem Chem Phys 17, 7606-7618 (2015) (26). 
 
 
Diagnosis and detection of amyloid fibrils are usually obtained by using amyloid binding molecules, 
such as Congo Red staining and Thioflavin-T (ThT) fluorescence (27). Congo Red staining can detect 
amyloid deposits thanks to their characteristic apple green birefringence under polarized light 
conditions. ThT assays measure the changes of fluorescence intensity of ThT upon binding to amyloid 
fibrils both in vivo and in vitro (28, 29). The enhanced fluorescence can be observed by fluorescence 
microscopy or by fluorescent spectroscopy.  
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It is widely accepted that the amyloid state is accessible to various amino acid sequences under proper 
conditions and can therefore be considered an inherent property of polypeptide chains (3, 30, 
31). Therefore, it is necessary to define the specific mechanisms by which proteins assume pathogenic 
behaviours that lead to amyloid aggregation and how this is generally avoided in living systems.  
 
1.1.3. β2-microglobulin  
1.1.3.1. Structure, function and dialysis-related amyloidosis 
Among amyloidosis-related proteins, β2-Microglobulin (β2m) is a well studied protein model. Wild-
type β2m (WT β2m) is composed by 99 amino arranged in seven anti-parallel β-strands organized in 
two facing β-sheets (ABED and CFG). It thus displays the typical immunoglobulin fold, with the β-
sandwich stabilized by an inter-strand disulphide bond between cysteine 25 and 80 (Fig. 3B, C) (32-
35). It has also been demonstrated that this bond is necessary for β2m folding in the endoplasmic 
reticulum, and it is not broken during fibrillogenesis in vivo (34).  
β2m is the non-covalently bound light chain of the Major Histocompatibility Complex class I (MHC-I, 
see also paragraph 1.2.1.1.), where, it plays a crucial role in chaperoning assembly of the complex for 
antigen presentation on the cell surface (Fig. 3A) (36, 37).  
 
 
 
Figure 3. X-ray crystal structure of MHC-I and β2m. (A) Schematic representation and 3D model (pdb code: 1S9W) 
showing the β2m non-covalently bounded to the heavy chain (a1, a2, a3) carrying the antigenic peptide in its cleft. (B) 3D 
model (pdb code: 2BSS) of the structure assumed by β2m in the MHC-I complex, AB loop has a “close” conformation.  (C) 
3D model (pdb code: 1LDS) of the monomeric β2m, AB loop has an “open” conformation. Cysteine residues 25 and 80 are 
showed as sticks in the ribbon structures of β2m, linked by the disulphide bridge. 
 
 
The region of the protein involved in the interaction with the heavy chain of the complex are the AB-
loop (residues 12-21) that assumes a “close conformation” (Fig. 3B), the A and D strands, and the DE-
loop (pdb code: 1S9W) (38). 
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β2m is highly stabilized thanks to the interactions within the MHC- I (39) and in physiological 
conditions its catabolism occurs through two steps: β2m dissociates as a monomer from the MHC-I 
heavy chain, then it is released into the serum (with a typical concentration of 0.1 µM), and finally 
degraded proximal tubules in the kidney (40). 
In patients suffering from renal dysfunction undergoing to regular haemodialysis treatments, β2m 
concentration starts gradually to concentrate into their serum, reaching up to 60-time that of healthy 
individuals (41). 
This causes a condition known as dialysis-related amyloidosis (DRA), where the β2m deposits as 
amyloid fibrils in joints and bones of the patients, leading to pathological bone fragility and articular 
pain (42, 43). 
 
1.1.3.2. In vitro studies 
DRA was firstly discovered by Assenat et al. in 1980 (44), but the mechanisms of β2m aggregation 
are still unclear.  
In vitro studies have demonstrated that increased β2m concentration is not sufficient on its own to 
trigger amyloid aggregation. In fact, incubating β2m for several months at physiological conditions 
(neutral pH, 37°C), the protein remains mostly monomeric even if at concentrations more than 20-fold 
higher than those found in DRA patients (45, 46). Thus, several factors have been shown to trigger 
β2m aggregation both in vitro and in vivo (47): presence of a divalent metal ions such as Cu2+ (48, 49), 
glycosaminoglycans (50), collagen (51) and others (52-55). 
Among vertebrates β2m possess a highly conserved sequence. The study of artificial mutants of WT 
β2m has being been a key tool to investigate the molecular process of fibrillogenesis. To this aim 
several mutants have been characterized in vitro from a biochemical and structural point of view in 
relation to their amyloidogenic properties. 
 
Chiti et al. (56) through a series of spectroscopic analyses demonstrated that WT β2m folds via two 
structurally distinct intermediates, I1 and I2, in three sequential phases folding process. The first 
intermediate, the faster one, is characterized by species showing partially folded elements and 
hydrophobic regions exposed to solvent. The second one, indeed, displays native-like secondary 
structure and can accumulate, reaching concentration well correlating with its involvement in amyloid 
elongation (57). 
Mutagenesis studies were performed to better investigate this mechanism,  demonstrating that the 
transition between intermediate I2 and the native structure is rate limited by trans to cis isomerization 
of the His31-Pro32 peptidyl–prolyl bond (58). Furthermore, the His31 residue was related to the 
copper ion-dependent fibrillogenesis: this residue mask the ion, which promotes the isomerization of 
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the Pro32 (59). Moreover, Pro32 residue mutations suggested that cis/trans isomerization of this 
residual constitutes a kinetically limiting stage in the formation speed of amyloid fibres (60). 
 
The correct structural fold and function of β2m is correlated with two evolutionary conserved 
Tryptophan (Trp) residues, with differential and complementary impact in the structure of β2m (61, 
62). Trp95, located at the end of β-strand G, is partially buried. When mutated, the fold stability of the 
protein is decreased and the protein unfold in solution, yielding non fibrillar aggregates.  
Conversely, Trp60 is exposed to the solvent at the apex of DE-loop (residues 57–60) that is involved 
in the interaction of β2m with the heavy chain of MHC-I. This region becomes totally exposed to 
solvent in monomeric β2m with an enhanced backbone dynamics (63) and variety in conformations in 
different crystal structures (Fig. 4). Consequently, due to its high frequency of intermolecular contacts, 
Trp60 is involved in the early steps of fibrillogenesis, as suggested by  molecular dynamics 
simulations (64). Moreover, NMR H/D exchange experiments pointed out that, once the protein has 
aggregated, Trp60 becomes solvent accessible in the fibrils (65). 
 
 
Figure 4. Cartoon representation of the W60G crystal (blue) and NMR average (red) structures superposed on WT β2m 
(yellow) as crystallized in the MHC-I complex (PDB code: 2BSS). Strands are labelled according to the convention adopted 
for β2m; residues Trp60 and Trp95 from crystal structures are shown as stick models. Figure acquired from G. Esposito et 
al., The controlling roles of Trp60 and Trp95 in beta2-microglobulin function, folding and amyloid aggregation properties. J 
Mol Biol 378, 887-897 (2008) (61). 
 
 
Rational mutation studies of the DE-loop have shown that alterations in this region can affect overall 
protein structure, fold stability, folding kinetics and amyloid aggregation properties. These properties 
have been related to the strained conformation in the WT β2m backbone structure. Indeed, residues in 
the DE-loop populate unfavorable regions of the Ramachandran plot in all the published structures of 
both monomeric β2m and in complex with the MHC-I heavy chain.  
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The replacement of Trp60 with a Gly residue, generates the W60G β2m variant and results in a 
structural relaxation of the DE-loop compared to the WT protein. This increases the W60G β2m 
stability, relative to the WT protein. Thermal protein unfolding monitored by near- and far-UV CD 
shows that the W60G mutation substantially increases thermal stability of the β2m fold, shifting the Tm 
of about +8°C (61). 
Additionally, the removal of the bulky hydrophobic Trp side chain also increase the solubility of the 
monomeric β2m and make it aggregation-resistant under mild conditions (61).  
As resulted from Nano-ESI-MS experiments, both WT β2m and W60G mutant assume a partially 
folded form at pH 2.5. However, despite having comparable structural compactness, the W60G mutant 
at pH 2.5 displays a slower kinetics of disulphide reduction. This results can be related either to its 
slightly more structured conformation, and reduced flexibility, that affect both native state and 
partially unfolded intermediate (66).   
Given these observations, other DE-loop mutants were designed. A Proline residue at position 59 
(Asp59→Pro) has been introduced to further increase the rigidity of the DE loop of the WT protein. 
The D59P crystal structure displays backbone conformational strains in the mutated region and 
thermal unfolding carried out on the mutant shows a decrease in stability relative to WT β2m and 
higher propensity to aggregation, confirming that the improvement of the backbone conformational 
strain can trigger long-range effects (62).  
The Trp60→Cys substitution, indeed, induces the same regular β-turn conformation as observed in the 
W60G β2m mutant. However, contrary to W60G, W60C β2m displays a measurable – though reduced 
- aggregation propensity compared to WT. This can suggest that the relaxation of the DE-loop 
geometry, alone, is not fully accounting for the lack of amyloidogenicity observed for W60G (Fig. 5) 
(62).  
 
 
 
Figure 5. Mutation of residues Asp58 and Trp60 in the DE-loop of β2m. Superposition of W60C (blue) and D59P (yellow) 
DE-loops (stereo view). Stick representation of residues 59 and 60 is shown in green for W60C and cyan for D59P. Figure 
acquired from S. Ricagno et al., DE loop mutations affect beta2-microglobulin stability and amyloid aggregation. Biochem 
Biophys Res Commun 377, 146-150 (2008) (62). 
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As W60C, also W60V mutant showed a thermal stability close to that of WT β2m, the same low 
efficiency in beta-aggregation at neutral pH and the common DE-loop conformation of W60G variant. 
The reduced tendency to form fibrils at mild conditions of the W60V and W60C β2m mutants, 
compared to those of WT protein, highlights the key role of the aromatic residues in the DE-loop in 
promoting β2m fibrillogenesis (66, 67). 
 
Colombo et al. introduced a Lys58→Pro mutation to the W60G β2m variant to stabilize the overall 
structure through an ideal type-I β-turn, mimicking the effect of a ‘native Pro’ residue (68).  
Compared to the WT protein, the K58P-W60G mutant shows enhanced stability and faster folding 
kinetic without passing through the folding slow phase (56).  
K58P-W60G β2m displays also peculiar feature: while all β2m variants show a completely oxidized 
disulphide bond, this mutant is purified as a mixture of oxidized (∼70%) and reduced (∼30%) 
molecules.  
This proved that in the K58P-W60G mutant the disulphide bond is not essential for its folding process, 
in apparent divergence with what proven for WT β2m (34),  and demonstrate that DE-loop properties 
affect not only fold stability but also the folding pathway. 
 
In this context Paper 1, aims to investigate whether W60G mutation has other effects on β2m beyond 
its stabilization. The work thus considers if the aggregation propensity is the result of an altered 
protein dynamics. 
The native state dynamics of both proteins were compared combining NMR spectroscopy and 
molecular dynamics simulations underlining an increased average protection of the aggregation-prone 
residues at W60G β2m surface. These findings allowed the rational design of three new β2m variants 
displaying at the same time an altered aggregation propensity and an un-altered protein stability. 
 
1.1.3.3. Hereditary systemic amyloidosis 
In 2012 Valleix et al. reported the first natural variant of human β2m discovered in members of a 
French family. It consists in a point mutation of residue 76 from Asp to Asn (D76N β2m) (22). This 
results in a new hereditary systemic amyloidosis with large widespread amyloid deposits found in 
visceral organs (liver, spleen, kidney, and heart) and whose main symptoms are chronic diarrhoea, loss 
of weight, sicca syndrome and polyneuropathy.  
Unlike DRA, the plasma concentration of monomeric β2m ranges in normal values and amyloid 
deposits display the presence of only full length mutated protein without any truncated forms or WT 
(22). 
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From the biophysical point of view, Asp76→Asn strongly destabilizes the protein and makes it much 
more prone to amyloidogenic aggregation than WT β2m even if its crystal structure shows only subtle 
conformational changes (Fig. 6). Mangione P. et al. also reported the significant increase of the 
partially structured I2 folding intermediate in D76N β2m variant compared to the WT protein (56, 69). 
These findings confirm the correlation between the amyloidogenic propensity of β2m species with the 
existence of a concentration of this partially structured intermediate (70).  
The molecular bases of D76N β2m instability and aggregation propensity have been further 
investigated characterizing different single point mutation variants, where all Asp residues have been 
individually substituted to Asn (D34N, D38N, D53N, D59N, D96N and D98N) (71). All new variants 
displayed thermal stability and aggregation propensity close to those of WT β2m suggesting that the 
amyloidogenic properties of the D76N mutant is not simply due to the loss of a negative charge (Fig. 
6). 
 
 
Figure 6. Crystal structure of D76N variant. (A) Ribbon representation of the D76N mutant. (B) is a close-up view of the E–
F loop (residues 70 to 80) shown in (A), superimposed on the wild-type β2-microglobulin structure (blue–green). Residues 
belonging to the D76N variant are yellow, and Tyr78 belonging to wild-type β2-microglobulin is blue–green; hydrogen (H) 
bonds are shown as dashed lines. (C) shows the surface electrostatic potential of the E–F loop region in the D76N variant 
(top) and in wild-type β2-microglobulin (bottom); circles indicate the mutated residue. Blue represents positively charged 
regions, and red negatively charged regions. Figure acquired from S. Valleix et al., Hereditary systemic amyloidosis due to 
Asp76Asn variant beta2-microglobulin. N Engl J Med 366, 2276-2283 (2012) (22). 
 
 
Given D76N β2m instability, Halabelian L. et al.  investigated the mechanisms that allow the D76N 
variant to escape the unfolded protein response system that targets misfolded/aggregated polypeptides 
(72). They, thus, performed structural and biophysical study on a MHC-I bearing the D76N variant, 
pointing out the high stability of the complex, matching with that of MCH-I bearing WT β2m (39). 
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Therefore, MHC-I has a role in the stabilization of D76N variant, acting as chaperone and protecting 
this variant from intracellular degradation.  
 
The set of these three β2m variants, WT, W60G and D76N is well suited for a comparative analysis of 
protein stability in solution and in crystal, having different thermal stability and aggregation 
properties, but a well comparable crystal packing and crystal structures. 
Manuscript 1, “New insights in protein stability: a crystalline point of view”, deals with a Fourier 
Transform Infrared spectroscopy (FT-IR) study on protein stability of these β2m variants. The stability 
of the proteins in solution and in crystal has been compared to evaluate whether the proteins maintain 
a dynamic also in crystallized conditions. The existence of these correlation would open protein 
dynamics exploration not only to solution state NMR but also to crystalline solid state NMR. 
 
1.2. Protein stability in immune response 
Several efforts have been focused on the understanding of the molecular basis of protein 
thermostability. Thermostability seems to be linked to the modulation of the canonical forces 
occurring in all proteins such as electrostatic (hydrogen bonds and ion-pairs (73)) and hydrophobic 
interactions together with many other stabilizing features (greater hydrophobicity, optimized folding, 
reduction of loops, increased occurrence of proline residues, increased helical content, increased polar 
surface area (74)). 
With this perspective, even the contribution of a single residue amino acid, can become crucial in 
determining the structural stability of a protein or a protein complex.  
 
1.2.1.1. MHC-I structure and stability 
The Major Histocompatibility Class I (also known as Human Leucocyte Antigen, HLA) is a 
heterotrimeric complex composed by a highly polymorphic heavy chain (a) with a transmembrane 
domain, a monomorphic light chain (β2m) and an antigenic peptide. It is located on the cell surface of 
almost all nucleated cells, exposing peptides derived from intracellular proteins, eliciting specific 
immune responses mediated by cytotoxic T lymphocytes (CTLs) (75, 76). 
The structure of MHC-I can be divided in two globular units. The region close to the membrane 
consists of the β2m and a3 heavy chain domains that non-covalently associate through the four-strand 
β-sheet. The second region, consists of a1 and a2 domains, composed of four antiparallel β-strands 
with a solvent exposed helical region, that associate forming a peptide-binding groove (77).  
The two domains are hydrogen bonded in a way that the eight β-strands form a flat surface on top of 
the β2m and a3 domains. The two a-helices form a cleft which is the antigen binding site.  
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The peptide, composed of 8-11 amino acids, is bound into the cleft and the most of residues side 
chains pointing outward for interaction with the TCR (Fig. 7). The side chains of residues in position 
1, 2 and at the C-terminus are, instead, involved in the binding with the heavy chain, acting as anchors 
(Fig. 8) (78, 79). 
 
 
 
Figure 7. Crystal structure of MHC-I complex (PDB code: 1S9W). (A) Complete view of MHC-I X-ray structure with heavy 
chain (blue), β2m (green) and peptide (magenta). (B) Zoomed view of the peptide-binding cleft. 
 
 
 
 
 
Figure 8. Allelic variations and anchor residues. (A) Mapping the sequence variability onto the structure of the HLA-A 
protein illustrates that the distribution of amino acid substitutions among HLA-A alleles in the population is not random. 
Large regions of the protein are unaffected by genetic polymorphism whereas the beta-sheet and the two alpha-helices 
defining the peptide antigen-binding site, are highly polymorphic (color code for variability, highest to lowest: red, orange, 
yellow, green and light blue). (B) Examples of peptides are reported. The most common anchor residues are highlighted in 
orange  
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Thanks to the polymorphic nature of the heavy chain (Fig. 8 B), the antigenic surface formed by the 
bound peptide and the neighbouring a-helices is unique to each pMHC structure and is determinant 
for recruiting of antigen-specific T-Cell Receptors (TCRs) (80).  
Despite the high amount of antigenic peptides and, obviously, the high polymorphic variability of the 
a-chain, the overall structures of the MHC-I are virtually identical, as determined by X-ray 
crystallography (81).  
On the other hand, depending on the antigenic peptide, the stability of MHC-I measured in vitro can 
considerably change ranging from 40°C to nearly 70°C (Fig 9.) (82-84). Experimental evidences have 
demonstrate the impact of MHC-I fold stability on downstream events determining the T cells 
activation (85, 86). The general idea is that the higher is the observed in vitro stability of  MHC-I, the 
longer is the cell surface presentation, and the more effective is T-cell responses (87). Indeed, it has 
been claimed that stability, rather than affinity, of pMHC-I complexes better correlates with 
immunogenicity and immune-dominance (88). 
 
 
 
 
Figure 9. Comparison of peptide/MHC apparent Tm values determined by differential scanning fluorimetry and circular 
dichroism. Notice how different peptides bound to the same MHC allomorph can affect complex stability. Figure acquired 
from L. M. Hellman et al., Differential scanning fluorimetry based assessments of the thermal and kinetic stability of 
peptide-MHC complexes. J Immunol Methods 432, 95-101 (2016) (82).  
 
 
1.2.1.2. Cancer vaccines: antigen stabilization 
MHC-I has an essential role in autoimmune diseases and cancer immune surveillance (89, 90). 
Eradication of tumours is associated with a strong cytotoxic T cell response to antigens expressed by 
the tumour (tumour-associated antigens (TAA)). Many TAA peptides are self-proteins or closely 
 
 
	 19 
related to self-proteins, and interact weakly with MHC-I heavy chain, thus being poorly immunogenic 
(91). For this reason, many efforts have been done to improve the efficacy of the immunogen, 
engineering synthetic peptides (92) to dispense to patients through peptide-base vaccines.  
Peptide-based vaccination strategies must consider the intrinsic instability of native peptides, since the 
extracellular environment is rich in proteases and, thus, peptides are rapidly cleared from the body.  
Therefore, peptide-based vaccines need to be engineered to improve formulation and storage 
properties. Furthermore, incorporation of non-natural amino acids with modified side chains or 
modified peptide bonds there have been engineered to improve peptide binding stability and maintain 
T cell cross-reactivity (93-95). 
Currently another approach being adopted to overcome peptide stability include the optimization of 
the binding to MHC-I by substituting key residues with more appropriate anchor residues.  
The ideal TAA for vaccination and immunotherapy should be expressed exclusively in cancerous 
tissue and are essential for its malignant phenotype. These features are rare, indeed, most TAAs are 
either self-proteins overexpressed in tumours or mutated self-proteins not easily detectible by the 
immune system. 
 
Several tumor-specific antigens have been discovered through the application of serological analysis 
of recombinant cDNA libraries from human tumours(96). 
Among these, NY-ESO-1 seems to be one of the most promising tumour-specific antigens (97): 
indeed about 20% to 40% of tumours express NY-ESO-1 mRNA (98-102), including melanoma, 
prostate, breast, lung and cervical carcinoma (Fig. 10). 
 
 
 
Figure 10. Bone marrow biopsy stained with NY-ESO-1–specific murine IgG1 monoclonal Ab shows strong expression of 
NY-ESO-1 protein in myeloma plasma cells. Images (left panel, original magnification × 10, numerical aperture 0.3; right 
panel, original magnification × 20, numerical aperture 0.46) were visualized with an Olympus microscope, type BH2-RFCA. 
Images were acquired with a SPOT camera (Diagnostics Instruments, Sterling Heights, MI) and SPOT Advanced version 
3.5.6 software without image manipulation. Figure acquired from F. van Rhee et al., NY-ESO-1 is highly expressed in poor-
prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses. Blood 105, 3939-3944 (2005) 
(102) 
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Thanks to its features, NY-ESO-1 thus offers the possibility to develop a broad-spectrum tumor-
specific cancer vaccine. However, several studies have highlighted problems of stability and 
bioavailability associated with NY-ESO-1 derived-peptide immunization and failure in eliciting robust 
T-Cells response to kill tumours (103, 104). 
Jager et al. reported three NY-ESO-1 derived peptides (residues 155–163, QLSLLMWIT; residues 
157–165, SLLMWITQC; residues 157–167, SLLMWITQCFL) as HLA-A*0201-restricted T-CD8+ 
cells response  from a melanoma patient (97).  
In a trial vaccination, a mixture of these peptides was administered to patients with NY-ESO-1 
expressing tumours, to evaluate their immunogenicity  underlining a strong T-CD8+ reactivity and 
response against NY-ESO-1157–165 (105). 
The presence of a Cys residue at the C-terminus of the peptide NY-ESO-1157–165 affects vaccines 
formulation reducing their immunogenic efficacy, the residue has been replaced with more 
conventional anchor residues generating peptide analogues (106, 107). These analogues have shown 
an increased binding affinity to the complex, but not an enhancement in the immunogenic reaction. 
It has been recently proposed a novel method for the design of altered ‘super-peptide’ ligands (APLs): 
non-anchoring peptide amino acids are mutate to obtain peptides that bind with high affinity to MHC-I 
(108, 109). 
Accordingly, recent outcomes provide insights into the mechanisms controlling the enhanced 
immunogenicity of super agonist peptides by demonstrating a correlation between the stability of the 
peptide–MHC–TCR complex, its ability to stimulate a faster formation of conjugates, resulting in 
improved immunogenic response. 
 
In Manuscript 2, “Novel MHC-I complex-stabilizing “superantigens” derived from the cancer target 
NY-ESO-1”, eight MHC-I bearing independent variants of the tumour antigenic peptide NY–ESO157-
165 have purified. The effects of such variants on MHC-I fold stability has been evaluated. Moreover, 
the crystal structure of one of the most stable complexes has been determined and its structural 
analysis helps to rationalise the roles of peptide residues in determining the overall MHC-I stability. 
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2. Aims of the thesis 
The variation of the canonical forces that constrain a polypeptide chain, such as electrostatic forces 
and hydrophobic interactions, can modulate the stability of a protein and hence its physiological and 
pathological properties. 
The main project is aimed at dissecting the crucial role that a definite amino acid can play on the 
protein stability and/or on its pathogenicity through two systems and two different biological contexts: 
β2m and the MHC-I. 
 
I 
 
β2m, responsible for Dialysis Related Amyloidosis in its wild type form, has been subjected to several 
mutational studies to investigate the molecular bases of its amyloid propensity. These analyses have 
revealed that among other mutants the W60G variant has an increased conformational stability and a 
reduced aggregation propensity if compared to WT protein.  
The work combines solution NMR spectroscopy and molecular dynamics simulations on WT and 
W60G β2m variants to investigate whether aggregation properties are exclusively related to the 
stability of the protein or is the result of an altered protein dynamics.  
Thus, to shed light on the molecular determinants that trigger β2m aggregation, three new β2m 
variants were designed and characterized both biochemically and structurally. The inserted mutations 
on WT and W60G β2m variants, should alter their aggregation prone exposed surface, modifying their 
aggregation propensity without altering their stability.  
 
II 
 
To date, it is not fully understood whether protein dynamics and stability are conserved in protein 
crystals, in other words, if such biophysical properties assessed in crystallo are representative of 
protein behaviour in solution. 
In order to start to address such questions, the present work takes as model system the above described 
three β2m variants WT, W60G and D76N, to carry out a comparative study of protein stability in 
solution and in the crystalline form. 
Thermal unfolding analyses of the proteins in solutions and in crystal have been performed following 
change in protein secondary structure by FT-IR spectroscopy to assess whether the differences in 
stability of these variants in solution correlates with the stability in the protein crystal.  
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III 
 
The heterotrimeric complex MHC-I triggers an immune response by displaying antigenic peptides on 
the cell surface for recognition by appropriate T cells. It has been previously demonstrated how the 
stability of the MHC-I complex in vitro is correlated to the bioavailability of the complex on the cell 
surface and to the affinity toward T cell receptors. 
Aim of the work is the exploration of the impact on protein fold stability of complex-stabilizing point 
mutations on the tumour antigenic peptide NY–ESO-1157-165, valid candidate for cancer vaccines. In 
this context, eight MHC-I bearing eight peptide variants have been biophysically characterized. 
Moreover, a structural characterization of the complexes has been performed to investigate the 
structural features that may contribute to MHC-I stabilization. 
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3. Results  
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Rational design of mutations that 
change the aggregation rate of a 
protein while maintaining its native 
structure and stability
Carlo Camilloni1,2, Benedetta Maria Sala3, Pietro Sormanni1, Riccardo Porcari4, 
Alessandra Corazza5, Matteo De Rosa3, Stefano Zanini5, Alberto Barbiroli6, 
Gennaro Esposito5,7, Martino Bolognesi3,8, Vittorio Bellotti4, Michele Vendruscolo1 & 
Stefano Ricagno3
A wide range of human diseases is associated with mutations that, destabilizing proteins native state, 
promote their aggregation. However, the mechanisms leading from folded to aggregated states 
are still incompletely understood. To investigate these mechanisms, we used a combination of NMR 
spectroscopy and molecular dynamics simulations to compare the native state dynamics of Beta-2 
microglobulin (β2m), whose aggregation is associated with dialysis-related amyloidosis, and its 
aggregation-resistant mutant W60G. Our results indicate that W60G low aggregation propensity can 
be explained, beyond its higher stability, by an increased average protection of the aggregation-prone 
residues at its surface. To validate these findings, we designed β2m variants that alter the aggregation-
prone exposed surface of wild-type and W60G β2m modifying their aggregation propensity. These 
results allowed us to pinpoint the role of dynamics in β2m aggregation and to provide a new strategy to 
tune protein aggregation by modulating the exposure of aggregation-prone residues.
Protein misfolding and aggregation is a widespread phenomenon associated with the intrinsic properties of pol-
ypeptide chains1,2, indeed, it has been observed that the cross-β structure characteristic of amyloid aggregates 
often represents the most thermodynamically stable state of polypeptide chains3,4. Thus, at least at typical cellular 
concentrations, proteins can be thermodynamically metastable in their native states and do not aggregate only 
because of the presence of high kinetic barriers3,4. It is therefore crucial to uncover the strategies that proteins 
adopt to remain soluble and escape aggregation in vivo, and shedding light on the design principles against aggre-
gation would allow a better control of this process5,6.
Protein aggregation mechanisms can be identified from the analysis of the many amyloidogenic mutants that 
have been characterized in recent years, including those of transthyretin, lysozyme, β2m, and gelsolin5,6. Known 
mutations in these proteins destabilize their native states, often by increasing their dynamics and flexibility7–11. 
When destabilized, native states can undergo larger structural fluctuations, or even unfolding, thus favoring the 
formation of non-native interactions and, ultimately, the deposition into amyloid aggregates11.
To determine the molecular origins of these processes, we compare here wild type β 2m and its W60G mutant, 
to investigate the correlation of thermodynamic stability and conformational flexibility versus aggregation pro-
pensity. β 2m is a single-domain protein, characterized by a seven-stranded β -sandwich fold typical of the immu-
noglobulin domain family; β -strands within the protein are named from A to G (Fig. 1A)12. β 2m is the light 
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chain of the major histocompatibility complex (MHC) class I12–14. While β 2m is highly stabilized by the inter-
actions within the MHC class I15, when β 2m is released as a monomer, it may turn into the etiological agent of 
dialysis-related amyloidosis, a condition triggered by renal impairment and the subsequent chronic accumulation 
of abnormally high concentrations of β 2m in body fluids. β 2m deposits in joints, bones and muscles, lead to 
movement impairment, bones fragility and articular pain16,17.
Recent efforts in elucidating the molecular determinants of β 2m aggregation have highlighted the complex 
role played by W60, an evolutionary-conserved, solvent-exposed residue. In silico simulations of wild-type β 2m 
suggested that W60 is heavily involved in intermolecular interactions18, therefore the non-natural mutation to 
Gly (W60G) was prepared, yielding to a variant with unexpected properties19. In particular, the (unfolding) ther-
modynamic stability of this mutant is higher than that of the wild-type β 2m, with Δ G°(H2O) 22.2 ± 2.0 and 
27.6 ± 3.3 kJ mol−1, for wild-type and W60G variants, respectively19. While both wild-type and W60G aggregate 
under strongly denaturing conditions (pH 2.5), W60G shows low aggregation propensity using the standard pro-
tocol at pH 7.4 and 20% TFE, conditions under which wild-type β 2m aggregates abundantly19,20. A wealth of data 
indicates that the DE loop, where W60 is located, is under backbone geometrical strain in wild-type β 2m18,21–23. 
The introduction in the DE loop of a residue endowed with higher conformational freedom, such as Gly, relieves 
the local conformational strain and results in a β 2m variant thermodynamically more stable in solution, with a 
decreased aggregation propensity19,24. The above observations prompted us to select wild-type β 2m and its W60G 
variant as a well-suited system to investigate, besides protein thermodynamic stabilities, other mechanisms that 
may tune protein aggregation propensity.
To gain further understanding into the molecular bases of the different solution properties displayed 
by wild-type and W60G forms, we characterized the equilibrium distribution of conformations for the 
two variants. We employed NMR solution chemical shifts measured under native conditions in combina-
tion with replica-averaged metadynamics (RAM) simulations25–27. RAM simulations allow integrating the 
physico-chemical knowledge of a system (i.e. the interactions among its atoms as defined in molecular force 
fields) with the knowledge derived by experimental measurements (i.e. chemical shifts), to provide an atomistic 
description of the Boltzmann distribution of structures that satisfy the experimental data and the maximum 
entropy principle28. Comparison of the resulting ensembles shows how the W60G mutation decreases the overall 
aggregation propensity by increasing the average β -structure content and by perturbing the overall dynamics of 
surface residues. To test whether a better average protection of aggregation-prone surface residues can actually be 
key in regulating protein aggregation, we designed surface mutations aiming to either decrease the aggregation 
propensity of wild-type β 2m, or increase that of the W60G variant. We found that the designed mutants do not 
cause any relevant structural rearrangement in the protein core, nor they alter β 2m thermodynamic stability, but 
display striking different aggregation propensities. Thus, the approach presented here helps to decouple different 
molecular determinants contributing together to determine a high aggregation propensity, this strategy may be 
used to understand and modulate the aggregation properties of other folded proteins without affecting their 
structures and thermal stabilities.
Results
NMR chemical shift assignment of the W60G mutant. Wild-type β 2m was already characterized in 
terms of 1H, 15N and 13C backbone and side chain assignment29, whereas for the W60G only 1H resonances 
and amide nitrogens were previously attributed19. Here we extended the NMR analysis to the full backbone, as 
well as to Cβ and Hα , and in favorable cases to Hβ . The 15N-1H HSQC spectrum at 310 K (Fig. 1B), shows 108 
(96 belonging to HNs) of the 110 peaks expected. The missing amide peaks belong to K58 and S88, which were 
not observed also in the wild-type type form due to unfavorable local exchange broadening30. In fact only at very 
low protein concentration (less than 50 m M), where the presence of dynamic dimers is scarce, these two peaks 
are visible. Moreover A15 and Y66 NHs overlap in the HSQC spectrum acquired at 500 MHz. The sequential 
backbone assignment was obtained using heteronuclear 3D triple-resonance experiments acquired on 13C, 15N 
Figure 1. NMR assigment of β2m. (A) Ribbon representation of the crystal structure of human β 2m  
(pdb code 2YXF) with β -strands labeled according to standard nomenclature. W60 is shown as sticks.  
(B) HSQC [1H, 15N] spectrum recorded at 11.7 T (500.13 MHz for 1H), 310K, of [U-13C, U-15N W60G β 2m] 
0.5 mM dissolved in 70 mM phosphate buffer at pH =  6.6 and 100 mM NaCl.
www.nature.com/scientificreports/
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uniformly labeled sample. The assignment percentage for C’, Cα , Cβ were 93%, 97%, 86%, respectively. 95% of 
Hα and only 23% of Hβ were identified through (H)CCH-TOCSY spectra.
Native state dynamics of β2m. We determined the conformational properties of wild-type and W60G 
β 2m using NMR chemical shifts and molecular simulations in the RAM framework25–27. In RAM the sampling of 
the conformational space is enhanced by employing bias-exchange metadynamics31, while the quality of the force 
field is improved by including the information content of equilibrium experiments, i.e. NMR chemical shifts25,26, 
within the framework of the maximum entropy principle28.
Using the RAM approach we obtained a converged sampling, resulting in a free energy landscape within a sta-
tistical uncertainty of less than 2 kJ/mol for free energies up to 20 kJ/mol (Figs S1 and S2). The free energy surfaces 
for the wild-type and W60G β 2m variants, as a function of the side-chain rotamer distribution (AlphaBeta collec-
tive variable, AB, see Methods) and the anti-parallel β -structure content (AntiBetaRMSD collective variable, β , 
see Methods), are shown in Fig. 2A,B. The free energy surfaces indicate that W60G hosts on average a higher con-
tent of β -structure than the wild-type protein. By closer inspection, the main differences in the β -sheet popula-
tions (β ) are localized in the B, C’ and D strands (Fig. 2C). These differences shows how the local relaxation of the 
strain of the backbone in position 60 propagates along the D strand up to C’ due to its reduced freedom on one 
side and through space to the C-terminal of the B strand on the other. Wild-type β 2m shows a single well-defined 
minimum at β = 22 and AB = 20, and a low-populated minimum at higher β -sheet content (β = 24), compatible 
with a fully structured D strand. Conversely, W60G shows two minima of comparable energy, one at β = 24 and 
AB = 18, and the other at β = 22 and AB = 22; both minima are close to the two minima of the wild-type protein 
(Fig. 2). The effect of the W60G mutation on the dynamics of β 2m is also reflected by the reduced structural fluc-
tuations in the 25–31 and 40–60 regions (B,C,C’ and D strands) as shown in Fig. S3.
Analysis of sequence and structural properties leading to protein aggregation. Wild-type and 
W60G are characterized by significantly different aggregation properties. While the wild-type protein can form 
fibrils under both neutral (pH 7.4) and acidic (pH 2.5) conditions, the mutant yields fibrils only under denatur-
ing (pH 2.5) conditions19,20. Such difference was explained in terms of the different thermodynamic stability of 
the two variants. NMR relaxation studies under conditions far from those favoring aggregation confirm that the 
Figure 2. β2m RAM Ensembles. Free energy surfaces (in kJ/mol) for wild-type (A) and W60G β 2m (B) as 
a function of the side chains rotameric state, AB, and the antiparallel β -structure content (β ). (C) β -structure 
populations for wild-type (red bars) and W60G (black bars) β 2m. The seven β -strands building the protein fold 
are identified by A through G labels.
www.nature.com/scientificreports/
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wild-type species exhibits a much more pronounced association propensity than the W60G mutant30. However, 
additional insight can be obtained by analyzing the amyloidogenic properties of β 2m in terms of sequence- and 
structure-based properties. The intrinsic and structurally corrected aggregation propensities were assessed using 
the CamSol method (Fig. 3A,B)32, which is highly accurate in predicting mutation-induced changes in protein 
solubility, a property often strongly correlated with aggregation33. In the present work we used aggregation pro-
pensity scores that are the inverse of the CamSol solubility scores (so that higher scores represent higher aggre-
gation propensity) and, in order to analyze the RAM ensemble, we have defined a ‘total structurally-corrected 
score’ (see Methods). The latter can be used to predict the tendency to aggregate of individual conformations of 
the ensemble; it is calculated from the structurally corrected CamSol profile in the same way the CamSol intrinsic 
score is calculated from the intrinsic profile32. The ensemble average of the total structurally corrected scores for 
the two β 2m variants is − 0.59 ± 0.01 and − 0.66 ± 0.01, for the wild-type and W60G, respectively. Such scores 
are in keeping with the experimental aggregation data, i.e. wild-type β 2m is more aggregation prone than W60G 
β 2m under native conditions.
The intrinsic and the structurally corrected profiles are represented in Fig. 3C,D, color-coded on the struc-
tures of wild-type and W60G. Aggregation-prone residues are mostly located in the B, E strands, and at the 
C-terminal of the F strand (Fig. 3A). These β -strands are the central strands in the two β 2m β -sheets; the B and 
E strands are flanked by the A and D strands (in the 4-stranded β -sheet), while the F strand is surrounded by 
the C and G strands (in the 3-stranded β -sheet) (Fig. 1A). It is noteworthy that all these flanking β -strands con-
sistently prove less aggregation-prone than the central ones, according to both the intrinsic and the structurally 
corrected CamSol profiles (Fig. 3B), an observation that may be interpreted as a strategy to protect the protein 
from unwanted aggregation. Furthermore, at least half of the aggregation-prone residues point towards the pro-
tein core, thus being excluded from the chance of unwanted interactions with other proteins under native condi-
tions (Fig. 3B). The analysis recognizes the A strand and the CD and EF loops as the protein protective regions. 
Interestingly, the strong aggregation propensity of the naturally occurring truncated β 2m variant, devoid of the 
first six residues (Δ N6)34, can be rationalized in the above context; in fact, by shortening the protective A strand, 
the C-terminal residues of the B strand, which are the most aggregation-prone, become solvent exposed. By the 
same token, one may also explain the behavior of D76N-β 2m, the naturally occurring mutant responsible for a 
severe systemic amyloidosis10. In fact, the ‘fatal’ mutation leading to the most amyloidogenic isoform of β 2m so 
far described occurs in the protective EF loop.
Figure 3. Predicted aggregation properties of β2m wild-type and W60G variants. (A) Intrinsic aggregation 
profiles of the wild-type (red) and W60G (black) variants. (B) Structurally corrected profiles calculated as 
ensemble averages for β 2m wild-type (red bars) and W60G (black bars). In (A,B) values larger than 1 denote 
aggregation-prone regions. (C) Projection on the structure of wild-type β 2m of the intrinsic profile (left) and 
the structurally corrected profile (right). The color code is blue for aggregation-resistant residues and red for 
aggregation-prone residues. (D) Same as (C) for the structure of W60G β 2m.
www.nature.com/scientificreports/
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The structurally corrected aggregation propensity profile for W60G shows an increase in the average protec-
tion of the aggregation-prone residues (Figs 3B,D and 4). Such an effect can be linked to the reduced strain at 
site 60 that propagates thorough the D strand in the 4-stranded β -sheet to the opposite β -sheet (Fig. 3D); indeed 
W60G shows on average a higher β -structure content distributed along all its β -strands (Fig. 2A–C) together with 
reduced fluctuations (Fig. S3).
Rational design of mutants with different aggregation propensities. The above analysis sug-
gests then that the role of the W60G mutation in reducing aggregation is not exclusively due to stabilization 
of the protein. In particular, by optimizing the geometry of the D strand through the W60G mutation, all the 
aggregation-prone residues of the central β -strands, in both β -sheets, become on average more protected (Fig. 3). 
These observations suggest that by specifically modulating the average surface properties arising from the native 
state dynamics, it may be possible to tune the aggregation properties of β 2m.
To test the role of dynamics on β 2m native state aggregation we searched for mutations able to decrease the 
aggregation propensity of wild-type β 2m, on one hand, or increasing the aggregation propensity of W60G, on the 
other, without affecting their thermodynamic stabilities and structures. In Fig. 4A the residues with an intrinsic 
score higher than 1, for which the W60G mutation results in a large variation (> 0.2) of the structurally corrected 
score with respect to the wild-type are highlighted. These seven residues are all located in the central strands of 
both β -sheets. Table S1 reports the amino acid substitutions, known within the β 2m protein family, that occur at 
such selected residue sites35; the sequence data highlight that none of these sites show strong residue conserva-
tion. Mutations of residues 65 and 67, in the E strand, have already been studied36, even though under different 
experimental conditions, showing that residues in this β -strand are critical for aggregation. Mutations in the F 
strand have not yet been investigated. By calculating the change in the protein intrinsic score upon all the possible 
single mutations at these seven sites (Fig. 4B), we suggest that the V85E β 2m variant should reduce the wild-type 
aggregation propensity, while two alternative specific mutations in the W60G β 2m variant (W60G-Y63W and 
W60G-N83V) are expected to weakly (the former) or largely (the latter) increase the W60G aggregation propen-
sity. Indeed, the score of V85E β 2m is lower than that of W60G, the one of W60G-N83V is comparable to that of 
the wild-type while W60G-Y63W is slightly larger than that of W60G (Fig. 4B). All three mutations are located 
on the protein surface, and two of them are also naturally occurring in vertebrates other than human; hence they 
should cause little perturbation to the protein structure and stability. It is noteworthy that the effects of surface 
mutations introducing or removing surface charges, do not correlate simply with aggregation propensity: the 
V84D and Y86E mutations in acylphosphatase from S. solfataricus do not protect the protein from unfolding and 
aggregation37. Furthermore, a D to N systematic scanning in β 2m indicated that the removal of a negative charge 
triggers measurable effects in aggregation propensity only when the D to N mutation occurs at a specific site38.
Figure 4. Rational design of β2m mutants. (A) Aggregation-prone residues (intrinsic score > 1) for which 
the protective effect of the W60G mutation is the highest, defined as those residues with the largest change in 
the structurally-corrected score between the wild-type (red) and W60G (black) β 2m. (B) Predicted aggregation 
propensity scores calculated using CamSol for all possible amino acid substitutions at the sites shown in panel 
A in the wild type (left box-plot in red) and in the W60G variant (right box-plot in black). The red and black 
dashed lines correspond to the aggregation propensity score of the WT and the W60G variant, respectively. 
Aggregation-protective and aggregation-promoting mutations selected for experimental validation are flagged. 
V85E and N83V mutations have been chosen as those with the largest predicted effect, while Y63W was 
chosen as a weakly aggregation promoting mutation. In each box the horizontal line denotes the median of the 
distribution; whiskers extend from the 5th to the 95th percentile of the distribution and boxes from the lower to 
the upper quartile.
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Structural characterization of three rationally-designed β2m surface mutants. The three β 2m 
surface mutants that we rationally designed (V85E, W60G-N83V, W60G-Y63W) were produced as recombinant 
proteins, purified to homogeneity, crystallized, and their structures determined at high resolution (1.75 Å, 1.49 Å, 
1.70 Å, for V85E, W60G-Y63W, and W60G-N83V, respectively). Although the three crystals belong to the same 
space group, unit cell edges differ and crystal packing is distinct for each of the three mutants (see methods). The 
three structures display electron density of excellent quality along the polypeptide chains. Data collection and 
refinement statistics are reported in Table S2.
Inspection of the refined X-ray crystal structures shows that all three surface mutations are well tolerated in 
the β 2m fold, and backbone conformational changes are relegated to loops (Table S3). Indeed, the largest struc-
tural deviations in the three mutants occur far from the mutation sites, at the AB loop (residues 12–21) that is 
typically in an open conformation in the crystal structures of isolated β 2m, while it is closed over the rest of the 
β -sandwich when β 2m is part of the MHC class I and in few structures of monomeric β 2m39–41. Notably, the AB 
loop in a closed conformation is consistently observed in solution NMR structures42. In particular, for the crystal 
structures here reported of the W60G-Y63W and V85E mutants a closed AB loop conformation was observed; by 
contrast, the wild-type β 2m, W60G and W60G-N83V 3D structures exhibit an open AB loop conformation. All 
these data suggest that the AB loop can easily adjust to different conformations, which, in the case of the present 
mutants, is likely the result of convenient molecular packing in the crystals.
Detailed inspection shows that the structure of the W60G-N83V mutant is perfectly superimposable onto that 
of W60G β 2m. In fact, in W60G the side chain of N83, which is located on the F-strand, although surrounded by 
two charged residues (E36 and R81), does not establish any hydrogen bond with the neighboring residues; thus, 
the N83V substitution leaves both the conformation of residue 83 and of the surrounding side chains unaffected 
(Fig. 5A).
Residue 63 lies in the E strand, in close vicinity of the DE loop (residues 57–60). The Y63W mutation trig-
gers just a minor reorientation of the DE loop backbone, but is responsible of extensive, though local, side chain 
reorganization. In the structure of the W60G-Y63W mutant the bulkier W63 side chain flips away from the DE 
loop and towards the D-strand, compared to what is observed in W60G. Such movement has two consequences: 
(1) the shift of S55, F56, L54 and F62 side chains away from W63, and (2) the DE loop moves about 2 Å towards 
residue 63 (Fig. 5B).
The comparison of the wild-type β 2m and the V85E mutant structures reveals that the mutation does not elicit 
local rearrangements in the FG loop where E85 is located, nor in the surrounding residues. The 3D-structure of 
V85E mutant displays modified conformations in the DE and C’D loops; however, given that both regions are far 
from the mutation site, these differences may be due to the specific crystal packing (Fig. 5C).
Stability of the rationally-designed β2m surface mutants. The stability of all three mutants 
described above was evaluated by monitoring their thermal denaturation through far-UV CD measurements. 
Figure 5. Structure, stability and aggregation of the β2m variants. (A) The superimposed structures of 
the W60G and W60G-V83N mutants are shown in cyan and yellow, respectively. (B) Zoom of the (D and E) 
strands: the superposed structures of the W60G and W60G-Y63W are shown in cyan and coral, respectively. 
(C) Superimposed structures of wild-type β 2m and the V85E variant, at the mutation site, shown in magenta 
and green, respectively. (D) Thermal unfolding of wild-type β 2m, of the W60G variant and of the three surface 
mutants, monitored by far-UV CD at 202 nm. In the table the measured Tm are reported (*the Tm of wild-type and 
W60G variants have been previously reported23). (E) Comparison of the kinetics of fibril formation of the various 
mutational variants of β 2m analyzed in this work monitored by fluorescence in a thioflavin T assay.
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In keeping with the goals set (i.e. designing mutants that maintained the same thermodynamic stability either 
of wild-type β 2m or of the W60G mutant) and with the outcomes of the crystallographic analyses, none of the 
three mutations was found to alter dramatically the protein stability. Upon V85E mutation, the wild-type β 2m 
stability was slightly impaired, with a Tm value decreased by about 3 °C relative to wild-type β 2m. The negative 
charge of E85 lies 4.5 Å away from the carboxylate of D34, the electrostatic repulsion between these two residues 
may contribute to the slightly lower stability observed for the V85E mutant compared to the wild-type protein 
(Fig. 5C). Conversely, introduction of the Y63W and N83V mutations (added to the W60G mutation) did not 
vary significantly the Tm value recorded for the W60G mutant (Fig. 5D).
Aggregation measurements of the rationally-designed β2m surface mutants. To further test the 
effects of the three designed mutations, the aggregation propensity of the V85E, W60G-Y63W, and W60G-N83V 
mutants was tested at pH 7.4 and in 20% TFE, conditions under which wild-type β 2m aggregates readily while the 
W60G mutant yields only small amounts of aggregates19,43. Figure 5E shows that the V85E mutation, despite being 
slightly less stable than the wild-type protein, almost totally abolished wild-type β 2m aggregation-propensity, and 
that the W60G-N83V variant presented a markedly increased aggregation trend with respect to W60G β 2m. The 
W60G-Y63W variant displayed the same very low aggregation propensity as the W60G mutant, suggesting that 
mutations should be chosen in order to maximize the difference of the total average CamSol score (Fig. 4B).
Discussion
As protein aggregates are often thermodynamically stable in living organisms1, the avoidance of the aggregation 
process has been optimized through evolution by means of multiple strategies44. While efficient protection mech-
anisms work at the cellular level by regulating protein homeostasis45,46, many strategies to prevent aggregation 
concern the properties of the native states of proteins, including a high thermodynamic and kinetic stability, 
limited conformational fluctuations, and the presence of structural motifs that are incompatible with the cross-β 
assembly1,4,47. As folded proteins are metastable with respect to aggregation3, mutation that destabilize the folded 
states can dramatically increase the rates of aggregation. Furthermore, mutations that change the accessibility to 
a high free energy state, without changing the overall stability of the protein native state, are enough to enhance 
aggregation11,48. Conversely, mutations that introduce structural protections on edge strands play a protective role 
independently of the overall protein stability37.
Here we investigated the different roles played by stability and dynamics in protein aggregation using human 
β 2m, a protein that, when released as a monomer and accumulated in patients’ sera, may become the etiological 
agent of dialysis-related amyloidosis, forming amyloid deposits in joints, bones and muscles17. Esposito et al. 
reported previously an engineered β 2m variant bearing the W60G mutation, which was found to be thermo-
dynamically very stable (Cm increased by 0.7 M GdHCl) and resistant to aggregation relative to the wild type 
β 2m19,20. To elucidate the molecular determinants underlying such distinct properties, we characterized the native 
state fluctuations of the wild-type protein and of the stable W60G mutant using NMR chemical shifts and RAM 
simulations, and analyzed the aggregation properties of the resulting conformational ensembles.
Our simulation results show that the W60G mutation greatly reduces the flexibility of the protein native state 
(Fig. S3), and increases the overall content of residues adopting β -structure (Fig. 2), in keeping with previous 
experimental data19,20,30. Moreover, our analysis shows that β 2m hosts three aggregation-prone regions located 
essentially in three β -strands that are central in the β 2m two β -sheets, i.e. strands B, E and F (Fig. 1A), and that 
in these regions those residues that are exposed on the surface are better protected on average in the W60G 
variant than in the wild-type (Fig. 3). The differences in the native state dynamics together with the similarity 
of their sequence-based intrinsic scores, explains the different behaviors observed under native and denaturing 
conditions, i.e. while both protein variants aggregate under denaturing conditions (pH 2.5), W60G shows little 
aggregation propensity under the standard aggregation protocol, at pH 7.4 and 20% TFE19,20.
To probe the role played by the residues in the three central β -strands in determining β 2m aggregation pro-
pensity, and to further investigate the protective effect of the W60G mutation, we designed three mutations aimed 
to modulate β 2m aggregation trends under native conditions, while leaving β 2m stability and structure unal-
tered. To this aim, we focused on mutations of protein surface residues that turned out to be better protected 
in the W60G ensemble compared to the wild-type protein. The V85E single site β 2m mutant, together with the 
W60G-Y63W and the W60G-N83V double mutants were accordingly designed and produced in recombinant 
form. Consistent with such rational approach, we found that all three surface mutants maintain unaltered the 
β 2m core structure (Fig. 5 and Table S2) and display fold stabilities very similar to wild-type β 2m (for V85E), or 
to W60G (for the two double mutants), respectively. Conversely, analysis of their aggregation properties indi-
cates that surface mutations can indeed modulate β 2m aggregation propensity. The V85E mutation, on the F 
strand, abrogates completely wild-type β 2m amyloidogenicity, under the tested conditions, despite being slightly 
less stable than the wild-type; the W60G-N83V mutant (residue 83 falls on the F strand) gains a non-negligible 
aggregation propensity relative to W60G without any difference in protein stability. We cannot rule out that the 
fibrillar aggregate may form following a different aggregation pathway compared to wild-type β 2m as it was 
shown in details for mutants of acylphosphatase from S. Solfataricus49. However in such case this phenomenon 
was coupled to very different thermodynamic stability of the native protein49. The W60G-Y63W double mutant, 
on the other hand, displays an aggregation trend comparable to W60G and in agreement with the small change 
in the aggregation score (Fig. 4B), indicating that this conservative mutation cannot encode noticeable changes 
of the aggregation propensity.
β 2m hosts extensive aggregation regions on protein surface (Fig. 3), this being rooted in its sequence and 
structure that are specifically optimized to be part of the MHC class I. In particular, the aggregation-prone res-
idues W60 and Y63 are buried at the interface between β 2m and the MHC class I heavy chain19, consistent 
with the observation that protein interface residues are typically aggregation prone50. On the contrary, the F 
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strand, which has not been previously studied, plays a pivotal role in the aggregation propensity of β 2m, and it is 
solvent-exposed in MHC class I. In particular, site 85 in human β 2m bears a dangerously aggregation-prone Val 
residue. Such apparent design error, however, could be reconciled with a recent observation15 whereby the MHC 
class I heavy chain stabilizes markedly the β 2m fold.
In summary our results provide an explanation for the resistance to aggregation associated with the W60G 
mutation of β 2m. This mutation not only brings a significant increase in the thermodynamic stability of the pro-
tein, but also generates a more regular and less flexible overall structure in which the surface aggregation-prone 
regions are better protected. We suggest that such second feature is primarily responsible for the reduced aggre-
gation propensity of this variant. Based on these observations, we showed that the aggregation propensity of 
β 2m can be tuned by mutating surface residues without affecting its structure and stability, thus highlighting the 
crucial role played by the dynamics of surface residues in protein aggregation. Our results elucidate a mechanism 
whereby the aggregation propensity of a protein can be modulated by mutations that change the average protec-
tion of its aggregation-prone surface residues with minor effects on the structure and stability of the protein itself.
Materials and Methods
Multidimensional NMR spectroscopy. All data were recorded on a U-13C, U-15N labeled W60G β 2m 
sample 0.5 mM in phosphate buffer 70 mM, NaCl 100 mM, pH 6.6, at 310K with a Bruker Avance 500 and with a 
Varian INOVA spectrometers operating at proton frequency of 500 and 800 MHz, respectively. Proton chemical 
shifts were referenced to 2,2-Dimethyl-2-silapentane-5-sulfonate sodium salt, DSS, whose resonance was set to 
0.0 ppm. 13C and 15N chemical shifts were referenced indirectly to DSS, using absolute frequency ratio51. Sequence 
specific assignment were achieved using [1H, 15N]-HSQC and [1H, 13C]-HSQC together with 3D triple-reso-
nance experiments, in particular by using the [15N, 1H]- HNCA/[15N, 1H]- HN(CO)CA for the identification 
of patterns of sequentially linked spin systems and 3D [15N, 1H]- HNCACB/[15N, 1H]-HN(CO)CACB pair of 
experiments, which allowed the identification of the amino acid types. 3D (H)CCH-TOCSY was used for the 
assignment of Hα and Hβ resonances.
The spectra were processed with Topspin 2.0 (Bruker Biospin) and analysed into the Sparky (T. D. Goddard 
and D. G. Kneller, SPARKY3, University of California, San Francisco) framework.
Molecular dynamics simulations. All the simulations in the present work were performed using 
GROMACS compiled with PLUMED and ALMOST. The system was simulated using the Amber03W force field 
in explicit TIP4P05 water. A time step of 2 fs was used together with LINCS constraints. van der Waals and 
short-range electrostatic interactions were cut-off at 0.9 nm while long range electrostatic was treated with the 
Particle Mesh Ewald method and a mesh size of 0.12 nm. The canonical ensemble was enforced by keeping the 
volume fixed and by thermosetting the system with the Nosé-Hoover thermostat at 310K. The starting confor-
mation for the wild-type was taken from the 1BMG X-Ray structure while for W60G was taken from the NMR 
structure 2VB5. The structures were protonated and solvated with 11500 water molecules in a dodecahedron box 
of 360 nm3 of volume.
Replica-averaged Metadynamics. RAM simulations were performed using chemical shifts as 
replica-averaged restraints and bias-exchange metadynamics. The bias-exchange metadynamics approach com-
bines replica exchange52 with metadynamics, in which several metadynamics simulations are performed in paral-
lel on different replicas of the system, each replica biasing a different collective variable (CV). Exchanges between 
the replicas are attempted periodically according to a replica-exchange scheme. Four replicas of the system were 
simulated in parallel at 310 K with a restraint applied on the average value of the CamShift back-calculated NMR 
chemical shifts where the force constant is set to 24 kJ/(mol ppm2).
Each of the four replica is bias along one of the following four collective variables, CVs: the anti-parallel β con-
tent (the ‘β ’ CV), the parallel β -sheet content (the ‘Pβ ’ CV), the AlphaBeta collective variable defined over all the 
chi1 angles for the hydrophobic side-chains (the ‘AB’ CV) and the AlphaBeta collective variable defined over all 
the phi and psi backbone dihedral angles of the protein (the ‘bbAB’ CV). The choice of the secondary structures 
CVs was guided by the fact that the protein is a full beta protein. The to AlphaBeta CVs are designed to sped up 
the fluctuations of the backbone and the side-chains irrelevant of their specific conformation. Gaussians deposi-
tion was performed with an initial rate of 0.125 kJ/mol/ps, a bias-factor of 8 and with σ values set to 0.1, 0.04, 0.16 
and 0.25, for β , Pβ , AB and bbAB, respectively. Furthermore, in order to limit the extent of accessible space along 
each collective variable and correctly treat the problem of the borders, we set the bias as constant outside a defined 
interval for each CV; intervals were set to 19–29, 3–7, 14–30 and 47–71 for the four CVs, respectively. Each replica 
have been evolved for 200 ns, with exchange trials every 50 ps.
The sampling of the four replicas was used to generate a four-dimensional free energy landscape, as a function 
of the before mentioned CVs, where a set of microstates is identified by dividing the four-dimensional CV-space 
into a homogeneous grid of small dimensional hypercubes and their free energy is obtained using a standard 
weighted histogram analysis. Bi-dimensional FESes are obtained integrating out the variables not showed.
Cloning, mutagenesis, expression and purification. Recombinant vectors pEX containing genes 
encoding for W60G-Y63W, W60G-N83V variants, flanking NdeI/XhoI sites were purchased from Eurofins 
MWG Operon©. An empty vector pET-29b and the vectors carrying the β 2m variants were digested with NdeI 
and XhoI enzymes (New England Biolabs (UK) Ltd©) to obtain a linearized pET29 vector and the isolated genes. 
Wild-type β 2m, W60G-Y63W and W60G-N83V genes were inserted in pET-29b vector with a ligation reaction 
(Thermo Scientific Rapid DNA Ligation Kit, Life Technologies©). pET-29b-WTβ 2m plasmid was used as template 
DNA for Site-Directed Mutagenesis to obtain the V85E mutant. The following primers were used: 5′ -GCC TGC 
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CGT GTG AAC CAT GAG ACT TTG TCA CAG CCC-3′ , 3′ -GG GCT GTG ACA AAG TCT CAT GGT TCA 
CAC GGC AGG C-5′ . All mutants were expressed and purified as previously reported34.
Crystallization and X-ray structure determination. All mutants were crystallized with sitting drops 
technique. Lyophilized W60G-Y63W, W60G-N83V and V85E β 2m mutants were solubilized in ddH2O at a con-
centration of 10 mg/mL, 8.5 mg/mL and 8 mg/mL respectively at 20 °C. β 2mW60G-Y63W crystals were obtained 
in 0.1 M HEPES pH 7.5, 20% (w/v) PEG 10K buffer (Crystal Screen HTTM, Hampton). The crystals were cryo-
protected in 0.08 M HEPES pH 7.5, 18% PEG 10K, and 20% (v/v) glycerol and flash-frozen in liquid nitrogen. 
W60G-N83V crystallized in 0.1 M MES pH 6, 21% PEG 4K, 15% glycerol, 0.2 M ammonium acetate, while V85E 
mutant was crystallized in 0.1 M ammonium acetate pH 5.5, 30% PEG 4K, 15% glycerol and 0.2 M ammonium 
acetate. The crystals were flash-frozen using mother liquor as cryoprotectant.
X-ray data were collected at ESRF (European Synchrotron Radiation Facility of Grenoble–France) at the 
ID23-2 beam line. The diffraction data were analyzed and processed using MOSFLM53, the crystal symmetry was 
then verified by POINTLESS54 and the intensities were merged with SCALA55. The crystal structure was deter-
mined by molecular replacement using MOLREP56 using the structure of W60V β 2m mutant (pdb code: 2Z9T) 
as searching model22. The model molecules placed in the asymmetric unit were subjected firstly to a rigid-body 
refinement and then to a restrained refinement using Phenix Refine in the Phenix program suite57. Manual model 
building, addition of water molecules and ligands were then performed using the molecular graphic software 
Coot58.
All three mutants crystallized in C2 space group however the underlying crystal packing is different: the two 
double mutants (W60G-Y63W, W60G-N83V) have one molecule in the asymmetric unit (AU); however, the dif-
ferent conformation of the AB loop determines distinct intermolecular interactions in the crystals. Unusually, the 
AU of the V85E structure contains two molecules. These different crystal packings determine some changes in the 
protein regions involved in the intermolecular interactions, however, these differences are not deemed relevant 
for the discussion on the properties of the three mutants.
Circular dichroism spectroscopy. Thermal stability experiments, performed in the far-UV region, were 
carried out on a J-810 spectropolarimeter (JASCO Corp., Tokyo, Japan) equipped with a Peltier system for tem-
perature control. The protein concentration was 0.1 mg/mL in 50 mM sodium phosphate pH 7.4. The tempera-
ture ramp measurements were recorded from 20 to 95 °C (temperature slope 50 °C/hour) in a 0.1 cm path length 
cuvette and monitored at 202 nm wavelength. Tm was calculated as the first-derivative minimum of the traces. 
Spectra before and after unfolding ramp were recorded (260–190 nm).
Aggregation assays. Samples (100 m L) of recombinant variants W60G, V85E, W60G-Y63W, W60G-N83V, 
and wild-type β 2m at 100 m M in 50 mM phosphate buffer (pH 7.4), 100 mM NaCl, 20% trifluoroethanol and 
containing 10 m M Thioflavin T (ThT) (SIGMA), were incubated at 37 °C in Costar 96-well black- wall plates 
sealed with clear sealing film (4TITUDE) and were subjected to 900 rpm double-orbital shaking. In each well 
fragmented fibrils of wild type β 2m were added as seeds. Bottom fluorescence was recorded at 15-min intervals 
(BMG LABTECH FLUOstar Omega). Fluorescence was monitored in three or more replicate tests.
NMR assignment deposition. 1H, 15N and 13C assignments of W60G β 2m have been deposited to 
Biological Magnetic Resonance Bank with accession code 25809.
Structure deposition. Atomic coordinates and structure factors for the β 2m mutants W60G-Y63W, 
W60G-N83V, V85E have been deposited with the Protein Data Bank, with accession codes 5CFH, 5CKA and 
5CKG, respectively.
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Abstract 
 
β2-Microglobulin (β2m) is the 99 residues light chain of Major Histocompatibility Class I complex 
(MHC-I). Wild type (WT) β2m is known to aggregate as amyloid fibrils Dialysis Related Amyloidosis 
(DRA) while the D76N destabilizing mutation is linked to a genetic systemic amyloidosis. 
β2m has been object of many mutational studies to investigate the molecular bases of its aggregation 
propensity. These analyses have revealed that Trp60, among other residues, plays a crucial role for β2m 
stability. In particular, W60G β2m mutant, has an increased conformational stability and a reduced 
amyloidogenicity compared to WT β2m.  
In this work, we seek a better understanding of the relationship between protein stability (usually 
measured in solution) and the interactions present in a protein crystal.  To such aim, the set of these 
three β2m variants, WT, W60G and D76N, is an ideal system given their differences in stability and 
aggregation properties but their identical crystal packing. 
The changes in secondary structure content have been monitored at increasing temperature on protein 
crystals compared to the protein in solution by Fourier transform infrared spectroscopy (FT-IR). 
Denaturation of proteins in the crystalline state is observed at much higher temperatures compared to 
solution; however, the differences in protein stability between the three variants are evident in crystalline 
form and they agree with the trend observed in solution.  
This work provides further insights in the biophysical properties of protein molecules in solid crystalline 
form.  
 
  
Introduction 
 
Human β2-Microglobulin (β2m), the light chain of Major Histocompatibility Class I complex (MHC-
I), is a 99 residues protein with an immunoglobulin-like fold. It is composed by seven β-strands that 
arrange in two β-sheets organized in the classic β-sandwich structure stabilized by an intramolecular 
disulphide bond (1).  
WT β2m is the causing agent of an amyloidosis affecting patients undergoing to long-term 
haemodialysis, condition known as dialysis-related amyloidosis (DRA) (2). Moreover, its only known 
genetic variant D76N is responsible for a familial systemic amyloidosis (3). These two kinds of 
amyloidosis are completely unrelated and differ for deposits tissue localization (4). In DRA, WT β2m 
aggregates selectively in bones and ligaments due to the high concentration of protein in the plasma (5). 
The genetic-type of amyloidosis, instead, is not triggered by any increase in β2m concentration; the 
amyloid fibres deposit in visceral organs, particularly in liver, kidney, spleen, and heart (3). 
WT and D76N β2m displays different properties in vitro: the D76N mutant presents a strongly 
decreased protein stability, higher propensity to aggregation, besides forming fibrils even under native 
conditions (6, 7).  
β2m has been object of many mutational studies to investigate the molecular bases of its aggregation 
propensity. Particular attention has been focused on D-E loop (8, 9). This loop is involved in the binding 
with the heavy chain for MHC-I formation, and becomes solvent exposed once β2m is released from 
the complex (10). The dynamic properties of this region have been associated to the strained 
conformation in the WT β2m backbone structure. The replacement of Trp60 with a Gly residues (W60G) 
is associated to a structural relaxation of the DE-loop, resulting in an increased protein stability and a 
decreased amyloidogenicity of W60G variant (9, 11, 12).  
Despite the β2m variants above described (WT, D76N and W60G) display quite different stabilities and 
aggregation propensities, crystallographic analyses of such mutants showed strong overall conservation 
of the native WT β2m structure (Figure S1) (3, 13). 
Indeed, the structure determined by X-ray diffraction on protein crystals is an average of contributions 
from all the different conformational states of the molecule during the data collection time. Thus, X-ray 
diffraction experiments provide only limited information on protein dynamics (14) (i.e. poor defined 
electron density in flexible and/or disordered regions (15)), and may be affected by crystal packing 
interactions. 
Consequently, protein crystal structures are regarded as rigid and molecules are caged in the crystal 
lattice, leading to the general view that little can be learnt about stability and protein dynamics from 
proteins in the crystalline form. Nevertheless, it should be possible to derive biophysical properties from 
protein crystals, given the fact that proteins retains their native structure and thus their specific intra-
molecular interactions (16, 17). 
Protein crystallization is determined by specific chemical attraction between macromolecules that result 
in the onset of intermolecular (ionic) bonds within the crystal. Bond strengths may be estimated by 
assigning binding energy to hydrogen bond or other ionic contacts, water-mediated hydrogen bonds, 
and other van der Waals interactions (18).  
Recent advances in high-resolution solid-state NMR (ssNMR) illustrate the potential for detailed, and 
site-specific dynamic studies of microcrystalline proteins under time scales not observable by other 
techniques. SsNMR also opens to the possibility of detecting structural heterogeneity in sample as the 
presence of slightly different conformations. Interestingly, this structural polymorphism observed in 
ssNMR spectra matches with regions that showed dynamics in solution NMR experiments on different 
timescales (19-21). To date, concerns remain on whether protein stability and dynamics assessed in 
crystals may be representative of what is observed in solution and ultimately in vivo.  
The present work aims to address this issue using the above-described WT, D76N and W60G β2m 
variants. Such proteins offer crucial advantages: their biophysical properties have been thoroughly 
characterised; furthermore these three β2m variants crystallise under the same conditions and have an 
identical crystal packing (3, 22). Thus, we expect that the results we obtained should be free of spurious 
crystallisation artefacts, while reflecting changes on protein stability due to the different mutations. 
Therefore, we followed through Fourier transform infrared (FT-IR) spectroscopy the changes in 
secondary structure of these proteins in solution and as crystals. FT-IR spectroscopy has been widely 
adopted for the analysis of protein samples in different conditions, resulting well suitable to compare 
the secondary structures of proteins both in solution and in crystals (23-26). Moreover, a recently 
published work by our group, gave new insights into the correlation between the structural changes 
induced by single mutations and β2m conformational stability and aggregation propensity through FT-
IR analysis and protocols how to acquire high quality spectra in solution and in single crystal were 
reported (27). 
In the present work FT-IR spectra of the three β2m variants were collected in solution and in crystalline 
form. Temperature ramps were carried out to monitor fold stability. Expectedly our data indicate an 
increased structural order in the crystals compared to the protein in solution; while temperature ramps 
show that the crystalline form exerts a marked stabilising effect on protein molecules compared to 
protein in solution. Nevertheless, the differences in protein stability between the three variants are well 
detectable in crystalline form and they well correlate with the trend observed in solution. 
  
Methods 
 
β2-Microglobulin expression and purification.  
All b2m variants were expressed in BL21 (DE3) pLysS E. coli strain as inclusion bodies. The proteins 
were extracted and purified following previously published protocols (28). 
 
Crystallization and sample preparation for Fourier transform infrared (FT-IR) spectroscopy. 
Lyophilized WT, W60G and D76N β2m variants were solubilized in ddH2O at a concentration of 8.5 
mg/ml. All mutants were crystallized with sitting drops technique at 20°C. 160 µl of protein solution 
was mixed in a bridge with the same amount of 0.1 M MES pH 6, 27% PEG 4K, 15% glycerol, and 
placed against 0.1 M MES pH 6, 30% PEG 4K, 15% glycerol as reservoir solution. In few days, needle-
like crystals were grown. Before FT-IR measurement the crystallization drop was collected and 
centrifuged at 2000 rcf for two minutes. Once removed the supernatant, the crystal pellet was washed 
and centrifuged three times with 0.1 M MES pH 6, 27% PEG 4K, 15% glycerol, all component 
solubilized in deuterated water to achieve the full D to H exchange of all exchangeable H. Crystals were 
then incubated overnight in 350 µl of the same deuterated buffer and washed once again before 
measurement. 
 
FT-IR of b2m crystals.  
For the IR analysis, crystals were resuspended in 20 µl of buffer (0.1 M MES pH 6, 27% PEG 4K, 15% 
glycerol) and then transferred in a temperature-controlled transmission cell with two BaF2 windows 
separated by a 150 µm Teflon spacer.  
FTIR spectra were collected at 25°C, in transmission mode, using a Varian 670-IR spectrometer (Varian 
Australia, Mulgrave, Australia), equipped with a mercury cadmium telluride detector nitrogen-cooled, 
under accurate dry air purging. Spectra were collected under the following conditions: 2 cm−1 resolution, 
25 kHz scan speed, 1000 scan coaddition, and triangular apodization.  
Thermal stability experiments, were carried out heating the sample from 25 °C to 100 °C at a rate of 0.4 
°C/min and 1 °C/min, collecting each transmission spectrum every 3.45 °C and 4.35 °C respectively. 
The FT-IR spectra were obtained after subtraction of solvent absorption, collected under the same 
conditions. Second derivative analysis (29) was performed by the Resolutions-Pro software (Varian 
Australia, Mulgrave, Australia) after Savitzky Golay smoothing of the measured spectra. 
 
FT-IR of b2m in solution.  
WT, W60G and D76N β2m variant were dissolved in deuterated buffer 50 mM Sodium Phosphate pH 
7.4, 100 mM NaCl, at a final concentration of 2.5 mg/ml. 20 µl of the sample were transferred in a 
temperature-controlled transmission cell with two BaF2 windows separated by a 150 µm Teflon spacer. 
Spectra and thermal stability experiment were collected at a rate of 0.4 °C/min following the conditions 
described above for the crystalline pellet and previously reported for β2m variants in solution (27). 
 
 
 
  
Results 
 
FT-IR spectra of WT β2m and mutated variants in solution and in crystalline state.  
The secondary structure of crystalline WT β2m was analysed by FT-IR spectroscopy in its crystallisation 
condition and the resulted spectrum was compared to the spectrum recorded in phosphate buffer 
solution.  
All in solution FT-IR experiments here presented have been firstly performed on WT β2m and on the 
other variants (see below) in the crystallisation solution to better compare the resulting data with the 
ones obtained from the crystalline state. However, under such conditions proteins are unstable and tend 
to precipitate leading to low quality non-reproducible measurements (see Supporting material and 
Figures S3). Thus, from now, experiments carried out on proteins in solution will refer to deuterated 
phosphate buffer solution as described in Methods. 
Figure 1 A shows the second derivative of the FT-IR absorption spectra of the samples. The second 
derivative of the spectrum of crystalline WT β2m display sharper peaks suggesting more rigid protein 
molecules compared to what observed in the solution spectrum below; this is in agreement with previous 
FT-IR studies on single WT β2m crystals (27). The peak related to the native antiparallel β-sheets, as 
expected, is downshifted from ~1636 cm−1 in solution to ~1628 cm−1, reflecting a stronger hydrogen 
bonding between the β-sheets of the protein related to the crystal packing (26, 27).  
Due to the increased structural order of the crystalline state, new and better-resolved bands are detectable 
in the crystalline sample. In fact, the turn absorption band at ~1670 cm−1 (30) is narrowed in WT β2m 
crystalline sample compared to solution. Moreover, two closed components at ~1689 and the new at 
~1677 cm−1 have been assigned to intramolecular β-sheet structures (30) and the new band at ~1649 cm−1 
has been related to loop regions. 
Spectra of the D76N and W60G variants were also performed both in solution and in crystalline state 
and compared to the analyses carried out on WT β2m, as shown respectively in Figure 1B and 1C. As 
mentioned above for the WT protein, the same relevant differences are notable between the spectra 
measured in solution and in crystal. Better resolved components are well detectable together with the 
downshift of the main native β-sheets band.  
Importantly, neither the comparison of spectra taken from crystalline samples nor the one from samples 
in solution detect significant differences between the three variants. 
 
Temperature ramps of the WT, D76N and W60G variants: protein unfolding.  
Temperature ramp of WT, W60G and D76N β2m variants in solution has been carried out at a heating 
rate of 0.4 °C/min. The loss of native β-sheet structure is followed by protein aggregation, as 
demonstrated from the appearance of new bands at ~1619 and 1684 cm−1, related to the formation of 
intermolecular β-sheet structures (Figure 4A and S2 A).  
The change in native secondary structure of WT, D76N and W60G crystallized variants were analysed 
increasing the temperature at a rate of 0.4 °C/min and 1 °C/min.  FT-IR spectra on crystals were recorded 
in the 25-100 °C temperature range (Figure 2 B, C and Figure S2 B, C).  
In all crystalline samples the progressive protein aggregation following the unfolding process is reduced 
compared to the protein in solution. Thus, the bands at ~1619 and 1684 cm−1 have a minor intensity at 
higher temperature in their spectra while the random coil component (peak around 1648 cm−1) is 
stronger, suggesting an increased unfolded population in the sample. Moreover, this trend is better 
noticeable increasing the temperature of the sample at 1 °C/min rate (Figure 4B and S2B). 
In addition, WT and D76N crystals display differences compared to the W60G variant: in Figure S2B, 
in WT and D76N, the magenta spectra have a higher intensity than in red (at 100 °C) indicating a partial 
melting of the formed aggregates at higher temperatures.  
Different rates result in non-negligible differences in the measured thermal stabilities (Figure 3A and 
Table 1). Thus, different heating rates result in an apparent change of the system stability, in other words 
the stability observed for all crystalline samples seems to have a relevant kinetic component. Crucially, 
at both heating rates the trend in fold stability of the three variants is in keeping with the one previously 
reported by experiments in solution (W60G > WT > D76N) (3, 11) (Table 1). 
We then compare the results recorded on crystalline material with those on solubilized proteins taking 
in consideration the different components described above in the previous paragraph. The temperature 
dependence of the native β-sheet peak intensity of the three variants in crystal and in solution are shown 
in Figure 3, while Table 1 reports the calculated melting temperature (Tm) extrapolated from the 
unfolding curves.  
It is noticeable an increasing in stability of the crystallized samples respect to the solubilized ones. This 
behaviour is in accordance with the downshift of the intramolecular β-structure component of the protein 
in the crystalline state thus linkable to the more order and tight structure of the protein under these 
conditions. Interestingly, the differences in stability among the three variants previously determined by 
CD experiments (3, 11, 13, 27) are visible in all conditions monitored by FT-IR: W60G β2m is the most 
stable variant followed in order by WT and D76N.  
 
Temperature ramps of the WT, D76N and W60G variants: crystal melting  
Further comparative analysis can be performed on the different events occurring during protein 
unfolding in the solution and crystalline state by monitoring the tyrosine band at ~1514 cm−1 (Figure 
4). This component reflects the environment of Tyr residues and displays minor changes in case of 
protein unfolding in solution (Figure 4 A). Conversely, in the crystalline samples the peak position 
corresponding to the maximum absorption by Tyr residues is shifting to higher wavenumbers. Thus, the 
temperature-dependence position of this peak can be plotted, resulting in an unfolding curve (Figure 4 
B) well reflecting the thermal stability of the variants. The change in Tyr absorption can be related to 
the crystal melting: the Tyr residues embedded into the crystal “are forced” to interact with the 
surrounding residues while, when crystals are disintegrating releasing protein molecules, the 
environment around the Tyr residues undergoes a drastic change. 
Another effect of the temperature, remarkable only on the crystalline samples, is the variation of the 
area of the absorption spectrum in the amide I region (data not shown). This area does not change 
significantly in the spectra recorded on the proteins in solution. Conversely, in the crystalline samples, 
as the temperature starts destabilizing the crystal, this band becomes more intense. This effect may 
provide a measure of how restrained the protein molecules are: indeed, they experience a highly 
constrained environment in the crystal lattice while once the crystal has melted unfolded protein 
molecules are completely free in solution.  
 
 
 
  
Discussion 
 
The present work aims to understand whether biophysical properties assessed in crystallo are 
representative of protein behaviour in solution. We thus take as model system three β2m variants WT, 
W60G and D76N, to carry out a comparative study of protein stability in solution and in the crystalline 
form given their equal crystal properties and their differences in stability and aggregation propensity. 
Thermal unfolding analyses of the proteins in solutions and in crystal have been performed following 
change in protein secondary structure by FT-IR spectroscopy.  
As FT-IR spectra on single crystals (27), spectra recorded on the crystalline samples report more 
information compare with the spectra recorded in solution, displaying better resolved components, 
suggesting that crystals are ideal samples to acquire FT-IR spectra of excellent quality. 
The thermal stabilities, here reported for WT, D76N and W60G β2m variants, are generally in good 
agreement with previous data (3, 22) confirming the hypothesis that information about fold stability can 
be assessed also from proteins in crystalline form. 
Additionally, in the spectra recorded on crystalline samples at increasing temperature (figure S2) is 
evident the reduction of the fraction of protein that aggregates. This event can be explained by the fact 
that, if soluble, the protein that unfolds at lower temperature starts to aggregate progressively. 
Conversely, in the crystalline samples, the late unfolding of the protein delays the aggregation process, 
resulting in a bigger population of unfolded protein at the end of the ramp. 
Moreover, FT-IR spectra collected at increasing temperature on crystalline samples bear information 
beyond protein unfolding: the temperature-dependent variation in position of the Tyr peak allows 
monitoring crystal melting. 
Therefore, the FT-IR experiments here reported point at the conservation of fold stability of proteins in 
crystalline state setting the base for future experiments comparing molecular dynamics of proteins in 
solution and in crystalline state. Such data together will be required for an exhaustive characterisation 
of the biophysical properties of proteins in the crystalline form. 
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Figures 
 
Figure 1. FT-IR spectroscopy of WT, D76N and W60G β2m variants. (A) The second derivative of 
the absorption spectrum of WT β2m in solution compared with that of WT protein in the crystalline 
state. (B) Comparison of the second derivatives of the absorption spectra of WT, D76N and W60G β2m 
in phosphate solution. (C) Comparison of the second derivatives of the absorption spectra of crystallized 
WT, D76N and W60G β2m. The peak position of the main Amide I components is reported. 
 
 
 
  
Figure 2. Second derivatives of the absorption spectra in the amide I region of WT, D76N and 
W60G β2m variants. (A) The second derivatives of the absorption spectra of WT, D76N and W60G 
β2m variants in phosphate buffer, reported in the 1700 – 1590 cm−1 region. (B) The second derivatives 
of the absorption spectra of WT, D76N and W60G β2m crystallized variants heated at a rate of 1 °C/min, 
reported in the 1700 – 1590 cm−1 region. (C) The second derivative of the absorption spectra of WT, 
D76N and W60G β2m crystallized variants heated at a rate of 0.4 °C/min, reported in the 1700 – 1590 
cm−1 region. 
 
 
  
Figure 3. Thermal stability of β2m variants assessed by FT-IR spectroscopy. (A) The temperature 
dependence of the native β-sheet peak intensity at ~1628 cm−1, taken from second derivative spectra of 
β2m analysed crystallized variants heated at a rate of 0.4 °C/min and 1 °C/min. (B) The temperature 
dependence of the native β-sheet peak intensity at ~1636 cm−1, taken from second derivative spectra of 
β2m analysed variants in phosphate solution at a rate of 0.4 °C/min.  
 
 
  
Figure 4. Thermal stability of β2m variants assessed from the temperature-dependent position of 
the tyrosine peak. (A) The temperature dependence of the tyrosine peak position taken from the second 
derivative spectra of β2m analysed variants in phosphate solution. (B) The temperature dependence of 
the tyrosine peak position taken from the second derivative spectra of β2m analysed crystallized variants 
heated at a rate of 0.4 °C/min and 1 °C/min. Inset: Curves recorded at a rate of 1 °C/min have been 
normalized to highlight the trends. 
 
 
  
Tables 
 
Table 1. Calculated melting temperature for the complexes. Tm values are assessed on native β-sheet 
peak intensity measured on the protein in phosphate solution, in crystalline state at a heating rate of 0.4 
°C/min and 1 °C/min, and on far UV CD curves (3, 11). Values are calculated fitting the data with the 
Boltzann function. 
 
Protein Tm / °C (solution 
FT-IR), PBS 
Tm / °C (crystal FT-
IR, 0.4 °C/min) 
Tm / °C (crystal 
FT-IR, 1 °C/min) 
Tm / °C 
(CD) 
WT 61.6  71.3 85.0 62.4 
D76N 52.1  70.2 74.8 53.2 
W60G 78.9  81.1  93.6 69.8 
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FT-IR experiments with WT, D76N and W60G β2m variants solubilized in the crystallization 
buffer. 1 mg of lyophilized protein for each β2m variant was dissolved in 2 ml of deuterated buffer 0.1 
M MES pH 6, 27% PEG 4K, 15% glycerol and let overnight at 4 °C. The samples, containing a high 
amount of pellet (precipitated protein), was centrifuged for 20 minutes at 10000 rpm.  20 µl of the sample 
were then transferred in a temperature-controlled transmission cell with two BaF2 windows separated 
by a 150 µm Teflon spacer. Spectra and thermal stability experiment were collected following the 
conditions described in Materials and Methods paragraph for the crystalline pellet. 
The thermal stability of β2m variants assessed by FT-IR spectroscopy on protein solubilized in 
crystallization buffer are shown in Figure S3.  
 
Figure S1. Crystal structure superposition for WT, D76N and W60G β2m variants. Structure 
superposition of WT (green), D76N (blue) and W60G (yellow) β2m variants (pdb codes 1LDS, 4FXL, 
2Z9T respectively). The main β-sheet strands are labelled according to the accepted β2m nomenclature. 
Asp76 and Trp60 are shown in sticks in WT β2m structure. 
 
 
 
 
 
 
  
Figure S2. Thermal stability of β2m variants assessed by FT-IR spectroscopy. (A) The second 
derivative of the absorption spectra of WT, D76N and W60G β2m variants in phosphate buffer recorded 
at increasing temperature. (B) The second derivative of the absorption spectra of WT, D76N and W60G 
β2m crystallized variants recorded at increasing temperature (1 °C/min). (C) The second derivative of 
the absorption spectrum of WT, D76N and W60G β2m crystallized variants recorded at increasing 
temperature (0.4 °C/min). 
 
 
 
  
 Figure S3. Thermal stability of β2m variants assessed by FT-IR spectroscopy on protein 
solubilized in crystallization buffer. The temperature dependence of the native β-sheet peak intensity 
at ∼1636 cm−1, taken from the second derivative spectra of β2m analysed variants solubilized in the 
crystallization solution. 
 
 
 
 
	 57 
3.3. Manuscript II  
 
Novel MHC-I complex-stabilizing “superantigens” derived from 
the cancer target NY-ESO-1 
 
Sala, B.M., Broggini, L., Pellegrino, S., Barbiroli, A., Achour, A., Ricagno, S. (2017). 
 
 
  
  
 
Novel MHC-I complex-stabilizing “superantigens” 
derived from the cancer target NY-ESO-1 
 
 
 
Benedetta Maria Sala1, Luca Broggini1, Sara Pellegrino2, Alberto Barbiroli3,  
Adnane Achour4*, Stefano Ricagno1* 
 
 
 
 
 
 
1 Department of Bioscience, Università degli Studi di Milano, Milano 20133, Italy; 
2 University of Milano, Department of Pharmaceutical Sciences, Milano 20133, Italy; 
3 DeFENS, Dep. of Food Environmental and Nutritional sciences, University of Milan, Milano 20133, 
Italy; 
4 Science for Life Laboratory, Department of Medicine, Karolinska Institute, Stockholm, Sweden. 
 
 
 
 
 
 
*Corresponding authors: Adnane Achour, adnane.achour@ki.se; Stefano Ricagno, 
stefano.ricagno@unimi.it.  
Abstract 
 
Major Histocompatibility Class I complexes (MHC-I) are hetero-trimers composed by the 
polymorphic heavy chain, the light chain β2-microglobulin (β2m) and an antigenic peptide. It has an 
essential role in immune response against external agents and in cancer immune surveillance, 
exposing antigenic peptides on the cell surface and triggering T cells activation. It has been assessed 
that stability, rather than affinity, of the peptide with the complexes better correlates with 
immunogenicity. A promising strategy for tumor eradication may consists in inducing a strong T-cell 
response against tumor-associated antigens (TAA).  
The antigen NY-ESO-1 is expressed in many cancer types, thus it is a valid candidate for cancer 
vaccine design. The studies on vaccine preparation with the antigenic peptide NY-ESO-1157-165 have 
revealed problems of stability and bioavailability associated with peptide immunization and the 
frequent failure to activate cytotoxic T lymphocytes. In this context, here we adopt a novel generation 
of engineered “super-peptides” ligands (APLs), to stabilize MHC-I and increase the affinity toward T 
cell receptors. 
Eight MHC-I bearing different NY-ESO-1157-165-derived antigenic peptides have been produced and 
purified; their stability has been monitored in vitro; though to different degrees, all considered peptide 
variants increase the fold stability of MHC-I.  
The X-ray crystal structure of one of the most stable MHC-I has been determined and its structure 
compared to those already published. Together, our results can contribute to the rationalization of the 
MHC-I anchor residues in tumour epitopes to enhance binding of the peptide to the complex, 
improving cancer vaccine design.  
  
Introduction 
 
The Major Histocompatibility Class I complex (MHC-I) consists in a highly polymorphic heavy chain 
(a) with a transmembrane domain, a monomorphic light chain (β2m) and an antigenic peptide (1). 
Presentation of peptides by MHC-I on cell surfaces results in the activation of immune responses 
mediated by CD8+ T lymphocytes (TCD8), including cytotoxic T lymphocytes (CTLs), and the 
subsequent lysis of target cells (2, 3). 
Cancer cells express a wide range of antigens that, once proteolized and exposed by MHC-I, are 
recognized by CTLs. Several clinical trials have highlighted that peptides coming from tumor-
associated antigens (TAA) interact weakly with MHC-I heavy chain (4). Thus, many efforts have been 
done to improve the efficacy of the peptides processed from TAA, engineering synthetic peptides to 
dispense to patients through peptide-base vaccines. (5, 6). 
NY-ESO-1, a 180-amino acid long protein with unknown function, is considered one of the most 
promising tumor-specific antigens (7). It is expressed by many cancer-type cells (such as breast, 
prostate, ovarian cancer, as well as melanoma) and not by healthy adult somatic tissues (8-11). Thanks 
to its high immunogenicity, NY-ESO-1 is a valid candidate for design specific cancer vaccines (12, 
13). Nevertheless, several studies have pointed out problems of stability and bioavailability associated 
with immunization using NY-ESO-1 derived-peptides (14, 15). 
So far, the most studied vaccine preparation for NY-ESO-1 makes use of wild type peptides 
administered with various adjutants for immunization of cancer populations expressing the antigen 
(16-18).  
Trial vaccinations with a mixture of NY-ESO-1 derived peptides, revealed a strong T-CD8+ reactivity 
and response against NY-ESO-1157–165 bound to human MHC-I (7, 19). This peptide presents at the C-
terminus a cysteine (Cys) residue that, due to cysteinylation and dimerization, affect vaccines 
formulation reducing their immunogenic efficacy (20). In fact, under physiological conditions, 
cysteine is the most chemically reactive amino acid due to its free sulphydryl group. 
It has been demonstrated either in vitro and in vivo, that reducing agents significantly enhanced the 
immunogenicity of cysteine-containing peptides (20): MHC-I molecules bearing reduced NY-ESO-
1157-165 are, indeed, recognized ten times more efficiently (12).  
Similar improved effects were obtained by replacing the Cys 165 with more common anchor residues 
generating new peptide variants (12, 21). 
In this context, the properties of MHC-I/NY-ESO-1157-165WT (from now MHC-I/WT) have been 
compared by Webb and colleagues to that of the complexes bearing the peptide with mutations C9A 
and C9S (from now MHC-I/9A and MHC-I/9S) (21). Substitution of the C-terminal Cys with an Ala 
do not affect complex thermal stability and CTL recognition. The mutation to Ser, instead, resulted in 
a lower cytotoxic response, although keeping peptide conformation in the binding groove of the heavy 
chain. 
Variants of NY-ESO-1157-165 where the C-terminal Cys had been replaced by valine, isoleucine, or 
leucine, have been generated by Chen and colleagues (12). These peptides bind more efficiently to 
MHC-I and are recognized at least 100 times more efficiently than the wild-type peptide by specific 
CTL.  Among these new peptides analogues, it has been demonstrated that NY-ESO-1157-1659V (from 
now MHC-I/9V) can improve T-Cell Receptors (TCR) affinity compared to the others. The 
introduction of a Val residue, optimize the antigenic peptide binding without altering the orientation of 
the key residue for TCR recognition (Met4 and Trp5) (22).  
Given the background, van Stipdonk has recently reported a novel procedure for the design of altered 
“super-peptides” ligands (APLs) to improve binding affinity to MHC-I (23).  These modified peptides 
hold a structural conformation similar to the WT infection-derived or non-immunogenic tumor-
associated peptides and act as highly immunogenic mimotopes of tumor associated antigens (TAAs) in 
several different cancer mouse models (23). 
This work aims to design a novel generation of APLs on the human cancer antigen NY–ESO-1 to 
identify peptides that strongly stabilize MHC-I. Seven variants of NY-ESO-1157-165 have been designed 
following van Stipdonk’s procedure, based on the previous observations that peptides, stabilizing 
MHC-I in vitro, also increase its half-life in cell yielding to an enhanced immune response (12). Chen 
et al. showed that positions 1, 3 and 9 are crucial for the interaction of the peptide with the heavy 
chain and for the interaction between MHC-I and TCRs. Mutations on N- and C-terminal residues are 
suggested to be directly involved in stabilizing the complex while mutations on the third residues 
should affect the conformation of the peptide within the groove, which entails a different spatial 
organization of the complex (12). 
Hence, in the present work one, two or three of the mutations - S1Y, L3Y, L3P, C9V - have been 
introduced into new NY-ESO-1157-165 peptide variants. Eight MHC-I bearing NY-ESO-1157-165 peptide 
variants (1Y3P9V, 3Y9V, 1Y9V, 1Y, 1Y3P, 9V, 3P9V and WT) have been purified. The effects 
caused on the complex thermal stability by a given peptide have been evaluated for all designed 
variants bound to MHC-I and compared to MHC-I/WT (21). Furthermore, the structural features, 
responsible for differences in stability have been examined through the X-ray structure of one of the 
most stable MHC-I. 
 
 
  
Methods 
 
Peptide Synthesis.  
The eight NY-ESO-1157-165 variant peptides (WT: SLLMWITQC,  1Y3P9V: YLPMWITQV, 3Y9V: 
SLYMWITQV, 1Y9V: YLLMWITQV, 1Y: YLLMWITQC, 1Y3P: YLPMWITQC, 9V: 
SLLMWITQV, 3P9V: SLPMWITQV) were prepared by microwave-assisted solid phase synthesis 
(24) based on Fmoc chemistry on preloaded pre-loaded Wang (0.6 eq/g loading) using a 5-fold molar 
excess of 0.2 M Fmoc-protected amino acids dissolved in dimethylformamide and using N-
hydroxybenzotriazole/O-(benzotriazol-1-yl)-N ,N, N′, N′-tetramethyluronium 
hexafluorophosphate/diiso-propylethylamine (5: 5: 10) as activators. Coupling reactions were 
performed for 5 min at 40 watts with a maximum temperature of 75 °C. Deprotection was performed 
in two stages using 20% piperidine in dimethylformamide (5 and 10 min each). Cleavage was 
performed using 10 ml of reagent K (TFA/phenol/water/thioanisole/ethanedithiol; 82.5/5/5/5/2.5) for 
180 min. Following cleavage, peptides were precipitated out and washed using ice-cold anhydrous 
ethyl ether. All peptides were purified by reverse phase HPLC using a gradient elution of 5–70% 
solvent B (solvent A: water/acetonitrile/TFA 95/5/0.1; solvent B: water/acetonitrile/TFA 5/95/0.1) 
over 20 min at a flow rate of 10 ml/min. The purified peptides were freeze-dried and stored at 0 °C. 
 
MHC-I Purification.  
The HLA-A*0201 (HLA-A2) heavy chain and β2-microglobulin (β2m) proteins were expressed 
individually as inclusion bodies using the BL21 (DE3) E.coli strain, following previous published 
protocols (25, 26). 
The refolding of MHC-I was carry out by dilution. The peptide and b2m were added firstly to the 
refolding buffer (100 mM Tris pH 8, 450 mM L-Arginine, 5 mM L-Glutathione reduced, 0.5 mM L-
Glutathione oxidized, 2 mM EDTA, 0.5 mM AEBSF) and the solution was left at 4°C under stirring 
for half an hour. The unfolded HLA-A2, solubilized in 6 M GdmHCl, 20 mM TrisHCl pH 8 was 
added. The final concentration of the components within the refolding buffer was 1 µm HLA-A2, 2 
µm WT b2m, 10 µm peptide. 
The refolding was completed after 72 hours at 4°C under stirring. The solution was concentrated 
trough Stirred Ultrafiltration Cell (Millipore) and Amicon Ultra-15 Centrifugal Filters (EMD 
Millipore) up to approximately 3 mL. The sample was then purified by size exclusion chromatography 
using a Superdex 75 column equilibrated with 20 mM TrisHCl pH 8, 150 mM NaCl. 
The eluted protein was analyzed by SDS-PAGE, frozen in liquid nitrogen and stored at -20°C. 
 
 
 
Circular Dichroism.  
Thermal unfolding experiments were performed by circular dichroism (CD) in the far-UV region on a 
J-810 spectropolarimeter (JASCO Corp., Tokyo, Japan) equipped with a Peltier system for 
temperature control. The protein concentration was 0.2 mg/mL in 20 mM Tris-HCl, pH 8.0, 150 mM 
Sodium Chloride. The temperature ramp measurements were recorded from 20 to 95°C (temperature 
slope 60° C/hour) in a 0.1 cm path length cuvette and monitored at 218 nm wavelength. Tm was 
calculated as the first-derivative minimum of the traces. Far-UV CD spectra were recorded before and 
after unfolding ramp (260-190 nm). 
 
Crystallization.  
MHC-I/3Y9V has been concentrated up to 6 mg/ml. Crystals were grown at 20°C with sitting drop 
techniques by mixing equal amounts of protein solution, and the reservoir solution in two conditions: 
(A) 0.2 M MgCl2, 0.1 M Tris-HCl pH 8.1, 31% PEG 3350 and (B) 28 % w/v Polyethylene glycol 
6000, 500 mM LiCl, 100 mM Tris-HCl pH 8.5. Crystals from condition (B) were cryoprotected with 
with 20 % w/v Polyethylene glycol 4000 and crystals from both conditions were then flash-frozen in 
liquid nitrogen. X-ray diffraction data were collected at the beam line ID-30a at ESRF (European 
Synchrotron Radiation Facility of Grenoble, France).  
 
Structure Determination.  
The diffraction data were processed using XDS (27) and the intensities were merged and scaled with 
AIMLESS (28). The structure was solved by molecular replacement using PHASER (29) using the 
structure of MHC-I bearing the WT peptide as search model (PDB code: 1S9W (21)). The model 
molecules were subjected firstly to a rigid-body refinement and then to a restrained refinement using 
REFMAC (30) program suite. Manual model building, was carried out using the COOT 
(Crystallographic Object-Oriented Toolkit) (31). 
 
 
  
Results  
 
MHC-I refolding and purification 
To evaluate effects on MHC-I stability by NY-ESO-1157-165 variants, HLA-A0201 (HLA-A2) heavy 
chain has been refolded in presence of β2m and eight different peptide variants. Following 
conventional protocols (26), the refolding process resulted in efficient production of most of the 
MHC-I molecules, except for MHC-I bearing WT and 1Y variant peptides. Purifications yields of all 
MHC-I are reported in Table1 (gel filtration chromatograms are shown in Figure S1). 
The lower MHC-I/WT and MHC-I/1Y purification yield may be explained by an altered refolding 
outcome. It is notably from the far UV spectra monitored by circular dichroism (Figure S2), that the 
profile of MHC-I/WT and MHC-I/1Y have a shifted intersection of the X-axis compared to all other 
complexes, suggesting a slightly different secondary content. 
 
MHC-I Stability measured by CD 
Unfolding of MHC-I bearing NY-ESO-1157-165 variants was monitored at increasing temperature by 
far-UV CD to investigate specific effects on complex stability due to the designed peptide mutations.  
As shown in Figure 1 the unfolding curves display a cooperative behaviour, thus confirming the 
presence of secondary structured proteins. Unfolding of MHC-I/WT, instead, is poorly cooperative 
and displays two inflection points and altered behaviour in different purification batches (WT and WT 
b in Figure 1). Due to MHC-I/WT instability, the heavy chain probably experiences denaturation prior 
to β2m. This could explain the presence of a first initial denaturation (the heavy chain unfolding) 
followed by a plateau (heavy chain aggregation) and then a second inflection point (β2m collapsing 
together with the formed aggregation). Likewise, also previous papers reporting thermodynamic 
stability measurement on MHC-I/WT revealed a very poor cooperativity of complex unfolding (21).   
Table 2 reports the calculated melting temperature (Tm) for all complexes.  The MHC-I/WT Tm has 
been not extrapolated from the unfolding curves, but it was considered that calculated by Webb et al.  
(21). Tm values of all other complexes bearing NY-ESO-1157-165 mutated peptides, revealed an increase 
in stability compared to the MHC-I/WT. In particular, MHC-I/1Y, MHC-I/9V, MHC-I/1Y9V and 
MHC-I/3Y9V are the most promising complexes since their peptides have the greatest effects on the 
stability of MHC-I. 
 
Structures of the MHC/ 3Y9V  
The X-ray crystal structure of MHC-I/3Y9V, one of the most stable MHC-I, has been determined at 
high resolution and its structure compared to those already published MHC-I/WT and MHC-I/1Y9V. 
This structure allows to inspect the structural contributions to the improved stability determined by the 
mutation at the third peptide residue. 
The complex crystallized in two different conditions showing different space groups and crystal 
packing: the crystal grown in condition A (MHC-I/3Y9Va) has P 21 21 21 space group and two 
molecules in the asymmetric unit (AU); while, the crystal grown in condition B (MHC-I/3Y9Vb) has 
P 21 space group and one molecule in the AU. Data collection and refinement statistics are reported in 
Table 3.  
In both crystal structures the electron density map is of excellent quality for HLA-A2, β2m and the 
peptide, allowing the model building of the whole three chains (Figure 2 A). L3Y, C9V peptide 
mutations are clearly detectable (Figure 2 B and C). The three structures comprise residues 1–274 of 
the HLA-A2 heavy chain, residues 1–99 of β2m, and the nine residues of the bound peptide and a 
variable number of water molecules. 
Overall, the quaternary structure of MHC-I/3Y9V seems not to be affected by the mutation of the 
peptide. In fact, it results very similar and perfectly superimposable to the previously reported MHC-
I/WT and MHC-I/1Y9V structures (21, 32). Therefore, our analysis will focus on the conformations 
that the peptides assume in cleft of HLA-A2. 
 
Peptide conformations of the MHC/ 3Y9V  
The NY-ESO-1157–165 variant peptide is bound in an extended conformation in both structures (Figure 
2 B, C and 3A).  
The residues of their the N- and C- termini are well superposable (Figure 3 A) while differences are 
located in the central region of the peptide. In particular, in MHC-I/3Y9Va, Trp5 is flipped and it 
heads towards the heavy chain and not to the solvent (Figure 4 A and B), as it does in the MHC-
I/3Y9Vb (Figure 4 C and D).  As consequence, in MHC-I/3Y9Va, Trp5 establishes an interaction with 
Arg97 of the heavy chain, and the Ile6 is displaced and points to the solvent. 
Interestingly, despite different peptide conformations, no big side chains rearrangements are detectable 
in the heavy chain. This observation suggests that the presence of two alternative conformations 
should be due to the flexibility of the peptide bound into the heavy chain cleft. 
MHC-I/3Y9Va and MHC-I/3Y9Vb peptides have been superposed to those of the previously reported 
MHC-I/WT and MHC-I/1Y9V structures (Figure 3 B and C) (21, 32). MHC-I/3Y9Vb peptide 
conformation results generally comparable to that of MHC-I/WT and MHC-I/1Y9V peptides. As 
reported above, in the MHC-I/3Y9Vb structure, Met4 and Trp5 residues form a bulky protrusion from 
the surface of the pMHC, known to play a crucial role for TCR recognition (Figure 3 and 4 C and D) 
(22).  
Such structural comparison reveals that L3Y and C9V substitution causes only very subtle difference 
in the general orientation of the side chain within the pocket of the HLA-A2 peptide-binding groove 
(Figure 3). The increase in stability of MHC-I/3Y9V, thus, cannot be associated to a stabilizing local 
rearrangement in the cleft but rather, it can be associated to the highly optimised local interactions 
between the peptide and the heavy chain. In both MHC-I/3Y9V structure, the position of the mutated 
residue Tyr3 is conserved and induces the displacement of Gln155 side chain in the binding cleft 
(Figure 5). Moreover, Tyr3 establishes stacking interactions with the adjacent Trp5, Gln155, Leu156, 
and Tyr159. Finally, this residue is further stabilized by an interaction with a water molecule, not 
present in both MHC-I/WT and 1Y9V structures. As also previously described by Chen et al. (22), the 
Val side chain in position 9 improved shape complementarity together with the buried surface within 
the binding pocket compared to a Cys, enhancing the van der Waal's contacts between the mutated 
peptide and heavy chain residues Asp77, Leu81, Tyr116 and Trp147. All these interactions established 
by the 3Y9V peptide are likely to account for the increased stability observed by thermal unfolding. 
The two alternative conformations of the 3Y9V peptide provide information into the role of peptide 
positions in determining the complex stability. Residues in position 4, 5 and 6 assume different 
conformations and establish different interactions in the two solved structures of MHC-I/3Y9V while 
the positions of residues 1, 3, 9 in NY-ESO-1157-165 is highly conserved. It is noteworthy that a single 
unfolding step is observed in the temperature ramp (Figure 1) indicating that the MHC-I/3Y9V 
complexes may have different peptide binding mode but they all have the same stability and just the 
different crystallization conditions may have favoured one of the two conformations. Crucially this 
observation directly rules out an important role for residues 4, 5, and 6 in determining MHC-I stability 
and further stress the relevance of the anchoring residues such as 1 3 and 9. 
  
Discussion 
 
In this work, eight MHC-I bearing peptide variants of the tumour antigenic peptide NY–ESO-1157-165 
have been purified and their fold stability has been characterized to assess the impact on MHC-I fold 
stability of designed mutations at positions 1, 3 and 9 of the bound peptide. 
As reported by previous studies, peptide residues 1 and 3 play a crucial role for the specificity of 
peptide binding together with the two "anchor" residues at position 2 and 9 (33, 34).  
Indeed, all MHC-I variants displayed a higher stability compared to MHC-I/WT in thermal unfolding 
experiments. Moreover, the structure of one of the most stable complexes, MHC-I/3Y9V, has been 
determined at high resolution in two different space groups, allowing the characterization of the 
structural contributions to the improved stability. As reported by Chen et al. for MHC-I/9V (22), the 
structural arrangement of the complex is conserved, and only subtle differences in peptide 
conformation can be observed despite the significant boost in stability compared to MHC-I/WT (21). 
In keeping with previous data (34), we demonstrate that the heavy chain binding pocket of residue 9 
ideally accommodate small size non-polar residues such as Val, indeed, Val has been shown to be the 
most dominant COOH-terminal peptide anchor residue bound to HLA-A2 haplotype (35-37). In 
addition, an aromatic residue such as Tyr is favoured at the peptide third position, as previously 
reported (34, 35).  
Thus, in line with reported HLA-A2 peptide preference, the mutations introduced to NY–ESO-1157-165 
seems to be enough to improve the van der Waal's contacts between the altered ligand peptide and 
HLA-A2, conferring enhanced stability to the complex. 
Our results provide new evidence into the mechanisms controlling the higher stability induced by 
APLs binding by confirming a correlation between the stability of the MHC-I complex and a rational 
peptide mutagenesis. In particular, our experiments have successfully identified several NY-ESO-1157-
165 variants, which display an excellent performance in vitro. In future experiments, the relative 
immunogenicity of each analogue compared to the WT peptide shall be tested for TCR recognition 
and for their effects on MHC-I half-live in cells. 
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Figures 
 
Figure 1. MHC-I stability measured by CD.  Variation of Far-UV CD signal as a function of 
temperature. Thermal unfolding was monitored at 218 nm of MHC-I bearing NY-ESO-1157-165 
variants. Melting temperatures assessed using CD curves are reported in Table 2.   
 
 
 
  
Figure 2. X-ray Crystal structure of MHC-I/3Y9Va and MHC-I/3Y9Vb. (A) Superposition of the 
structures of MHC-I/3Y9Va (cyan) and MHC-I/3Y9Vb (pink) (RMSD: 0.91 382/382 Ca) (B) 3Y9V 
peptide in the binding pocket of MHC-I/3Y9Va structure. Electron density map is clipped around the 
peptide. (C) 3Y9V peptide in the binding pocket of MHC-I/3Y9Vb structure. Electron density map is 
clipped around the peptide. 
 
 
 
Figure 3. 3Y9V, WT and 1Y9V peptides superimposition. (A) Superposition of the peptides of MHC-
I/3Y9Va (cyan) and MHC-I/3Y9Vb (pink) structures. (B) Superposition of the peptides of MHC-
I/3Y9Va (cyan) and MHC-I/WT (yellow, pdb 1S9W) and MHC-I/1Y9V (green, pdb 4L29) structures. 
(C) Superposition of the peptides of MHC-I/3Y9Vb (pink) and MHC-I/WT (yellow, pdb 1S9W) and 
MHC-I/1Y9V (green, pdb 4L29) structures. 
 
 
 
 
 
  
Figure 4. Relative position of Trp5 and Arg97 in the crystal structure of MHC-I/3Y9Va and MHC-
I/3Y9Vb. A and B show the site on MHC-I/3Y9Va from two different perspectives. C and D show the 
site on MHC-I/3Y9Vb. 
 
 
 
 
 
Figure 5. Relative position Gln155 in the crystal structure of MHC-I/3Y9Va (cyan) and MHC-
I/3Y9Vb (pink) and MHC-I/WT (green, pdb code 1S9W). 
 
 
Tables 
 
Table 1. Purification yields for all complexes are reported. Notably, complexes bearing the WT 
peptide and the 1Y variant, has the lowest yield.  
 
Peptide Complex Yield % 
SLLMWITQC WT 4.2 
YLPMWITQV 1Y3P9V 15.9 
SLYMWITQV 3Y9V 14.8 
YLLMWITQV 1Y9V 16.8 
YLLMWITQC 1Y 2.6 
YLPMWITQC 1Y3P 8.8 
SLLMWITQV 9V 7.9 
SLPMWITQV 3P9V 11.9 
 
 
Table 2. Calculated melting temperature for the complexes. Tm values are assessed on Far-UV CD 
curves.  
 
Complex Tm / °C 
WT 57* 
1Y3P9V 61.7 
3Y9V 65.5 
1Y9V 64.9 
1Y 64.5 
1Y3P 59.0 
9V 64.1 
3P9V 59.5 
 
* as reported by Webb et al. (21). 
 
  
Table 3. Data collection and refinement statistics for MHC-I/3Y9V. Values in parenthesis are for the 
highest resolution shell. 
 
Structure Crystallization condition (A) Crystallization condition (B) 
Beam Line ID30a (ESRF) ID30a (ESRF) 
Space group P 21 21 21 P 1 21 1 
Unit cell constants (Å, °) 
a = 63.94, b = 86.40, c = 153.83; 
a = 89.95, b = 89.80, g = 89.94  
a = 41.04, b = 53.35, c = 85.16;  
a = 90.13, b = 94.11, g = 90.05 
Resolution (Å) 
49.17 - 2.50 
(2.60 - 2.50) 
45.22 – 1.65 
(1.68 – 1.65) 
Rmerge (%)a 16.5 (69.7) 7.6 (35.4) 
I/sI 8.6 (2.9) 8.1 (2.2) 
Completeness (%) 100.0 (100.0) 99.8 (99.1) 
Multiplicity 3.5 (3.6) 3.3 (3.1) 
Unique reflections 30297 (3353) 44267 (2175) 
Refinement   
   Rwork (%)b 19.13 19.4 
   Rfree (%) 25.49 23.1 
   Number of atoms 6707 3581 
   Protein 6306 3147 
   Water 401 434 
   Heteroatoms - - 
Ramachandran plot, n (%)   
   Most favoured region 722 (96.52) 352 (96.70) 
   Allowed region 22 (2.94) 10 (2.75) 
   Outliers 4 (0.53) 2 (0.55) 
 
a Rmerge = Σhkl ΣjIhkl,j - <Ihkl>/ΣhklΣjIhkl,j where I is the observed intensity and <I> is the average 
intensity.  
b Rwork = ΣhklFo - Fc/ΣhklFo for all data except 5–10%, which were used for the Rfree calculation. 
  
Supporting Tables and Figures 
 
Figure S1. Gel filtration chromatograms of MHC-I/WT and MHC-I/3P9V. The rectangle highlight the 
elution peak of the refolded complexes. MHC-I/WT and MHC-I/1Y display similar elution profiles 
and lower yields compared to that of MHC-I/3P9V (as example of all the other MHC-I/NY-ESO-1155-
167 variant peptides). 
 
 
 
 
 
Figure S2. Far-UV spectra of all complexes monitored by circular dichroism. 
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4. Conclusions  
 
My thesis aims to provide further understanding on the effects that a single amino acid mutation can 
play on protein stability and protein physiologic and pathologic properties using two systems and two 
different biological contexts: β2m and the MHC-I. 
 
I 
 
To identify key resides that trigger β2m amyloid aggregation, the native state dynamics of WT β2m 
and W60G β2m have been compared, combining solution NMR spectroscopy and molecular dynamics 
(MD) simulations.  
The work provides insights into structural determinants of the lack of aggregation propensity of W60G 
β2m. The W60G mutation not only increases the protein fold stability but also generates a more 
regular and more rigid overall structure in which the superficial aggregation-prone regions are better 
protected, drastically reducing the aggregation properties typical of WT β2m.  
Thus, to validate the role of protein dynamics in determining aggregation propensity, three new β2m 
variants (V85E, W60G-N83V and W60G-Y63W) were designed and characterized both biochemically 
and structurally. Mutations on WT and W60G β2m were inserted to alter their aggregation prone 
exposed surface, modifying their aggregation propensity without altering their stability. All newly 
designed variants have displayed the expected structure, stability and aggregation propensity.  
These results demonstrated that the aggregation propensity of β2m can be modulated by mutating 
surface residues that regulate the protection of aggregation-prone surfaces, with negligible effects on 
protein structure and stability. 
 
II 
 
To date, it is not fully understood whether biophysical properties assessed in crystallized proteins are 
representative of protein behaviour in solution. 
The project deals with a comparative study of protein stability in solution and in the crystalline form 
on three β2m variants: WT, W60G and D76N. These variants, besides their differences in stability and 
aggregation propensity, display equal crystal properties, thus resulting in an ideal system for this kind 
of experiments. 
Thermal unfolding analyses of the proteins in solutions and in crystal were carried out. The change in 
protein secondary structure was monitored at increasing temperature by Fourier transform infrared 
(FT-IR) spectroscopy.  
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Crystals results to be valid alternative samples for acquiring FT-IR spectra. Indeed, the increased 
structural order of the crystalline state contributes to provide better resolved spectral components 
compared to those collected in solution and crucially, the crystalline samples displayed thermal 
stabilities in good agreement with trend observed in solution (W60G > WT > D76N). Besides being a 
reliable tool to evaluate protein stability, FT-IR on crystalline samples allowed us to obtain also 
information about crystal melting through the temperature-dependent variation in maximum of the Tyr 
peak detectable only in crystals spectra. 
Therefore, the FT-IR experiments carried out on β2m variants suggest that protein stability can be 
studied in crystals point at the possibility to study other biophysical properties such as protein 
dynamics exploration not only in solution also in crystalline samples. 
 
III 
 
The heterotrimeric complex MHC-I triggers an immune response by displaying antigenic peptides on 
the cell surface for recognition by appropriate T cells. It has been widely demonstrated that the overall 
MHC-I stability together with peptide-complex affinity is fundamental for successful antigen 
presentation. 
In this context, this work dissects the impact on protein fold stability of designed complex-stabilizing 
point mutations on the tumour antigenic peptide NY–ESO-1157-165 to produce more effective cancer 
vaccines.  
Eight MHC-I bearing peptide variants were purified and characterized. Thermal stability experiments 
revealed a higher stability in all MHC-I variants compared to MHC-I/WT validating the strategy of 
“super-peptides” engineering. Moreover, the structural characterization of one of the most stable 
complexes allowed to deeply inspect the contributions to the improved stability obtained by rational 
peptide mutagenesis. Finally, our experiments have successfully identified several NY-ESO-1157-165 
variants, which display an excellent performance in vitro and shall be tested for TCR recognition and 
for their effects on MHC-I half-live in cells. 
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FRET studies of various conformational states adopted by transthyretin 
Ghadami S.A., Bemporad F., Sala B.M., Tiana G., Ricagno S., Chiti F. 
 
The paper deals with the investigation of the conformational changes occurring to TTR during the 
amyloid aggregation and provides a deep insight into the processes of folding, unfolding and 
aggregation of TTR.  
The laboratory of Prof. Chiti at the Section of Biochemistry of the University of Florence has 
exploited fluorescence resonance energy transfer (FRET) experiments in TTR, labelled with a 
coumarin derivative, N-(7-dimethylamino-4-methylcoumarin-3-yl) maleimide, (DACM). 
My task aimed to structurally characterize the labelled WT and M-TTR variants providing the exact 
position of DACM to better interpret the FRET data and assess if the DACM labelling interferes with 
the native TTR fold. Both TTR variants had been crystallized, DACM-WT-TTR and DACM-M-TTR 
are perfectly superimposable onto the non-labelled ones, demonstrating that the bound DACM does 
not perturb the native fold of the protein, thus validating FRET results. 
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Abstract Transthyretin (TTR) is an extracellular protein
able to deposit into well-defined protein aggregates called
amyloid, in pathological conditions known as senile sys-
temic amyloidosis, familial amyloid polyneuropathy,
familial amyloid cardiomyopathy and leptomeningeal
amyloidosis. At least three distinct partially folded states
have been described for TTR, including the widely studied
amyloidogenic state at mildly acidic pH. Here, we have
used fluorescence resonance energy transfer (FRET)
experiments in a monomeric variant of TTR (M-TTR) and
in its W41F and W79F mutants, taking advantage of the
presence of a unique, solvent-exposed, cysteine residue at
position 10, that we have labelled with a coumarin
derivative (DACM, acceptor), and of the two natural
tryptophan residues at positions 41 and 79 (donors). Trp41
is located in an ideal position as it is one of the residues of
b-strand C, whose degree of unfolding is debated. We
found that the amyloidogenic state at low pH has the same
FRET efficiency as the folded state at neutral pH in both
M-TTR and W79F-M-TTR, indicating an unmodified
Cys10–Trp41 distance. The partially folded state populated
at low denaturant concentrations also has a similar FRET
efficiency, but other spectroscopic probes indicate that it is
distinct from the amyloidogenic state at acidic pH. By
contrast, the off-pathway state accumulating transiently
during refolding has a higher FRET efficiency, indicating
non-native interactions that reduce the Cys10–Trp41 spa-
tial distance, revealing a third distinct conformational state.
Overall, our results clarify a negligible degree of unfolding
of b-strand C in the formation of the amyloidogenic state
and establish the concept that TTR is a highly plastic
protein able to populate at least three distinct conforma-
tional states.
Keywords Protein aggregation  Protein misfolding 
Protein folding  Folding intermediate  SSA  FAP 
FAC
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Introduction
Transthyretin (TTR) is a homotetrameric protein with a
total molecular mass of 55 kDa that is mainly synthesized
in the liver, choroid plexus of the brain, and retina [1, 2],
albeit further studies have demonstrated significant syn-
thesis in the pancreas, kidneys, Schwann cells and neurons
[3–7]. In the plasma TTR transports thyroxine (T4) and the
retinol binding protein (RBP), whereas in the cerebrospinal
fluid (CSF) TTR is the primary transporter of T4 [8, 9].
TTR is also one of the few proteins associated with
systemic amyloidoses, a group of disorders resulting from
the extracellular deposition of well-defined protein aggre-
gates characterized by a fibrillar morphology, cross-b
structure and peculiar tinctorial properties in the presence
of specific dyes such as Congo red or thioflavin S [10, 11].
Amyloid deposition of wild-type TTR occurs in the heart
of 10–25% of humans older than 80 years, resulting in
senile systemic amyloidosis (SSA), often leading to con-
gestive heart failure [12, 13]. Amyloid deposition by TTR
is accelerated by the presence of any of the approximately
100 different amyloidogenic mutations of TTR responsible
for early-onset TTR amyloidosis with autosomal dominant
inheritance, such as familial amyloid polyneuropathy
(FAP), familial amyloid cardiomyopathy (FAC) and lep-
tomeningeal amyloidosis [14, 15]. A list of all TTR
mutations associated with such disorders is reported in a
database named ‘‘Mutations of Hereditary Amyloidosis’’
(http://www.amyloidosismutations.com/mut-attr.php).
While the main component of amyloid fibrils in patients
suffering from sporadic SSA is wild-type TTR and its
fragments, the main component of amyloid fibrils in TTR
familial amyloidoses is mutant TTR, with the wild-type
counterpart only scarcely represented [10, 16–18]. The
single-site mutations that cause such diseases do not sig-
nificantly change the tertiary or quaternary structure of
tetrameric TTR; instead they appear to be responsible for
the reduced thermodynamic and/or kinetic stability of
native tetrameric TTR in favor of the monomeric, partially
unfolded amyloidogenic intermediate, which self-assem-
bles into amyloid fibrils under mildly denaturing
conditions, at pH 3.9–5.0 [19–21].
Considerable effort has been expended to determine the
structure of the monomeric amyloidogenic state of TTR
populated at weakly acidic pH values. Biophysical and
limited proteolysis experiments have led to the conclusion
that upon acidification, tetrameric TTR dissociates into
monomers with the subsequent unfolding of the b-strand C,
the b-strand D and the connecting CD loop [22, 23]. In
another report it was proposed, on the basis of hydrogen/
deuterium exchange experiments coupled to NMR, that the
b-sheet CBEF is the most destabilized upon acidification of
TTR at pH 4.5 [24]. Significant advances have been
reached with a double mutant of TTR carrying two single
mutations (F87M/L110M) designed to destabilise the
molecular interface between the subunits that compose the
tetramer [25]. This double mutant, generally referred to as
M-TTR, was shown to be stable as a monomer at neutral
pH and has proved a unique tool for characterizing, at the
molecular level, the transition from the folded non-amy-
loidogenic monomer populated at neutral pH to the
amyloidogenic state populated at low pH [25]. Solution
NMR studies have shown that M-TTR is folded at neutral
pH, with many of the resonances of the b-sheet DAGH
exhibiting line broadening, particularly the b-strand H,
indicative of structural fluctuations [26]. By contrast, the b-
sheet CBEF is not just folded, but also substantially
packed. Upon acidification to pH values promoting amy-
loid fibril formation, line broadening extends to the b-
strand D, the D–E loop, the E–F helix, and the residues of
the A–B loop forming interactions with the helix, whereas
most residues of the b-sheet CBEF maintain sharp, non-
broadened resonances [26]. These observations have been
confirmed later on tetrameric TTR at mildly low pH [27].
Hence, it is not yet clear if the partial unfolding of the
monomeric folded unit of TTR to produce the amyloido-
genic state involves the b-strands C and D and the
interconnecting loop [22, 23], the CBEF b-sheet [24] or
only the peripheral portion of the DAGH b-sheet [26].
In an independent study, the folding process of M-TTR
was characterized kinetically and at equilibrium using a
number of biophysical probes, leading to the identification
of a molten globule state populated at equilibrium at low
urea concentrations and to an off-pathway partially folded
state populated transiently during the folding process of
M-TTR [28]. The correspondence between any of such
conformational states and the amyloidogenic state of
M-TTR populated at weakly acidic pH has not yet been
established.
To clarify these unresolved issues, we have carried out
fluorescence resonance energy transfer (FRET) experi-
ments, taking advantage of the presence of a unique,
solvent-exposed, cysteine residue at position 10 and of the
two naturally occurring tryptophan residues at positions 41
and 79 in M-TTR. We have labelled the Cys10 residue of
M-TTR with a coumarin derivative that acts as a FRET
acceptor of the intrinsic fluorescence emitted by the Trp41
and Trp79 residues that thus act as FRET donors. Trp41 is
located in an ideal position as it is one of the residues of b-
strand C which has been reported to be either unfolded or
fully folded in the various structural characterizations
described above. Cys10 is solvent-exposed and its labelling
is expected to have only minor influence on the structure of
M-TTR. Hence, labelled M-TTR is expected to contain a
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new solvent-exposed environmental probe at position 10,
thus permitting the measurement of the spatial distance
between the probe linked to Cys10 and Trp41/Trp79. We
have also produced and labeled with coumarin two single
mutants of M-TTR, namely W41F and W79F, to monitor
the spatial distance between Cys10 and the two tryptophan
residues separately. The utility of FRET results from the
strong dependence of the efficiency of energy transfer on
the sixth power of the spatial distance between donor and
acceptor, which has led to the often quoted reference to
FRET as a ‘spectroscopic ruler’ [29].
We will report the FRET efficiency values of the various
labelled mutants under various experimental conditions to
shed light on the structure of the various conformational
states of M-TTR so far characterized, including the fully
folded and fully unfolded states at neutral pH, the amy-
loidogenic state at low pH, the equilibrium partially folded
state at low urea concentrations and the kinetically trapped
state transiently populated during folding.
Materials and methods
Materials
Dimethyl sulfoxide (DMSO), glutathione (GSH), Tris(2-
carboxyethyl)phosphine hydrochloride (TCEP), trifluo-
roacetic acid (TFA) and urea were purchased from Sigma-
Aldrich (St Louis, MO, USA). N-(7-Dimethylamino-4-
methylcoumarin-3-yl)maleimide (DACM) was purchased
from Thermo Fisher Scientific (Waltham, MA, USA).
Protein expression, purification and mutagenesis
Production of M-TTR and its mutants was carried out as
previously described [9], except for the bacterial growth
temperature of the W41F-M-TTR which was an overnight
incubation at 25 C. Purified proteins were stored at
-20 C in 20 mM phosphate buffer, pH 7.4. Mutations in
the gene coding for M-TTR were generated using the
QuickChange site-directed mutagenesis kit (Agilent Tech-
nologies, Santa Clara, CA, USA). The DNA sequences of
the wild-type and mutated genes were checked with DNA
sequencing. The molecular masses of the purified variants
were checked with MALDI mass spectrometry. Protein
purity was found by SDS-PAGE to be[95% in all cases.
Labeling with DACM
Each protein variant was diluted to 0.2 mM in 20 mM
phosphate buffer at pH 7.4, 25 C. Aliquots of DACM
dissolved in pure DMSO were added to a tenfold molar
excess of dye. The sample was wrapped with aluminium
foil and incubated under shaking for 1 h at 37 C. The
reaction was quenched with 5 ll of TFA. The unbound dye
was removed by extensive dialysis, using membranes with
a 3.0 kDa molecular weight cut off, and the sample was
then centrifuged to remove any precipitate. DACM con-
centration of the resulting labelled protein sample was
determined using e381 = 27,000 M
-1 cm-1. Protein con-
centration was measured at 280 nm using
e280 = 18,450 M
-1 cm-1 for labelled M-TTR,
e280 = 12,950 M
-1 cm-1 for labelled W79F and W41F-
M-TTR, and after subtraction of the contribution of an
equimolar concentration of DACM-GSH. An
e280 = 77,600 M
-1 cm-1 for labelled WT-TTR was used
as previously reported [19], To this purpose, the optical
absorption spectra of DACM-GSH and DACM-M-TTR (or
its mutants) were normalised to match identical maximum
coumarin absorbance and have fully comparable spectra.
Dynamic light scattering (DLS) measurements
Samples were prepared at a final protein concentration of
15 lM in 20 mM phosphate buffer, pH 7.4, 25 C or
20 mM acetate buffer, pH 4.4, 25 C. Before the mea-
surements, the protein samples were filtered with Anotop
filters having a cutoff of 20 nm (Whatman, Little Chalfont,
UK). DLS measurements were performed using a Zetasizer
Nano S device from Malvern Instruments (Malvern,
Worcestershire, UK) thermostated with a Peltier system.
Low-volume 10 9 4 mm disposable cells were used. The
values of refractive index and viscosity set on the instru-
ment were determined using the software provided with the
instrument, based on the information of buffer and tem-
perature provided by the user. The presented size
distributions were the average of three consecutive
measurements.
X-ray crystallography
DACM-WT-TTR and DACM-M-TTR were concentrated
and buffer-exchanged at 4 C with Amicon Ultra-4 Cen-
trifugal Filter Unit with Ultracel-3 membrane, Ultracel-
3K (Merck Millipore, Billerica, MA, USA) down to a final
concentration of 12 mg ml-1, in 100 mM KCl, 20 mM
Sodium Phosphate, pH 7.4. Both were crystallized by sit-
ting-drops technique at 20 C: DACM-WT-TTR
crystallized in 0.2 M of CaCl2, 0.1 M of HEPES sodium,
pH 7.5, 28% v/v polyethylene glycol 400; DACM-M-TTR
crystallized in 0.2 M of CaCl2, 0.1 M of sodium acetate,
pH 4.6, 20% v/v 2-propanol. Both were cryoprotected
adding glycerol to the crystallization solution (final con-
centration 30% v/v) and flash-frozen in liquid nitrogen.
Diffraction data for DACM-WT-TTR and DACM-M-TTR
were collected at the European Synchrotron Radiation
FRET studies of various conformational states adopted by transthyretin 3579
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Facility (ESRF, Grenoble, France) at the ID23-1 and at the
ID23-2 beam line to the resolution of 1.42 and 1.7 A˚,
respectively.
To assess if DACM was damaged during the X-ray data-
collection, crystal absorption spectra were collected before
and after the diffraction experiment at ID29S (ESRF): both
spectra display the maximum absorption at 384 nm typical
of DACM and their intensities are comparable ruling out
major radiation damage (data not shown).
The diffraction data were integrated and processed using
MOSFLM [30], POINTLESS and SCALA [31–33]. The
crystal structure of DACM-WT-TTR was determined using
BALBES [34] while that of DACM-M-TTR was deter-
mined by MOLREP [35] using the structure of M-TTR
(pdb code: 1GKO [25]) as a search model. Refinement was
performed using Refmac5 and Phenix Refine [36, 37].
Manual model building, visual inspection, addition of
water molecules were carried out with Coot [38]. Images of
all TTR structures were generated by CCP4mg [33].
Molecular dynamics (MD) simulations
M-TTR was modelled with the Amber99sb force field [39],
while DACM was modelled with the GAFF force field
[40]. Starting from the X-ray crystallographic structure of
DACM-M-TTR, the system was solvated with 5171 TIP3P
water molecules in a volume of 1750 A˚3. A MD simulation
was carried out with Gromacs 4.5.5 for 20 ns at the tem-
perature of 300 K, maintained by a Nose`–Hoover
thermostat. Atomic coordinates and structure factors for the
TTR variants DACM-WT-TTR and DACM-M-TTR have
been deposited with the Protein Data Bank, with accession
codes 5LLL and 5LLV, respectively.
Fluorescence spectroscopy
Fluorescence emission spectra (excitation 290 nm) were
recorded using a PerkinElmer LS 55 spectrofluorimeter
(Waltham, MA, USA) equipped with a thermostated cell
holder attached to a Haake F8 water bath (Karlsruhe,
Germany). For typical FRET measurements protein sam-
ples were diluted to a concentration of 3 lM in 0.5 ml, in
20 mM phosphate buffer, 0.0–7.8 M urea, pH 7.4 25 C,
unless stated otherwise. Pipetting of the protein mother
solution for the various protein samples was carried out
using a Handy Step from Brand (Wertheim, Germany) to
secure accuracy. Each sample was analysed in triplicate
(three samples) and three spectra were recorded in each
case, implying that each spectrum is the average of nine
spectra. For FRET measurements during aggregation pro-
tein samples were diluted to a concentration of 1, 3, 7, 14,
28 lM in 0.7 ml under the conditions reported in the
‘‘Turbidimetry’’ section. A 2 9 10 mm and a 4 9 10 mm
quartz cuvette were used for the two sets of experiments,
respectively.
Equilibrium urea unfolding
28–34 samples were prepared containing 3 lM protein in
20 mM phosphate buffer, pH 7.4, with urea concentrations
ranging from 0 to 7.8 M and were incubated for 1 h at
25 C. Pipetting of the protein mother solution for the
various protein samples was carried out using a Handy Step
from Brand (Wertheim, Germany) to secure accuracy.
Each sample was analysed in triplicate (three samples) and
three spectra were recorded in each case, implying that
each spectrum is the average of nine spectra. Fluorescence
spectra were acquired at 25 C from 300 to 550 nm (ex-
citation 290 nm) using the spectrofluorimeter, water bath
and cuvette described above. Plots of fluorescence at a
given wavelength (either 348, 362 or 462 nm) versus urea
concentration were analyzed with the two-state unfolding
model provided by Santoro and Bolen [25, 41] to obtain
quantitative measurements of the free energy change upon
denaturation in the absence of denaturant (DGUFH2O ), the
dependence of the free energy change upon denaturation on
urea concentration (m value) and the concentration of
middle denaturation (Cm).
Stopped-flow measurements
Unfolding and refolding reactions were followed using a
Bio-Logic (Claix, France) SFM-3 stopped-flow device
equipped with an FC-08 cuvette, coupled to a fluorescence
detection system and thermostated with a Haake F8 water
bath (Karlsruhe, Germany). Excitation wavelength was
290 nm. Band-pass filters cutting emission below 385 and
320 nm were used to monitor DACM and tryptophan flu-
orescence, respectively. All the experiments were
performed in 20 mM phosphate buffer at pH 7.4 and 25 C,
at final protein concentrations of 1.5–2.9 lM. For the
unfolding experiments, native proteins in 0.5 M urea were
diluted into solutions containing urea at final concentra-
tions ranging from 3.0 to 6.5 M. Refolding reactions were
initiated by 10- to 20-fold dilutions of the protein denatured
with 5 M urea into solutions containing low urea at final
concentrations ranging from 0.25 to 3.5 M. The dead time
was generally 10.4 ms. Folding/unfolding kinetic traces
were analysed as previously described [28]. In another set
of experiments, the equilibrium signal measured at the end
of unfolding kinetics was plotted versus urea concentration
to linearly extrapolate the fluorescence of the labelled or
unlabelled unfolded protein under native conditions (0.5
and 2.1 M urea).
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Turbidimetry
15 lM M-TTR and 15 lM DACM-M-TTR were incu-
bated in 20 mM acetate buffer, pH 4.4, 37 C, in the
presence of 0, 30, 60, 90 or 137 mM NaCl. 15 lM W79F-
M-TTR and 15 lM DACM-W79F-M-TTR were incubated
in 20 mM acetate buffer, pH 5.6, 37 C, in the presence of
0, 30, 60, 90 or 137 mM NaCl. The time dependent
development of turbidity at 450 nm was followed at 37 C
using a Jasco V-630 spectrophotometer (Tokyo, Japan),
thermostated within ±0.1 C by a Haake F8 water bath
(Karlsruhe, Germany) and using a 10 mm path length cell.
All turbidity values were blank subtracted.
Far-UV CD spectroscopy
Far-UV CD spectra of samples containing 16 lM non-
mutated, W41F and W79F-M-TTR in 20 mM sodium
phosphate buffer, pH 7.4, 25 C were collected from 185 to
250 nm using a J-810 Spectropolarimeter from Jasco
(Tokyo, Japan) equipped with a thermostated cell holder
attached to a Thermo Haake C25P water bath (Karlsruhe,
Germany). A 0.1 mm path-length cell (Hellma, Mu¨llheim,
Germany) was used. All spectra were blank subtracted and
converted to mean residue ellipticity per residue [H].
Results
Purification and labeling of M-TTR
We first purified M-TTR and labelled it with N-(7-
dimethylamino-4-methylcoumarin-3-yl)maleimide
(DACM), as described in the ‘‘Materials and methods’’
section. The samples containing the purified unlabelled and
labelled proteins were analysed with MALDI mass spec-
trometry (Fig. 1a). A single peak at 13,895 ± 10 and
14,193 ± 10 Da were detected for unlabelled and labelled
M-TTR, respectively, in agreement with the expected
molecular weights of the two protein samples, i.e. 13,894.7
and 14,193.0 Da, respectively. In the mass spectrum of
DACM-M-TTR we could not detect peaks corresponding
to the molecular weights of M-TTR with double or triple
DACM labelling, excluding the presence of M-TTR
labelled with two or more DACM moieties. We could not
detect any peak corresponding to unlabelled M-TTR,
indicating that no detectable unlabelled protein remained at
the end of the labeling reaction.
As an evidence that unlabelled and labelled M-TTR are
monomeric, we assessed the size distributions of M-TTR,
DACM-M-TTR and wild-type tetrameric TTR (WT-TTR)
by means of dynamic light scattering (DLS) at pH 7.4,
25 C (Fig. 1b). An apparent hydrodynamic diameter of
4.20 ± 0.11 nm was observed for M-TTR, which is con-
sistent with the hydrodynamic diameter of monomeric
folded M-TTR, as reported previously [25, 28, 42]. An
apparent hydrodynamic diameter of 5.03 ± 0.10 nm was
observed for DACM-M-TTR. This diameter is higher than
that of unlabelled M-TTR, possibly due to the presence of
the covalently attached and solvent-exposed DACM moi-
ety. A diameter of 5.03 ± 0.10 nm is, however,
significantly lower than that measured for wild-type tetra-
meric TTR (6.17 ± 0.02 nm) and of that expected for
labelled dimeric M-TTR ([5.2 nm) and labelled tetrameric
M-TTR ([6.5 nm) based on purely geometric considera-
tions and of the diffusion of dimeric and tetrameric species
in solution in the three dimensions. Overall, the DLS
results indicate that both M-TTR and DACM-M-TTR are
monomeric.
Next, to gauge the labelling degree of DACM-M-TTR,
we acquired optical absorption spectra of DACM-M-TTR
and of DACM covalently attached to glutathione (DACM-
GSH) at pH 7.4, 25 C and at the same probe concentration
(Fig. 1c). The concentration of DACM bound to M-TTR
was determined by measuring the optical absorption at
381 nm (A381), using a molar extinction coefficient (e381)
of 27,000 cm-1 M-1 (Fig. 1c, blue spectrum). Protein
optical absorption in the DACM-M-TTR sample was then
reconstructed by subtracting the spectrum of DACM-GSH
(Fig. 1c, green spectrum) from that of DACM-M-TTR
sample (Fig. 1c, blue spectrum). In the resulting difference
spectrum (Fig. 1c, red spectrum), protein concentration
was measured at 280 nm (A280), using a molar extinction
coefficient (e280) of 18,450 cm
-1 M-1 (an e280 value of
12,950 cm-1 M-1 was used for the W79F mutant descri-
bed below). Labelling degree d was then calculated using:
dð%Þ ¼ 100 ðA381=e381Þ=ðA280=e280Þ: ð1Þ
The spectroscopic investigation described below was
carried out with samples having d C 95%.
The fluorescence spectrum of M-TTR at pH 7.4, 25 C
(excitation at 290 nm) is dominated by a major large band
at 330–350 nm (Fig. 1d, red spectrum), resulting largely
from Trp41 as the fluorescence of Trp79 is largely quen-
ched [23]. The fluorescence spectrum of an equimolar
quantity of DACM-GSH, acquired under the same condi-
tions (excitation at 290 nm), is very low in intensity and
negligible (Fig. 1d, green spectrum). By contrast, the flu-
orescence spectrum of an equimolar quantity of DACM-M-
TTR under the same conditions (excitation at 290 nm) is
characterized by a significant decrease of tryptophan fluo-
rescence intensity, relative to the spectrum of M-TTR, and
a substantial enhancement of the DACM emission inten-
sity, relative to the spectrum of DACM-GSH, indicating
that FRET is occurring. FRET is largely due to the energy
transfer from Trp41 to DACM, both because the
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fluorescence of Trp79 is quenched and because Trp79 is
more distant from DACM compared to Trp41. Importantly,
the fluorescence intensity of the tryptophan band is not
completely cancelled, leading to a FRET efficiency value
(E) intermediate between 0 (no FRET) and 1 (full FRET),
making it possible to monitor changes of the distance
between donor (Trp41) and acceptor (DACM) by FRET
measurements.
Fig. 1 Labelling of M-TTR. aMALDI mass spectrometry analysis of
M-TTR (red) and DACM-M-TTR (blue). The expected molecular
weights for human M-TTR and DACM-M-TTR are 13,894.7 and
14,193.0, respectively. b Size distributions of M-TTR (blue), DACM-
M-TTR (pale blue), WT-TTR (red) and DACM-WT-TTR (orange)
samples obtained with DLS at pH 7.4, 25 C. c Optical absorption
spectra of DACM-M-TTR (blue) and DACM-GSH (green) at pH 7.4,
25 C and at the same probe concentration. The difference spectrum
obtained by subtracting the latter from the former is also shown (red).
d Fluorescence spectra of M-TTR (red), DACM-M-TTR (blue) and
DACM-GSH (green) at pH 7.4, 25 C (excitation 290 nm)
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Overall, these data indicate that DACM-M-TTR is
monomeric, singly labelled with an efficiency close to
100% and with donor/acceptor distance ideal for FRET
measurements.
X-ray crystal structures of DACM-M-TTR
and DACM-WT-TTR
To determine if DACM labeling on Cys10 affects M-TTR
structure, the X-ray crystal structures of DACM-WT-TTR and
DACM-M-TTR were determined at high resolution and com-
pared with that of WT-TTR and M-TTR previously deposited
in the Protein Data Bank [25, 43]. Data collection and refine-
ment statistics are reported in Table 1. In both structures, from
Cys10 to Asn124, all polypeptide chains are well traceable into
the electrondensitymapand, in the caseofDACM-M-TTR, the
F87M/L110Mmutations are clearly detectable. As observed in
most of the previous TTR structures, the first nine residues are
flexible and not present in the electron density. In bothDACM-
WT-TTR and DACM-M-TTR, the presence of some extra
density around Cys10 suggests the presence of DACM. The
quality of such density is too poor to allow the building of
DACM in the model, suggesting a high degree of conforma-
tional flexibility of the DACM moiety.
DACM-WT-TTR and DACM-M-TTR crystallised in
P21221 and P212121 space group, respectively: DACM-
WT-TTR has two molecules in the asymmetric unit (AU),
whereas the AU of the DACM-M-TTR structure contains
four molecules, as already observed in the M-TTR struc-
ture [25]. Superimposition of the DACM-labelled variants
with the corresponding non-labeled variants shows that the
structures of the DACM-WT-TTR and DACM-M-TTR are
perfectly superimposable onto those of WT-TTR and
M-TTR, respectively, indicating that DACM labeling does
not interfere with the TTR native fold in the crystal
(Fig. 2a, b; Table 1).
As mentioned above, DACM was not traceable in the
electron density, due to its high mobility. Thus, MD sim-
ulations of the solvated DACM-M-TTR were performed,
as described in the Materials and Methods, to provide the
correct distribution of the DACM conformers, weighted
according to Boltzmann statistics. The DACM moiety was
not found to be randomly distributed in space during the
simulation, with certain conformations more populated
than others (Fig. 2c). The mean Trp41–DACM and Trp79–
DACM spatial distances, calculated over the centers of
mass, were found to be 23.2 ± 2.0 and 26.2 ± 2.0 A˚,
respectively (Fig. 2d).
Table 1 Data collection and refinement statistics for DACM-WT-TTR and DACM-M-TTR
Crystala DACM-WT-TTR DACM-M-TTR
Space group P 21221 P 212121
Unit cell constants (A˚) a = 43.68, b = 64.49, c = 85.27
a, b, c = 90 C
a = 64.44, b = 83.76, c = 86.53
a, b, c = 90 C
Resolution (A˚) 22.35–1.42 (1.50–1.42) 22.04–1.70 (1.79–1.70)
Rmerge (%)
b 9.7 (73.0) 11.1 (77.2)
I/rI 8.1 (2.1) 8.1 (1.9)
Completeness (%) 99.1 (99.2) 99.5 (99.8)
Multiplicity 5.0 (5.0) 4.1 (4.3)
Molecules per asymmetric unit 2 4
Refinement
Rwork (%)
c 16.0 15.0
Rfree (%) 21.7 22.3
Ramachandran plot, n (residues)
Most favored region 200 421
Allowed region 3 8
Outliers 0 2
RMSDd 0.31 A˚ 114/114 Ca 0.60 A˚ 115/115 Ca
a Values given in parenthesis refer to the high-resolution shell
b Rmerge = Rhkl RjIhkl,j - Ihklh i/RhklRjIhkl,j where I is the observed intensity and Ih i is the average intensity
c Rwork = RhklFo - Fc/RhklFo for all data except 5–10%, which were used for the Rfree calculation
d RMSD values calculated from the structural superposition of the DACM-WT-TTR and DACM-M-TTR structures with the non-labeled WT-
TTR (pdb code: 1BMZ) and M-TTR (pdb code: 1GKO)
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Fig. 2 X-ray crystal structures of DACM-M-TTR and DACM-WT-
TTR. a Superposition of the structures of DACM-M-TTR (blue),
DACM-WT-TTR (magenta) and WT-TTR (yellow, pdb code: 1BMZ
[43]). b Tetrameric structure of DACM-M-TTR. The residues Met87
and Met110, that destabilize the tetrameric structure in solution,
are shown as sticks. c MD simulations of DACM-M-TTR: Trp41,
Trp79 and the most populated conformation of Cys10-DACM are
shown as sticks. d Distributions of the spatial distances between the
centers of mass of Trp41 and DACM (black) and those of Trp79 and
DACM (red), calculated using MD simulations starting from the
crystal structure of DACM-M-TTR. The dashed lines indicate the
mean spatial distances assuming a single average conformer for the
DACM moiety
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FRET efficiency of native M-TTR and Fo¨rster
distance of the Trp/DACM pair
We first determined the FRET efficiency of DACM-M-
TTR under conditions in which the protein is folded, at pH
7.4, 25 C. To this aim, we mixed different volumes of
samples containing M-TTR and DACM-M-TTR, each at
the same concentration of 3 lM, to achieve different per-
centages of labelled M-TTR, from 0 to 100%. Fluorescence
emission spectra were obtained for all the resulting samples
using an excitation wavelength of 290 nm (Fig. 3a). The
emission spectrum of unlabeled M-TTR (0% DACM-M-
TTR) showed an intense peak at 330–350 nm, resulting
from tryptophan fluorescence emission, and no emission at
465 nm due to the absence of the DACM moiety (Fig. 3a,
red spectrum). By contrast, the emission spectrum of
labeled M-TTR (100% DACM-M-TTR) shows a low
intensity peak at 330–350 nm and an intense peak at
465 nm, due to the energy transfer from the excited tryp-
tophan residues to the DACM group, which fluoresces at
465 nm (Fig. 3a, blue spectrum). The samples presenting
intermediate degrees of labelling have an intermediate
behaviour, with the donor and acceptor peaks decreasing
and increasing in intensity with labelling degree, respec-
tively (Fig. 3a, red to blue spectra).
The FRET efficiency can be calculated using [44]:
E ¼ 1 FDA
FD
; ð2Þ
where E is the FRET efficiency, FDA and FD are the flu-
orescence emission values of the donor in the presence and
absence of acceptor, respectively, i.e. the tryptophan
emission values at 348 nm measured for the samples
containing 100 and 0% DACM-M-TTR, respectively. This
led to E = 0.70 ± 0.02. To achieve more accurate mea-
surements of FDA, FD and E we plotted the tryptophan
fluorescence emission at 348 nm versus the percentage of
DACM-M-TTR and analyzed the resulting plot with a
procedure of best fitting using a linear equation (Fig. 3b).
This provided more accurate values of FDA and FD and a
value of E = 0.72 ± 0.02.
We then measured the fluorescence spectra of M-TTR
and DACM-M-TTR at various protein concentrations
ranging from 1 to 10 lM (Fig. 3c) and measured the
E values at each of these concentrations (Fig. 3d). E was
found to be independent of protein concentration, indicat-
ing that M-TTR and DACM-M-TTR remain largely
monomeric under this range of protein concentration. In
addition, the value of E remains lower than that measured
for tetrameric DACM-WT-TTR (data not shown), corrob-
orating the absence of protein tetramerisation under the
conditions studied here.
To determine the distance between Trp41 (donor) and
DACM (acceptor) in the folded monomer using the E
value, we first determined experimentally the Fo¨rster dis-
tance using:
R60 ¼ 8:79 105 j2n4QDJ kð Þ
 
; ð3Þ
where R0 is the Fo¨rster distance (in A˚), j
2 is the orientation
factor describing the relative orientation of the transition
dipole moments of the donor and the acceptor, n is the
refractive index of the aqueous solution, QD is the quantum
yield of an isolated donor, and J(k) is the integral
expressing the degree of spectral overlap between donor
emission and acceptor absorption (units of nm4 M-1 cm-1)
[44, 45]. A k2 value of 0.87 was used as a good
approximation of a donor–acceptor orientation factor of a
folded protein [46], whereas n, QD and J(k) were
determined experimentally (Table 2). This allowed the R0
parameter to be determined for folded M-TTR as
24.9 ± 1.4 A˚ (Table 2). We then used these R0 and E
values determined experimentally for folded DACM-M-
TTR to determine the donor–acceptor distance (R) using
the equation [44]:
R6 ¼ R60ð1=E  1Þ; ð4Þ
where R is the distance between the centers of mass of
Trp41 and DACM (in A˚). This led to a value of R of
21.3 ± 1.6 A˚, in good agreement with that determined
from X-ray crystallography (R = 23.2 ± 2.0 A˚).
FRET efficiency of urea-induced unfolded
and molten globule states of M-TTR
Next, we acquired fluorescence spectra of M-TTR and
DACM-M-TTR (excitation 290 nm) at urea concentrations
ranging from 0 to 7 M at pH 7.4, 25 C (Fig. 4a, b). The
corresponding urea denaturation curves (spectroscopic
signal versus urea concentration at equilibrium) were
obtained using tryptophan fluorescence at 362 nm as a
spectroscopic probe for both the labelled and unlabeled
proteins (Fig. 4c). The analysis yielded values of confor-
mational stability in the absence of denaturant (DGUFH2O ) of
20.4 ± 1.5 and 11.1 ± 1.5 kJ mol-1, dependencies of
DGUFH2O on urea concentration (m value) of 6.9 ± 0.5 and
4.3 ± 0.5 kJ mol-1 M-1 and midpoint of denaturation
(Cm) of 3.0 ± 0.1 and 2.6 ± 0.1 M for M-TTR and
DACM-M-TTR, respectively. The values obtained for M-
TTR are in reasonable agreement with those obtained
previously under slightly different conditions [28]. The
urea denaturation curve of DACM-M-TTR was also
obtained using DACM fluorescence at 462 nm as a spec-
troscopic probe (Fig. 4d). This led to values of
12.4 ± 1.3 kJ mol-1, 4.9 ± 0.4 kJ mol-1 M-1 and
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2.5 ± 0.1 M for DGUFH2O , m and Cm, respectively, in
agreement with those obtained using tryptophan fluores-
cence as a spectroscopic probe. This analysis indicates that
the conformational stability of DACM-M-TTR is signifi-
cantly lower than that of M-TTR, indicating that the
labeling has an effect on protein conformational stability,
as it is often observed for mutations.
In principle, one can obtain a urea denaturation curve by
plotting E versus urea concentration. However, such a
curve suffers from different conformational stabilities of
labelled and unlabelled M-TTR which makes it difficult to
compare fluorescence spectra for the two proteins at the
same urea concentration and determine E at each urea
concentration. In spite of these difficulties, it is possible to
determine the E values at low (\1.2 M) and high ([4.8 M)
urea concentrations when the major conformational tran-
sition has not yet and has completely occurred,
respectively, for both labelled and unlabeled proteins. The
Fig. 3 FRET of native M-TTR. a Fluorescence spectra of mixtures of
M-TTR and DACM-M-TTR at the indicated percentages of the latter,
at 3 lM total protein concentration, pH 7.4, 25 C. b Tryptophan
fluorescence emission at 348 nm versus the percentage of DACM-M-
TTR. The straight line represents the best fit of the data points to a
linear function. The equation indicates how E was determined.
c Fluorescence spectra of M-TTR (dashed lines) and DACM-M-TTR
(continuous lines) at various protein concentrations ranging from 1 to
10 lM, pH 7.4, 25 C (excitation 290 nm). d Plot of E versus M-TTR
concentration. The straight line represents the average value
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FRET E values at 5.0 and 6.0 M urea, when DACM-M-
TTR is unfolded, are remarkably lower than those deter-
mined at 0.0 and 1.0 M urea, indicating a significantly
higher distance between the DACM moiety attached to
Cys10 and the two tryptophan residues (Fig. 4e). The R0
and R values, determined as described above using Eqs. 3
Table 2 FRET parameters of M-TTR adopting different conformational states
Conformational state R (A˚) E R0 (A˚) QD n J(k) (nm
4 M-1 cm-1) j2
Folded (0 M urea) 21.3 (±1.6) 0.72 (±0.02) 24.9 (±1.4) 0.050 (±0.008) 1.332 (±0.001) 1.96 9 1014 (±0.20 9 1014) 0.87 (±0.2)
Unfolded (6 M urea) 30.8 (±1.7) 0.29 (±0.01) 26.5 (±1.4) 0.070 (±0.004) 1.384 (±0.002) 3.09 9 1014 (±0.15 9 1014) 0.67 (±0.2)
Equilibrium partially
folded (1 M urea)
24.0 (±1.6) 0.63 (±0.02) 26.2 (±1.3) 0.054 (±0.003) 1.358 (±0.001) 2.66 9 1014 (±0.13 9 1014) 0.87 (±0.2)
Amyloidogenic
partially folded (0 M
urea, pH 4.5)
21.1 (±1.2) 0.73 (±0.02) 24.9 (±1.4) 0.049 (±0.003) 1.332 (±0.001) 2.03 9 1014 (±0.10 9 1014) 0.87 (±0.2)
E values were determined experimentally from the fluorescence spectra of DACM-M-TTR and M-TTR, respectively. QD was determined
experimentally using free tryptophan as a reference. n was determined experimentally using a 2WAJ ABBE bench refractometer from Optika
Microscopes (Bergamo, Italy). J(k) was determined experimentally as the integral expressing the degree of spectral overlap between donor
emission and acceptor absorption [44, 45]. j2 was assumed to be 0.87 ± 0.2 for folded proteins [46] and 2/3 (0.67 ± 0.2) for unfolded proteins
[44]. R0 values were determined using Eq. 3. R values were determined from E and R0 values using Eq. 4
Fig. 4 FRET of urea-unfolded and molten globule states of M-TTR.
a, b Fluorescence spectra of M-TTR (a) and DACM-M-TTR (b) at
urea concentrations ranging from 0 to 6.2 M at pH 7.4, 25 C
(excitation 290 nm). c Urea denaturation curves (spectroscopic signal
versus urea concentration) using tryptophan fluorescence at 362 nm
as a spectroscopic probe for both M-TTR and DACM-M-TTR. d Urea
denaturation curve of DACM-M-TTR, using DACM fluorescence at
462 nm as a spectroscopic probe. e FRET E values at the indicated
urea concentrations, pH 7.4, 25 C
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and 4, confirm a larger mean distance between donor and
acceptor in the unfolded state (Table 2). The large decrease
of the FRET E value upon unfolding indicates that such
distance can be monitored with high sensitivity. The
DACM fluorescence at 462 nm also decreases from
0.0–1.0 M to 5.0–6.0 M urea (Fig. 4d), confirming that the
spatial distance between DACM and the two tryptophan
residues increases upon unfolding and gives us the
opportunity to observe the movement of DACM from
Trp41 in the transition region in which the FRET E value
could not be calculated.
Importantly, the FRET E value at 1.0 M urea is similar,
within experimental error, to that determined at 0.0 M urea
(Fig. 4e). This also results into a similar R value, deter-
mined as described above using Eqs. 3 and 4 (Table 2).
The DACM fluorescence also does not change significantly
(Fig. 4d). This indicates that the equilibrium molten glob-
ule state previously detected at low urea concentrations and
having a transition at 0.0–2.4 M urea [28] has an unmod-
ified distance between the DACM moiety and Trp41.
FRET efficiency of the transiently populated
partially folded state of M-TTR
We then monitored the folding and unfolding processes of
M-TTR and DACM-M-TTR in real time by diluting the
urea-unfolded proteins into solutions containing low urea
concentrations (folding) and by diluting the folded protein
into solutions containing high urea concentrations (un-
folding) using a stopped-flow device coupled to a
fluorescence detection system. Representative folding tra-
ces recorded in 0.5 M urea, pH 7.4, 25 C and monitored
with intrinsic tryptophan fluorescence at 320–385 nm are
shown for M-TTR and DACM-M-TTR (Fig. 5a, b). In
addition to the major folding phase, two more low-ampli-
tude exponential phases were observed for M-TTR, which
were complete on a longer time scale, as observed previ-
ously [28]. Moreover, in addition to the major unfolding
phase, one additional low-amplitude unfolding phase was
apparent on a long time scale, again as observed previously
[28]. This behaviour was also observed for the labelled
protein.
The analysis of the resulting kinetic traces of folding
and unfolding with a procedure of best fit using exponential
functions allowed the rate constants for the major folding/
unfolding transition (k) to be determined at the various urea
concentrations (see ‘‘Materials and methods’’ for further
details). These values were used to build the plot of
ln(k) versus urea concentration, generally referred to as
Chevron plot, for both the labelled and unlabelled proteins
(Fig. 5c). The Cm values obtained from the analysis of
these plots, calculated as the urea concentration at which
extrapolated refolding and unfolding rate constants are
equal (3.2 ± 0.2 and 2.2 ± 0.2 M for M-TTR and DACM-
M-TTR, respectively), were in good agreement with those
determined from equilibrium experiments (3.0 ± 0.1 and
2.5 ± 0.1 M, respectively). The downward curvature in the
folding branch of the M-TTR plot results from a rapidly
formed, off-pathway, partially folded species that forms
rapidly and accumulates during the folding process [28].
Such a curvature was also observed for DACM-M-TTR
(Fig. 5c). The refolding rate constant did not vary as the
concentration of DACM-M-TTR ranged from 0.005 to
0.080 mg ml-1, ruling out that the downward curvature
arises from DACM-M-TTR aggregation during folding
(data not shown). The extrapolated unfolding rate constants
in the absence of denaturant were 1.82 ± 0.18 s-1 [28] and
6.73 ± 0.70 s-1 for M-TTR and DACM-M-TTR, respec-
tively. Given the conformational stabilities obtained by
equilibrium experiments, the folding rate constants under
the same conditions would be *7100 s-1 [28] and
*890 s-1, respectively, on the assumption they were two-
state folders. By contrast, the refolding rate constants
extrapolated by experimental data were orders of magni-
tude lower than the calculated values, i.e. 81 ± 8 s-1 [28]
and 60 ± 5 s-1 for M-TTR and DACM-M-TTR, respec-
tively. This corroborates the hypothesis that a partially
folded species accumulates for both M-TTR and DACM-
M-TTR.
The spectroscopic signals at 320–385 nm recorded for
M-TTR and DACM-M-TTR at the beginning and at the
end of the kinetic traces in 0.5 M urea, pH 7.4, 25 C
(Fig. 5a, b) were thus used to calculate transient and
equilibrium FRET E values of the folded and partially
folded states under these conditions. These were found to
be 0.66 ± 0.03 and 0.72 ± 0.03, indicating a slightly
higher FRET E value for the partially folded state relative
to the folded state. We also monitored the DACM fluo-
rescence emission of such a partially folded state by
inspecting the kinetic trace for folding in 0.5 M urea using
a band-pass filter that cuts the signal below 385 nm, to
monitor the fluorescence of the DACM moiety and exclude
that of the tryptophan indole groups (Fig. 5d). Such a
kinetic trace involved a decrease in DACM fluorescence,
complete in *50 ms in 0.5 M urea, as DACM-M-TTR
underwent refolding (Fig. 5d). The signal of the folded
protein and that of the unfolded protein extrapolated down
to 0.5 M urea by linear extrapolation from measurements at
high urea concentrations, where the protein is 100%
unfolded, were remarkably lower (Fig. 5d). This analysis
suggests that the transient partially folded state of M-TTR
has a DACM fluorescence higher not just than the unfolded
state, but also than the fully folded state. The observation
of an increase of FRET efficiency by monitoring both
tryptophan and DACM fluorescence and using the same
stopped-flow apparatus and experimental conditions
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indicates that the increase is significant. As a control, the
kinetic trace for folding in the presence of 2.1 M urea,
where the partially folded state cannot be detected, did not
show such a burst-phase increase of DACM fluorescence
(data not shown). Phenomena different from FRET may
concur to the hyperfluorescence exhibited by DACM in the
partially folded state, including a different local environ-
ment experienced by the coumarin moiety.
DACM fluorescence emission was also followed during
unfolding. A decrease in DACM emission was observed, in
agreement with an increase in distance between donor and
acceptor during the process. As previously observed using
intrinsic fluorescence as an optical probe [28], such
decrease involved two phases, lasting ca. 0.1 and 30 s,
respectively, in the trace recorded in 4.5 M urea taken here
as an example (data not shown).
FRET efficiency of the amyloidogenic state of M-
TTR
The FRET analysis was also used to investigate the
structure of M-TTR under conditions in which the protein
Fig. 5 FRET during M-TTR refolding. a, b Refolding time course of
M-TTR (red filled circles) and DACM-M-TTR (blue open circles)
monitored by tryptophan fluorescence (excitation 290 nm, emission
320–385 nm) in 0.5 M urea at pH 7.4, 25 C. c Natural logarithm of
the observed folding/unfolding microscopic rate constants for
DACM-M-TTR (blue open circles) compared to data previously
published for M-TTR (red filled circles) [28], plotted as a function of
urea concentration (chevron plot), at pH 7.4, 25 C. d Refolding time
course of DACM-M-TTR (blue open circles) monitored by DACM
fluorescence (excitation 290 nm, emission[385 nm) in 0.5 M urea at
pH 7.4, 25 C. The signals of folded and unfolded DACM-M-TTR are
also indicated
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is initially monomeric but slowly converts into amyloid
fibrils, i.e. at pH 4.4, 37 C [23, 25]. To check that these
conditions of pH and temperature also promoted aggrega-
tion of DACM-M-TTR and identify conditions suitable for
slow aggregation (so that the initial monomeric DACM-M-
TTR can be monitored), DACM-M-TTR aggregation was
studied at a protein concentration of 15 lM, in 20 mM
acetate buffer, pH 4.4, 37 C, under the effect of different
ionic strengths, that is in the presence of 0, 30, 60, 90 and
137 mM NaCl. The time courses of turbidity at 450 nm
show a gradual increase of the rate of turbidity develop-
ment with the increase of ionic strength (Fig. 6a). The
sigmoidal pattern of the intermediate time courses indicates
that formation of amyloid fibrils involves the typical three
phases of the amyloid fibril formation process: an initial lag
phase, a subsequent growth phase and a final saturation
phase (plateau). At 30 mM NaCl the time length of the first
phase was relatively large but aggregation could still be
observed, so that we selected this condition of ionic
strength to study the aggregation of the protein.
DLS measurements confirmed that DACM-M-TTR was
monomeric immediately after incubation at pH 4.4 (Fig. 6b).
Indeed, the size distributions ofM-TTR and DACM-M-TTR
at pH 7.4, used here as references of monomeric conforma-
tions, had major peaks of hydrodynamic diameters at
4.20 ± 0.11 and 5.03 ± 0.10 nm, respectively, with the
slightly higher increase of the latter due to the presence of the
DACM moiety (see above). The size distributions acquired
immediately after incubation at pH 4.4 were found to have
major peaks at 4.65 ± 0.26 and 5.60 ± 0.30 nm, respec-
tively (Fig. 6b). Thesewere both slightly higher than those of
the corresponding proteins at pH 7.4, most likely as a con-
sequence of the partial unfolding of the proteins at pH 4.4
[23], but were still lower than those of partially unfolded
dimers or higher order oligomers.
Hence, both M-TTR and DACM-M-TTR were incubated
at 1, 3, 7, 14, 28 lM in 20 mM acetate buffer, 30 mM NaCl,
pH 4.4, 37 C, and fluorescence spectra were collected at
different time points, to measure the FRET efficiency
(E) values as aggregation proceeded (Fig. 6c–e). Since
M-TTR and DACM-M-TTR aggregate with different rates
under the selected conditions, the FRET E values are mean-
ingful only immediately after incubation (time 0 s) and at the
plateau of the aggregation process (time 3000 s) when both
proteins are completely monomeric and aggregated, respec-
tively. The FRET E value of the amyloidogenic state at 0 s
from the five different kinetic traces and the resulting R value
determined with Eqs. 3 and 4 were found to be 0.73 ± 0.02
and 21.1 ± 1.2 A˚, respectively, which are very similar to
those measured for the folded proteins at pH 7.4, 25 C,
indicating an unchanged distance between Trp41 and Cys10
upon partial unfolding at pH 4.4, 37 C (Fig. 6f). The FRET
E value at 3000 s was found to be 0.82 ± 0.01. This value is,
however, difficult to interpret because both tryptophan and
coumarin fluorescences are quenched in the aggregated state,
the Fo¨rster distance can change following aggregation and is
difficult to determine and a population of different aggregates
may exist in the sample.
Purification and analysis of W41F and W79F
mutants of M-TTR
Although Trp79 is quenched and more distant than Trp41
to Cys10 in the folded state, doubts remain in partially or
fully unfolded states, where Trp79 may not be quenched
and may be placed closer to Cys10 than Trp41. We
therefore, inserted single point mutations in the gene
encoding M-TTR and we purified and labelled two single
mutants of M-TTR, replacing either Trp41 or Trp79 by a
phenylalanine residue (W79F and W41F) and repeated the
FRET experiments to assess the involvement of individual
inter-residue distances in the overall measured FRET.
The W79F mutant has a far-UV circular dichroism (CD)
spectrum very similar to that of non-mutated M-TTR in
20 mM phosphate buffer, pH 7.4, 25 C, with a negative
peak around 215 nm and a positive peak at 196 nm, typical
of b-sheet structure (Fig. 7a). By contrast, the W41F mutant
is remarkably different, with mean residue ellipticity peaks
characterized by a low intensity, that is reminiscent of pro-
tein aggregation (Fig. 7a). The DLS analysis at pH 7.4,
25 C confirmed that both W79F-M-TTR and DACM-
W79F-M-TTR aremonomeric, whereas bothW41F-M-TTR
and DACM-W41F-M-TTR are aggregated (Fig. 7b). As a
further evidence that W41F-M-TTR aggregates rapidly
under native conditions, the time courses of turbidity at
15 lM protein concentration, 20 mM phosphate buffer,
0–137 mMNaCl, pH 7.4, 37 C indicate thatW41F-M-TTR
has a high turbidity at time 0 s in all kinetic traces under
native conditions, including at 0 mM NaCl (Fig. 7c).
Comparison of the FRET efficiency values of mutant
and non-mutated M-TTR
Since W79F-M-TTR, unlike the W41F variant, appears to
be soluble and monomeric at pH 7.4, 25 C, we repeated
cFig. 6 FRET of the amyloidogenic and aggregated states of M-TTR.
a Effect of different NaCl concentrations on the kinetics of 15 lM
DACM-M-TTR aggregation in 20 mM acetate buffer, pH 4.4, 37 C,
monitored with turbidimetry at 450 nm. b DLS size distributions of
M-TTR and DACM-M-TTR at both pH 7.4 and 4.4. c, d Fluorescence
spectra at different time points for M-TTR (c) and DACM-M-TTR
(d) in 20 mM acetate buffer, 30 mM NaCl, pH 4.4, 37 C. e Change
of E during aggregation. Conditions as in c, d. f FRET E values for
native M-TTR at pH 7.4, 25 C (first bar), amyloidogenic monomeric
M-TTR at pH 4.4, 37 C, 0 s (second bar) and aggregated M-TTR at
pH 4.4, 37 C, 3000 s (third bar)
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the same experiments carried out with non-mutated
M-TTR, as the mutant provides the opportunity to measure
the distance between DACM and Trp41 in the absence of
possible artefacts (Fig. 8). The FRET E value of the folded
state of W79F-M-TTR at pH 7.4, 25 C was found to be
0.76 ± 0.02 (Fig. 8a), which is close to the value of non-
mutated M-TTR (E = 0.72 ± 0.02). This indicates that the
mutation does not alter significantly the inter-residue dis-
tance between Cys10 and Trp41 in native M-TTR and
reinforces the view that the FRET E value determined for
wild-type M-TTR mainly reports on Trp41 and its distance
from DACM.
The analysis of the urea denaturation curves of the
unlabelled and labelled W79F mutant, monitored with
tryptophan fluorescence, yielded values of DGUFH2O of
13.0 ± 1.4 and 8.6 ± 0.9 kJ mol-1, respectively, m values
of 4.3 ± 0.4 and 4.2 ± 0.4 kJ mol-1 M-1, respectively,
Cm values of 3.0 ± 0.1 and 2.0 ± 0.2 M, respectively
(Fig. 8b). The DGUFH2O values of W79F-M-TTR and
DACM-W79F-M-TTR are significantly lower than those of
the corresponding wild-type proteins, indicating that the
mutation lowers the conformational stability of the folded
state. Moreover, the DGUFH2O value of DACM-W79F-M-
TTR is significantly lower than that of W79F-M-TTR,
indicating that the DACM-labelling lowers the conforma-
tional stability of the folded state, as observed for non-
mutated M-TTR. The FRET E values measured after
denaturation in 5 and 6 M urea (E = 0.30 ± 0.05 and
Fig. 7 Structural and aggregation properties of W41F and W79F-M-
TTR mutants. a Far-UV CD spectra of the non-mutated and mutant
forms of M-TTR obtained in 20 mM phosphate buffer, pH 7.4, 25 C.
b Size distributions by DLS of unlabelled and labelled non-mutated,
W79F- and W41F-M-TTR at pH 7.4, 25 C. c Aggregation time
courses of W41F-M-TTR at pH 7.4, 37 C in the presence of
0–137 mM NaCl
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Fig. 8 FRET of W79F-M-TTR under different conditions. a Trypto-
phan fluorescence emission at 348 nm versus the percentage of
DACM-W79F-M-TTR, at pH 7.4, 25 C. The straight line represents
the best fit of the data points to a linear function. b Urea denaturation
curves (spectroscopic signal versus urea concentration at equilibrium)
using tryptophan fluorescence at 330 and 365 nm as a spectroscopic
probe for W79F-M-TTR and DACM-W79F-M-TTR, respectively, pH
7.4, 25 C. c Urea denaturation curve of DACM-W79F-M-TTR,
using DACM fluorescence at 462 nm as a spectroscopic probe, pH
7.4, 25 C. d FRET E values at the indicated urea concentrations.
e Effect of different NaCl concentrations on the kinetics of 15 lM
DACM-W79F-M-TTR aggregation in 20 mM acetate buffer, pH 5.6,
37 C, monitored with turbidimetry at 450 nm. f FRET E during
aggregation. Conditions were 20 mM acetate buffer, 30 mM NaCl,
pH 5.6, 37 C. g FRET E values for native W79F-M-TTR at pH 7.4
(first bar), amyloidogenic monomeric W79F-M-TTR at pH 5.6, 0 s
(second bar) and aggregated W79F-M-TTR at pH 5.6, 3000 s (third
bar)
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E = 0.24 ± 0.02, respectively) are lower than those in 0
and 1 M urea (E = 0.70 ± 0.04 and E = 0.68 ± 0.03,
respectively), indicating a higher distance between the
DACM group and the Trp41 residue (Fig. 8d). The FRET
E value in 1.0 M urea is similar or just slightly lower than
that determined in 0.0 M urea, confirming that the equi-
librium molten globule state detectable at low urea
concentrations has an unmodified distance between the
DACM moiety and Trp41. The plot of DACM fluorescence
versus urea concentration confirms that the distance
between the DACM moiety and the Trp41 residue increa-
ses upon unfolding (Fig. 8c).
Folding of W79F-M-TTR and DACM-W79F-M-TTR
was monitored in real time using the stopped-flow appa-
ratus, similarly to the non-mutated protein (Fig. 9a–c). The
spectroscopic signals analysed by imposing an off-pathway
model [28] were thus used to calculate transient and
equilibrium FRET E values of the folded (F), unfolded (U),
and partially folded (PF) states (Fig. 9d). Interestingly, the
folded and partially folded states of W79F-M-TTR were
found to have similar FRET E values, unlike non-mutated
M-TTR (Fig. 9d). In addition, the transiently populated
partially folded state for W79F-M-TTR has a DACM flu-
orescence significantly higher than those of both the folded
and unfolded states (Fig. 9c), but this effect is less dramatic
than that observed for the non-mutated protein (Fig. 5d).
Kinetic data analysis and calculation of the FRET E values
highlighted several interesting features (Fig. 9a–d).
Apparent refolding rates in 0.5 M urea were found equal to
16.3 ± 0.2 and 172 ± 20 s-1 for M-TTR and W79F-M-
TTR, respectively, suggesting a strongly destabilized par-
tially folded state following the W79F mutation. However,
when the DACM label is attached to M-TTR, refolding
rates in 0.5 M urea were found to be 20.2 ± 0.2 for both
DACM-M-TTR and DACM-W79F-M-TTR, suggesting a
higher energy barrier for refolding when the label is
attached to the W79F mutant. The FRET E value (Fig. 9d)
of the W79F-M-TTR partially folded state in 0.5 M urea is
slightly lower than that of M-TTR (0.68 ± 0.03, as
opposed to 0.72 ± 0.03), an observation that, together with
that obtained with the refolding rates, is reminiscent of a
slightly less compact partially folded state in the mutant.
We then attempted to study the aggregation process of
the labelled and unlabeled W79F mutant at pH 4.4, 37 C,
as we did for the non-mutated M-TTR. However, the
aggregation process was too fast and DLS measurements
showed that the protein was aggregated immediately after
incubation under these conditions. We therefore, per-
formed a preliminary study with DLS to identify a pH
value and ionic strength ideal for slow aggregation of the
labelled and unlabeled W79F mutant at a concentration of
15 lM and we found that at pH 5.6, both W79F-M-TTR
and DACM-W79F-M-TTR aggregated sufficiently slowly
to allow the detection and analysis of both the monomeric
amylodogenic state and the aggregated state (data not
shown). We therefore, acquired time courses of aggrega-
tion for 15 lM W79F-M-TTR and DACM-W79F-M-TTR
in 20 mM acetate buffer, pH 5.6, 37 C in the presence of
0, 30, 60, 90 and 137 mM NaCl, using turbidimetry at
450 nm as a probe for aggregation (Fig. 8e). We selected a
NaCl concentration of 30 mM for FRET measurements and
performed the experiments as described above for the wild-
type protein (Fig. 8f) determining a FRET E value of
0.67 ± 0.01 for the amyloidogenic state (Fig. 8g). A FRET
E value of 0.41 ± 0.04 was obtained for the aggregated
state (Fig. 8g), although this value is difficult to interpret
for the reasons explained above. Overall, the FRET E val-
ues measured for the native states at pH 7.4 and for the
amyloidogenic states at mildly acidic pH for M-TTR and
W79F-M-TTR are all similar, within experimental error,
indicating that the distance between the DACM moiety
attached to Cys10 and Trp41 does not change significantly
in the transition from the native to the amyloidogenic state.
Discussion
The production of a mutant of human wild-type TTR that is
stable as a monomer, generally referred to as M-TTR [25],
has greatly facilitated the study of the folding process of
this protein, of the structural perturbations occurring in the
conversion of the fully folded monomer to the amyloido-
genic state at weakly acidic pH values, of the aggregation
process from such a state and of the mechanism of action of
TTR as a toxin detoxifier [25, 26, 28, 47–49]. Following
the observation that M-TTR contains only a solvent-ex-
posed cysteine residue at position 10 that can be potentially
labelled with a coumarin derivative able to act as an
acceptor of the fluorescence of the naturally present tryp-
tophan residues at positions 41 and 79, we generated a
coumarin-labelled M-TTR molecule (DACM-M-TTR) to
investigate the spatial distance between the coumarin
moiety at position 10 and Trp41/Trp79, particularly Trp41,
which is non-quenched and spatially closer to Cys10.
Five conformational states of M-TTR have been inves-
tigated, namely (1) the fully folded state at pH 7.4, (2) the
urea-unfolded state at pH 7.4, (3) the molten globule state
populated at equilibrium at low urea concentrations, pH
7.4, (4) the partially folded state accumulating transiently
during folding, pH 7.4 and (5) the amyloidogenic state at
pH 4.4.
The first study performed at pH 7.4, 25 C, no added
denaturants, indicated that DACM-M-TTR is folded,
monomeric in solution, singly and uniformly labelled, and
maintains a structure superimposable to that of unlabeled
M-TTR. The labelled protein is less stable than the
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unlabeled one, as indicated by the lower free energy
change of unfolding (DGUFH2O ), but this is attributable to the
high sensitivity of the DGUFH2O value to covalent modifica-
tions, as indicated by the many observations accumulated
so far that most mutants of TTR are indeed less stable than
the wild-type protein, regardless of the position and type of
the mutation [20]. A FRET E value of 0.72 ± 0.02 was
obtained for DACM-M-TTR at pH 7.4. Such a value is
largely due to the energy transfer from Trp41 to DACM,
both because the fluorescence of Trp79 is quenched [23]
and because Trp79 is more distant than Trp41 from Cys10
[25, 43]. The observation that the W79F mutant of DACM-
M-TTR features a similar FRET E value under the same
conditions, supports this hypothesis. A FRET E value of
Fig. 9 RET of W79F-M-TTR during refolding. a, b Refolding time
course of W79F-M-TTR (red filled circles) and DACM-W79F-M-
TTR (blue open circles) monitored by tryptophan fluorescence
(excitation 290 nm, emission 320–385 nm) in 0.5 M urea at pH 7.4,
25 C. c Refolding time course of DACM-W79F-M-TTR (blue open
circles) monitored by DACM fluorescence (excitation 290 nm,
emission[385 nm) in 0.5 M urea at pH 7.4, 25 C. d Comparison
between the FRET E values calculated, from the spectroscopic data,
for the folded (F), unfolded (U) and partially folded (PF) states of
M-TTR and W79F-M-TTR in 0.5 M urea at pH 7.4, 25 C
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0.72 ± 0.02 results into a spatial distance of
21.3 ± 1.6 nm, between Trp41 and DACM.
The conversion of the non-mutated and W79F mutant
forms of M-TTR from their folded state to the amyloido-
genic state at pH 4.4 (or 5.6 in the case of the W79F-M-
TTR) does not change significantly the FRET E value and
the related distance between DACM and Trp41, indicating
that b-strand C, where Trp41 is located, does not increase
its distance from Cys10 and does not unfold upon such
conversion. This observation is particularly important as
previous structural investigations on WT-TTR, carried out
with spectroscopic methods, limited proteolysis and
hydrogen/deuterium exchange monitored with NMR,
attributed such a structural conversion mainly to the
unfolding of b-strands C/D and the interconnecting loop
[23] or to the entire b-sheet CBEF [24]. If this was the case,
a decrease of the FRET E value should have been observed
upon acidification, given the high sensitivity of FRET to
even minor structural perturbations or increased dynamics.
Our observation is indeed in agreement with more recent
observations obtained with solution NMR that the whole
CBEF b-sheet, including b-strand C, does not unfold, nor
does it increase its structural dynamics, upon conversion of
native M-TTR and WT-TTR into the amyloidogenic state
at mildly acidic pH [26, 27, 50]. A unifying picture of the
amyloidogenic state of TTR at mildly low pH (pH 3.9–5.5)
that is consistent with all recent data obtained so far with
different techniques is that of a largely native-like state
with the entire DAGH b-sheet, the D–E loop, the E–F a-
helix and its associated residues from the A–B loop,
exhibiting structural fluctuations, in the presence of a
substantially folded and packed CBEF b-sheet.
The equilibrium molten globule state of M-TTR, or
W79F-M-TTR, populated at low urea concentrations, pH
7.4, has a FRET E value and a resulting R value similar to
those of the folded and amyloidogenic states of the same
protein isoforms, suggesting that the Cys10–Trp41 distance
is not significantly altered in such a conformational state. It
is interesting to compare the structural information col-
lected so far on such molten globule state of M-TTR [28]
with that obtained for the amyloidogenic state of M-TTR
and WT-TTR at pH 3.9-5.0 [23, 25–27, 50], to assess
whether the two conformational states are essentially
similar albeit populated under different conditions. The two
conformational states share similar FRET E and R values
and similar near-UV CD spectra, but different intrinsic
fluorescence and far-UV CD spectra. The molten globule
state of M-TTR in 2.0 M urea, pH 7.4, has a far-UV CD
spectrum different from that of the folded/amyloidogenic
states [27], which appear to be similar between them
[23, 28]. Indeed, the molten globule state indicates a sub-
stantial unfolding of some portions of the protein [28]. The
molten globule state in 2.0 M urea, pH 7.4, unlike the
amyloidogenic state at pH 4.4, has an intrinsic fluorescence
spectrum similar to that of the folded state at pH 7.4
[23, 28]. Hence, it appears that the two conformational
states are structurally distinct. It will be important to
establish the amyloidogenic nature of the molten globule
state, which may be as important as the amyloidogenic
state populated at low pH.
As far as the off-pathway, partially folded state formed
transiently during folding at pH 7.4 is concerned, it has a
FRET E value significantly higher than that of the folded
and amyloidogenic states, suggesting that Trp41 is closer to
Cys10 than it is in the folded/amyloidogenic states. This
result reinforces the view that such a conformational state
is an off-pathway species with some non-native contacts
that need to be unfolded before folding can proceed [28].
The kinetic and amyloidogenic conformational states share
similar values of mean residue ellipticity, at least at
219 nm, and both induce an increase and blue-shift of the
ANS dye [23, 25, 28]. However, in addition to showing
different FRET E values, they also differ for the intrinsic
fluorescence spectra, exhibiting a fluorescence intensity
higher and lower than the folded state at pH 7.4, respec-
tively [23, 28]. Again, it appears that the two
conformational states are structurally distinct.
Another interesting observation emerging from these
results is the high aggregation propensity exhibited by the
W41F mutant, which was indeed found to be insoluble even
under native conditions, limiting our FRET analysis. Among
the many mutants of TTR associated with TTR diseases, one
has been reported to involve Trp41 (W41L) and to cause
vitreous opacity with amyloid-material positive for TTR in
the vitreous fluid of the index patient [51, 52]. W41F and
W41L TTRs share similarly high aggregation propensities,
observed in vivo and in vitro, respectively, suggesting that
Trp41 is a very important amino acid residue for maintaining
the stability and solubility of native TTR.
Conclusions
In conclusion, the FRET study described here provides
insight into the structural changes occurring during the
folding, unfolding and aggregation of TTR, a protein
whose aggregation has been linked to systemic amyloi-
doses. The most important achievements of our results is
the clarification of the degree of unfolding and dynamics of
b-strand C in the formation of the amyloidogenic state and
the establishment of the concept that both the molten
globule state and kinetically trapped species accumulating
during folding are structurally distinct from such a state,
indicating that TTR is a highly plastic protein able to
populate a number of structurally discrete conformational
states.
3596 S. A. Ghadami et al.
123
Acknowledgements We thank the Iranian Ministry of Science
Research and Technology for providing the studentship for S.A.G.
and the University of Florence for Fondi di Ateneo. F.B.’s research is
funded by the Italian MIUR (Programma per Giovani Ricercatori Rita
Levi Montalcini 2010). We also thank Martino Bolognesi for
insightful discussion. We thank Joel Buxbaum and Xinyi Li for
providing the gene coding M-TTR.
References
1. Soprano DR, Herbert J, Soprano KJ, Schon EA, Goodman DS
(1985) Demonstration of transthyretin mRNA in the brain and
other extrahepatic tissues in the rat. J Biol Chem
260(21):11793–11798
2. Stauder AJ, Dickson PW, Aldred AR, Schreiber G, Mendelsohn
FA, Hudson P (1986) Synthesis of transthyretin (pre-albumin)
mRNA in choroid plexus epithelial cells, localized by in situ
hybridization in rat brain. J Histochem Cytochem 34(7):949–952
3. Herbert J, Wilcox JN, Pham KT, Fremeau RT Jr, Zeviani M,
Dwork A, Soprano DR, Makover A, Goodman DS, Zimmerman
EA et al (1986) Transthyretin: a choroid plexus-specific transport
protein in human brain. The 1986 S. Weir Mitchell award.
Neurology 36(7):900–911
4. Jacobsson B (1989) Localization of transthyretin-mRNA and of
immunoreactive transthyretin in the human fetus. Virchows Arch
A Pathol Anat Histopathol 415(3):259–263
5. Jacobsson B, Collins VP, Grimelius L, Pettersson T, Sandstedt B,
Carlstrom A (1989) Transthyretin immunoreactivity in human
and porcine liver, choroid plexus, and pancreatic islets. J His-
tochem Cytochem 37(1):31–37
6. Murakami T, Ohsawa Y, Zhenghua L, Yamamura K, Sunada Y
(2010) The transthyretin gene is expressed in Schwann cells of
peripheral nerves. Brain Res 1348:222–225. doi:10.1016/j.
brainres.2010.06.017
7. Wakasugi S, Maeda S, Shimada K (1986) Structure and expres-
sion of the mouse prealbumin gene. J Biochem 100(1):49–58
8. Buxbaum JN, Reixach N (2009) Transthyretin: the servant of
many masters. Cell Mol Life Sci 66(19):3095–3101. doi:10.1007/
s00018-009-0109-0
9. Reixach N, Foss TR, Santelli E, Pascual J, Kelly JW, Buxbaum
JN (2008) Human-murine transthyretin heterotetramers are
kinetically stable and non-amyloidogenic. A lesson in the gen-
eration of transgenic models of diseases involving oligomeric
proteins. J Biol Chem 283(4):2098–2107. doi:10.1074/jbc.
M708028200
10. Sekijima Y (2015) Transthyretin (ATTR) amyloidosis: clinical
spectrum, molecular pathogenesis and disease-modifying treat-
ments. J Neurol Neurosurg Psychiatry 86(9):1036–1043. doi:10.
1136/jnnp-2014-308724
11. Sipe JD, Benson MD, Buxbaum JN, Ikeda SI, Merlini G, Saraiva
MJ,Westermark P (2016) Amyloid fibril proteins and amyloidosis:
chemical identification and clinical classification International
Society of Amyloidosis 2016 Nomenclature Guidelines. Amyloid
23(4):209–213. doi:10.1080/13506129.2016.1257986
12. Lie JT, Hammond PI (1988) Pathology of the senescent heart:
anatomic observations on 237 autopsy studies of patients 90 to
105 years old. Mayo Clin Proc 63(6):552–564
13. Tanskanen M, Peuralinna T, Polvikoski T, Notkola IL, Sulkava
R, Hardy J, Singleton A, Kiuru-Enari S, Paetau A, Tienari PJ,
Myllykangas L (2008) Senile systemic amyloidosis affects 25%
of the very aged and associates with genetic variation in alpha2-
macroglobulin and tau: a population-based autopsy study. Ann
Med 40(3):232–239. doi:10.1080/07853890701842988
14. Connors LH, Lim A, Prokaeva T, Roskens VA, Costello CE
(2003) Tabulation of human transthyretin (TTR) variants, 2003.
Amyloid 10(3):160–184. doi:10.3109/13506120308998998
15. Garzuly F, Vidal R, Wisniewski T, Brittig F, Budka H (1996)
Familial meningocerebrovascular amyloidosis, Hungarian type,
with mutant transthyretin (TTR Asp18Gly). Neurology
47(6):1562–1567
16. Cornwell GG 3rd, Sletten K, Johansson B, Westermark P (1988)
Evidence that the amyloid fibril protein in senile systemic amy-
loidosis is derived from normal prealbumin. Biochem Biophys
Res Commun 154(2):648–653
17. Saraiva MJ, Costa PP, Goodman DS (1988) Transthyretin (pre-
albumin) in familial amyloidotic polyneuropathy: genetic and
functional aspects. Adv Neurol 48:189–200
18. Westermark P, Sletten K, Johansson B, Cornwell GG 3rd (1990)
Fibril in senile systemic amyloidosis is derived from normal
transthyretin. Proc Natl Acad Sci USA 87(7):2843–2845
19. Mccutchen SL, Colon W, Kelly JW (1993) Transthyretin muta-
tion Leu-55-Pro significantly alters tetramer stability and
increases amyloidogenicity. Biochemistry 32(45):12119–12127.
doi:10.1021/bi00096a024
20. Sekijima Y, Wiseman RL, Matteson J, Hammarstrom P, Miller
SR, Sawkar AR, Balch WE, Kelly JW (2005) The biological and
chemical basis for tissue-selective amyloid disease. Cell
121(1):73–85. doi:10.1016/j.cell.2005.01.018
21. Steinrauf LK, Hamilton JA, Braden BC, Murrell JR, Benson MD
(1993) X-ray crystal structure of the Ala-109 ? Thr variant of
human transthyretin which produces euthyroid hyperthyroxine-
mia. J Biol Chem 268(4):2425–2430
22. Kelly JW, Colon W, Lai ZH, Lashuel HA, McCulloch J,
McCutchen SL, Miroy GJ, Peterson SA (1997) Transthyretin
quaternary and tertiary structural changes facilitate misassembly
into amyloid. Adv Protein Chem 50:161–181. doi:10.1016/
S0065-3233(08)60321-6
23. Lai Z, Colon W, Kelly JW (1996) The acid-mediated denatura-
tion pathway of transthyretin yields a conformational
intermediate that can self-assemble into amyloid. Biochemistry
35(20):6470–6482. doi:10.1021/bi952501g
24. Liu K, Cho HS, Hoyt DW, Nguyen TN, Olds P, Kelly JW,
Wemmer DE (2000) Deuterium–proton exchange on the native
wild-type transthyretin tetramer identifies the stable core of the
individual subunits and indicates mobility at the subunit interface.
J Mol Biol 303(4):555–565. doi:10.1006/jmbi.2000.4164
25. Jiang X, Smith CS, Petrassi HM, Hammarstrom P, White JT,
Sacchettini JC, Kelly JW (2001) An engineered transthyretin
monomer that is nonamyloidogenic, unless it is partially dena-
tured. Biochemistry 40(38):11442–11452
26. Lim KH, Dyson HJ, Kelly JW, Wright PE (2013) Localized
structural fluctuations promote amyloidogenic conformations in
transthyretin. J Mol Biol 425(6):977–988. doi:10.1016/j.jmb.
2013.01.008
27. Lim KH, Dasari AK, Hung I, Gan Z, Kelly JW, Wemmer DE
(2016) Structural changes associated with transthyretin misfold-
ing and amyloid formation revealed by solution and solid-state
NMR. Biochemistry 55(13):1941–1944. doi:10.1021/acs.
biochem.6b00164
28. Conti S, Li X, Gianni S, Ghadami SA, Buxbaum J, Cecchi C,
Chiti F, Bemporad F (2014) A complex equilibrium among
partially unfolded conformations in monomeric transthyretin.
Biochemistry 53(27):4381–4392. doi:10.1021/bi500430w
29. Clegg RM (1995) Fluorescence resonance energy transfer. Curr
Opin Biotechnol 6(1):103–110
30. Leslie AGW (1992) Joint CCP4 and ESF-EACMB newsletter on
protein crystallography. SERC Daresbury Laboratory,
Warrington
FRET studies of various conformational states adopted by transthyretin 3597
123
31. Collaborative Computational Project N (1994) The CCP4 suite:
programs for protein crystallography. Acta Crystallogr D Biol
Crystallogr 50(Pt 5):760–763. doi:10.1107/S0907444994003112
32. Evans P (2006) Scaling and assessment of data quality. Acta
Crystallogr D Biol Crystallogr 62(Pt 1):72–82. doi:10.1107/
S0907444905036693
33. McNicholas S, Potterton E, Wilson KS, Noble ME (2011) Pre-
senting your structures: the CCP4mg molecular-graphics
software. Acta Crystallogr D Biol Crystallogr 67(Pt 4):386–394.
doi:10.1107/S0907444911007281
34. Long F, Vagin AA, Young P, Murshudov GN (2008) BALBES: a
molecular-replacement pipeline. Acta Crystallogr D Biol Crys-
tallogr 64(Pt 1):125–132. doi:10.1107/S0907444907050172
35. Vagin A, Teplyakov A (1997) MOLREP: an automated program
for molecular replacement. J Appl Crystallogr 30:1022–1025.
doi:10.1107/S0021889897006766
36. Adams PD, Afonine PV, Bunkoczi G, Chen VB, Davis IW,
Echols N, Headd JJ, Hung LW, Kapral GJ, Grosse-Kunstleve
RW, McCoy AJ, Moriarty NW, Oeffner R, Read RJ, Richardson
DC, Richardson JS, Terwilliger TC, Zwart PH (2010) PHENIX: a
comprehensive Python-based system for macromolecular struc-
ture solution. Acta Crystallogr D Biol Crystallogr 66(Pt
2):213–221. doi:10.1107/S0907444909052925
37. Murshudov GN, Vagin AA, Dodson EJ (1997) Refinement of
macromolecular structures by the maximum-likelihood method.
Acta Crystallogr D Biol Crystallogr 53(Pt 3):240–255. doi:10.
1107/S0907444996012255
38. Emsley P, Cowtan K (2004) Coot: model-building tools for
molecular graphics. Acta Crystallogr D Biol Crystallogr 60(Pt 12
Pt 1):2126–2132. doi:10.1107/S0907444904019158
39. Hornak V, Abel R, Okur A, Strockbine B, Roitberg A, Sim-
merling C (2006) Comparison of multiple Amber force fields and
development of improved protein backbone parameters. Proteins
65(3):712–725. doi:10.1002/prot.21123
40. Wang J, Wolf RM, Caldwell JW, Kollman PA, Case DA (2004)
Development and testing of a general amber force field. J Comput
Chem 25(9):1157–1174. doi:10.1002/jcc.20035
41. Santoro MM, Bolen DW (1988) Unfolding free energy changes
determined by the linear extrapolation method. 1. Unfolding of
phenylmethanesulfonyl alpha-chymotrypsin using different
denaturants. Biochemistry 27(21):8063–8068
42. Pires RH, Karsai A, Saraiva MJ, Damas AM, Kellermayer MS
(2012) Distinct annular oligomers captured along the assembly
and disassembly pathways of transthyretin amyloid protofibrils.
PLoS One 7(9):e44992. doi:10.1371/journal.pone.0044992
43. Peterson SA, Klabunde T, Lashuel HA, Purkey H, Sacchettini JC,
Kelly JW (1998) Inhibiting transthyretin conformational changes
that lead to amyloid fibril formation. Proc Natl Acad Sci USA
95(22):12956–12960
44. Lakowicz JR (2006) Principles of fluorescence spectroscopy, 3rd
edn. Springer, New York
45. Nazarov PV, Koehorst RB, Vos WL, Apanasovich VV, Hem-
minga MA (2006) FRET study of membrane proteins:
simulation-based fitting for analysis of membrane protein
embedment and association. Biophys J 91(2):454–466. doi:10.
1529/biophysj.106.082867
46. Visser NV, Westphal AH, van Hoek A, van Mierlo CP, Visser
AJ, van Amerongen H (2008) Tryptophan-tryptophan energy
migration as a tool to follow apoflavodoxin folding. Biophys J
95(5):2462–2469. doi:10.1529/biophysj.108.132001
47. Hurshman AR, White JT, Powers ET, Kelly JW (2004) Trans-
thyretin aggregation under partially denaturing conditions is a
downhill polymerization. Biochemistry 43(23):7365–7381.
doi:10.1021/bi049621l
48. Cascella R, Conti S, Mannini B, Li X, Buxbaum JN, Tiribilli B,
Chiti F, Cecchi C (2013) Transthyretin suppresses the toxicity of
oligomers formed by misfolded proteins in vitro. Biochim Bio-
phys Acta 1832 12:2302–2314. doi:10.1016/j.bbadis.2013.09.011
49. Cappelli S, Penco A, Mannini B, Cascella R, Wilson MR, Ecroyd
H, Li X, Buxbaum JN, Dobson CM, Cecchi C, Relini A, Chiti F
(2016) Effect of molecular chaperones on aberrant protein oli-
gomers in vitro: super-versus sub-stoichiometric chaperone
concentrations. Biol Chem 397(5):401–415. doi:10.1515/hsz-
2015-0250
50. Das JK, Mall SS, Bej A, Mukherjee S (2014) Conformational
flexibility tunes the propensity of transthyretin to form fibrils
through non-native intermediate states. Angew Chem Int Ed Engl
53(47):12781–12784. doi:10.1002/anie.201407323
51. Yazaki M, Connors LH, Eagle RC Jr, Leff SR, Skinner M,
Benson MD (2002) Transthyretin amyloidosis associated with a
novel variant (Trp41Leu) presenting with vitreous opacities.
Amyloid 9(4):263–267
52. Yazaki M, Varga J, Dyck PJ, Benson MD (2002) A new trans-
thyretin variant Leu55Gln in a patient with systemic amyloidosis.
Amyloid 9(4):268–271
3598 S. A. Ghadami et al.
123
 
 
	 107 
Side Project II 
 
Optimization of a protocol for expression and purification of a glycosylated protein through 
Leishmania tarentolae expression system. 
 
E. coli can express only the 15% of eukaryotic proteins in their active form. This prokaryotic 
expression system, indeed, lacks the posttranslational modifications often essential for the activity of 
eukaryotic proteins. To face this problem alternative many expression systems have been developed. 
Among others, Leishmania tarentolae expression system (LEXSY), combines eukaryotic protein 
expression with highly complex and efficient folding and post-translational machineries and with easy 
handling broadly comparable to the one of bacterial expression systems. 
L. tarentolae is a trypanosomatid protozoan host not pathogenic to mammals, first isolated from the 
Moorish gecko Tarentola mauritanica. Trypanosomatidae are rich in glycoproteins, which can 
account for more than 10% of their proteome. Probably due to their parasitic lifestyle, the 
oligosaccharide structures of their glycoproteins are often chemically similar to those of mammalians. 
Therefore, LEXSY is a very promising expression system to heterologously express glycosylated 
proteins. 
In this context, I spent a three months period in Prof. Achour laboratory the SciLifeLab 
(www.scilifelab.se, Karolinska Institute, Stockholm, Sweden) to optimize a protocol to express and 
purify a Neuroserpin, human glycosylated protein expressed in the central nervous system. Prof. A. 
Achour, is a long-term collaborator and in his lab all the necessary expertise for LEXSY was 
available.  
 
A synthetic gene was cloned into pLexsy-Sat2 plasmid for a secreted constitutive protein expression in 
LEXSY with an 6xHis-Tag to facilitate the purification process. The sequence of the protein was 
optimized based on the L. tarentolae codon usage, and fused with a Leishmania secretory signal 
peptide for secreted expression.  
After sequencing, the plasmid was amplified and linearized. LEXSY host P10 cells (Jena Bioscience) 
were, thus, transfected with the linearized construct. The transfected cells were selected by plating on 
agar plates. LEXSY colonies were then selected and transferred into culture plates.  
The constitutive secretory expression of the protein was tested through dot blot and the culture with 
highest expression was scaled up to 4 L culture to purify the glycosylated protein from the medium 
(Figure 1). 
The glycosylated protein was isolated first through a nickel affinity chromatography followed by a gel 
filtrations. The SDS-PAGE of the eluted fractions showed that the protein was pure. 
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Therefore, during this stage, I could learn all the crucial steps of heterologous protein expression in 
LEXSY and applied all relevant protocols for the constitutive expression of human Neuroserpin, 
which I successfully purified at the end of the stage. In the months following the stage, I collaborated 
with other lab members to install this technology in Prof. Ricagno’s lab (Dept. of Bioscience, 
University of Milan).  
 
 
 
Figure 1: (A) Dot Blot of the medium of transfected cells. Only two clones, highlighted with the red arrow, show expression 
of NS. (B) SDS-PAGE of the eluted fractions of the affinity chromatography. Two distinct bands around NS molecular 
weight indicate that spontaneous proteolysis has occurred.  
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